Page last updated: 2024-11-05

selegiline

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Selegiline is a selective monoamine oxidase type B (MAO-B) inhibitor. It was initially synthesized in 1965 and was initially marketed under the brand name 'Deprenyl'. Selegiline is used to treat Parkinson's disease, as it increases levels of dopamine in the brain. It is also used to treat depression and Alzheimer's disease. Selegiline is believed to have neuroprotective properties, and research is ongoing to investigate its potential in treating other neurological disorders. Selegiline is a prodrug that is metabolized to desmethylselegiline, which is the active form of the drug. Desmethylselegiline is a potent and selective inhibitor of MAO-B. MAO-B is an enzyme that breaks down dopamine in the brain. By inhibiting MAO-B, selegiline increases the levels of dopamine in the brain. This can help to improve motor function in people with Parkinson's disease. Selegiline is also being studied for its potential to treat other conditions, such as depression, Alzheimer's disease, and cancer. Studies have shown that selegiline can have antidepressant effects, and it may also be beneficial in slowing the progression of Alzheimer's disease. Selegiline is also being investigated for its potential to inhibit tumor growth. Selegiline is a safe and effective treatment for Parkinson's disease. It is generally well-tolerated, but some side effects can occur. These include insomnia, headache, and nausea. Selegiline can interact with other medications, so it is important to talk to your doctor about all of your medications before starting selegiline.'

Selegiline: A selective, irreversible inhibitor of Type B monoamine oxidase that is used for the treatment of newly diagnosed patients with PARKINSON DISEASE, and for the treatment of depressive disorders. The compound without isomeric designation is Deprenyl. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID26757
CHEMBL ID972
CHEBI ID9086
SCHEMBL ID22232
MeSH IDM0019601

Synonyms (87)

Synonym
BRD-K86434416-003-03-1
BRD-K86434416-001-02-7
otrasel
jumex
n-methyl-n-[(1r)-1-methyl-2-phenylethyl]prop-2-yn-1-amine
emsam (tn)
selegiline (usan/inn)
D03731
BSPBIO_001589
(-)-deprenil
(r)-(-)-n,alpha-dimethyl-n-2-propinylphenethylamine
l-e 250
benzeneethanamine, n,alpha-methyl-n-2-propynyl-, (alphar)-
selegyline
(r)-(-)-n-methyl-n-(1-phenyl-2-propyl)-2-propinylamin
(-)-(n)-methyl-n-((1r)-1-methyl-2-phenylethyl)prop-2-yn-1-amine
benzeneethanamine, n,alpha-dimethyl-n-2-propynyl-, (r)-
carbex
selegiline, (r)-isomer
selegilina [inn-spanish]
emsam
selegilinum [inn-latin]
NCGC00024994-01
PRESTWICK2_000552
selegilinum
CHEBI:9086 ,
selegilina
PRESTWICK3_000552
C07245
14611-51-9
selegiline
l-deprenyl
DB01037
us8633208, deprenyl
(-)-selegiline
methyl[(2r)-1-phenylpropan-2-yl]prop-2-yn-1-ylamine
n-methyl-n-[(2r)-1-phenylpropan-2-yl]prop-2-yn-1-amine
l-deprenalin
bdbm15579
chembl972 ,
NCGC00024994-02
PRESTWICK0_000552
SPBIO_002544
PRESTWICK1_000552
BSPBIO_000623
BPBIO1_000687
NCGC00024994-04
NCGC00024994-03
HMS2089D09
HMS1989P11
AKOS000281115
l-selegiline
HMS1791P11
(2r)-n-methyl-1-phenyl-n-prop-2-ynylpropan-2-amine
selegiline [usan:inn:ban]
2k1v7gp655 ,
selgene
zalapar
(r)-(-)-selegiline
unii-2k1v7gp655
anipryl
STK640578
selegiline [who-dd]
selegiline [mi]
benzeneethanamine, n,.alpha.-methyl-n-2-propynyl-, (.alpha.r)-
selegiline [vandf]
selegiline [usan]
selegiline [inn]
selegiline [orange book]
selegene
gtpl6639
SCHEMBL22232
MEZLKOACVSPNER-GFCCVEGCSA-N
HMS3402P11
DTXSID6023575 ,
(r)-(-)-n,2-dimethyl-n-2-propynylphenethylamine
methyl[(2r)-1-phenylpropan-2-yl](prop-2-yn-1-yl)amine
Q47495783
(r)-n-methyl-n-(1-phenylpropan-2-yl)prop-2-yn-1-amine
102741-42-4
BRD-K86434416-003-06-4
EN300-4271449
selegilinum (inn-latin)
n-methyl-n-((2r)-1-phenylpropan-2-yl)prop-2-yn-1-amine
dtxcid403575
n04bd01
selegilina (inn-spanish)

Research Excerpts

Overview

Slegiline is an irreversible, selective type-B monoamine oxidase inhibitor (MAOI) approved for Parkison's disease-oral and major depressive disorder-transdermal formulation. It has been shown to have neurotrophic and anti-apopsychotic effects.

ExcerptReferenceRelevance
"Selegiline is a selective monoamine oxidase B (MAO-B) inhibitor used to treat Parkinson's disease."( Effect of selegiline as a monomine oxidase B inhibitor on the expression of neurotrophin mRNA levels in a contusion rat model of spinal cord injury.
Abdanipour, A; Anarkooli, IJ; Mirzaei, M; Mohammadi, P, 2023
)
2.03
"Selegiline is an irreversible, selective type-B monoamine oxidase inhibitor (MAOI) approved for Parkison's disease-oral and major depressive disorder-transdermal formulation) resulting in non-selective MAOI activity at oral doses≥20 mg/day. "( Efficacy and safety of selegiline across different psychiatric disorders: A systematic review and meta-analysis of oral and transdermal formulations.
Birkenhager, TK; Caiazza, C; Cattaneo, CI; de Bartolomeis, A; Fornaro, M; Gillman, K; Iasevoli, F; Rossano, F; Ruhé, HG; Sobrino, A; Solini, N; Stahl, S; Van den Eynde, V; Vellucci, A; Zotti, N, 2023
)
2.66
"Selegiline (SE) is a selective, irreversible monoamine oxidase-B inhibitor, used for reducing symptoms in early-stage Parkinson's disease. "( Detection of l-Methamphetamine and l-Amphetamine as Selegiline Metabolites.
Choi, H; Kang, S; Kim, J; Park, Y; Shin, I; Yang, W, 2021
)
2.31
"Selegiline is a selective and irreversible MAO-B inhibitor and, although clinical trials already shown the beneficial effect of selegiline on cognition of AD patients, its mechanism of action remains to be elucidated."( Selegiline reverses aβ₂₅₋₃₅-induced cognitive deficit in male mice.
da Cunha, C; Ferreira, AP; Ferreira, J; Gomes, GM; Mello, CF; Pazini, AM; Pinheiro, F; Rubin, MA; Villarinho, JG, 2013
)
2.55
"Selegiline (L-deprenyl) is a selective, irreversible inhibitor of monoamine oxidase B (MAO-B) at the conventional dose (10 mg/day oral) that is used in the treatment of Parkinson's disease. "( Evidence that formulations of the selective MAO-B inhibitor, selegiline, which bypass first-pass metabolism, also inhibit MAO-A in the human brain.
Alexoff, DL; Apelskog-Torres, K; Carter, P; Fahn, S; Fowler, JS; Gilmor, M; Hubbard, B; Jayne, M; King, P; Logan, J; McCall-Perez, F; Muench, L; Shea, C; Shumay, E; Telang, F; Volkow, ND; Wang, GJ; Xu, Y, 2015
)
2.1
"Selegiline (l-deprenyl) is a selective monoamine oxidase type B inhibitor that has been shown to have neurotrophic and anti-apoptotic properties and to protect neurons in different experimental models of cerebral ischaemia. "( An explorative study regarding the effect of l-deprenyl on cognitive and functional recovery in patients after stroke.
Bartolo, M; Capone, A; Pierelli, F; Sandrini, G; Zucchella, C, 2015
)
1.86
"Selegiline is a monoamine oxidase-B (MAO-B) inhibitor with anti-Parkinsonian effects, but it is metabolized to amphetamines. "( N-Methyl, N-propynyl-2-phenylethylamine (MPPE), a Selegiline Analog, Attenuates MPTP-induced Dopaminergic Toxicity with Guaranteed Behavioral Safety: Involvement of Inhibitions of Mitochondrial Oxidative Burdens and p53 Gene-elicited Pro-apoptotic Change.
Jang, CG; Jeong, JH; Kim, HC; Lee, JW; Lee, PH; Nabeshima, T; Nam, Y; Nguyen, PT; Oh, YJ; Shin, EJ; Tran, TV; Yoo, JE; Youdim, MBH, 2016
)
2.13
"Selegiline is an irreversible monoamine oxidase (MAO) type B inhibitor which increases striatal dopamine levels and exerts an antidepressant effect."( Involvement of D1 and D2 dopamine receptors in the antidepressant-like effects of selegiline in maternal separation model of mouse.
Alijanpour, S; Amini-Khoei, H; Amiri, S; Haj-Mirzaian, A; Mehdizadeh, M; Mohammadi-Asl, A; Olson, CO; Rahimi-Balaei, M; Rastegar, M; Razmi, A; Zarrindast, MR, 2016
)
1.38
"Selegiline is a monoamine oxidase B (MAO-B) inhibitor and is used in the treatment of Parkinson's disease. "( Design Expert(®) supported optimization and predictive analysis of selegiline nanoemulsion via the olfactory region with enhanced behavioural performance in Parkinson's disease.
Ali, J; Baboota, S; Kumar, S, 2016
)
2.11
"Selegiline (Sel) is a noncompetitive monoamino oxidase B inhibitor that has neuroprotective effects and has been administered to PD patients as monotherapy or in combination with l-dopa."( The anti-Parkinsonian drug selegiline delays the nucleation phase of α-synuclein aggregation leading to the formation of nontoxic species.
Braga, CA; Di Giovanni, S; Foguel, D; Follmer, C; Freitas, MS; Khattar, E; Lashuel, HA; Palhano, FL; Romão, L; Silva, JL, 2011
)
1.39
"Selegiline is a monoamine-B specific inhibitor used to treat Parkinson's disease. "( Tolerability and efficacy of switching from oral selegiline to Zydis selegiline in patients with Parkinson's disease.
Davidson, A; Hunter, C; Isaacson, SH; Ondo, WG; Silver, DE; Stewart, RM; Tetrud, JW, 2011
)
2.07
"Selegiline is a propargyl amphetamine derivative that undergoes extensive first-pass metabolism to L-methamphetamine and L-amphetamine."( Selegiline and rasagiline: twins or distant cousins?
Knudsen Gerber, DS, 2011
)
2.53
"Selegiline is a selective irreversible inhibitor of the B-type of monoamine oxidase (MAO-B). "( The effect of selegiline on total scavenger capacity and liver fat content: a preliminary study in an animal model.
Adler, I; Bekesi, G; Dinya, E; Lengyel, G; Magyar, K; Marczell, I; Nagy-Repas, P; Racz, K; Schaff, Z; Stark, J; Szombath, D; Tulassay, Z, 2012
)
2.18
"Selegiline was found to be a mechanism-based inactivator of the 7-ethoxy-4-(trifluoromethyl)coumarin O-deethylation (7-EFC) activity of CYP2B6 as well as bupropion metabolism."( Inhibition of bupropion metabolism by selegiline: mechanism-based inactivation of human CYP2B6 and characterization of glutathione and peptide adducts.
Hollenberg, PF; Kenaan, C; Sridar, C, 2012
)
1.37
"Selegiline is a type B monoamine oxidase inhibitor (MAOI) that is metabolized to amphetamine and methamphetamine stimulant compounds that may be useful in the treatment of ADHD."( Selegiline in the treatment of attention deficit hyperactivity disorder in children: a double blind and randomized trial.
Akhondzadeh, S; Amini, H; Arabgol, F; Davari-Ashtiani, R; Tavakolian, R, 2003
)
2.48
"Selegiline is a specific MAO-B inhibitor. "( Reduced cardiovascular effects of methamphetamine following treatment with selegiline.
Gee, WL; Gilman, JP; Graczyk, Z; Schindler, CW; Wang, G, 2003
)
1.99
"Selegiline is an irreversible inhibitor of monoamine oxidase (MAO) with psychostimulant and neuroprotective effects which can prevent decreases in dopamine efflux that follow opiate withdrawal. "( Selegiline modifies the extinction of responding following morphine self-administration, but does not alter cue-induced reinstatement, reacquisition of morphine reinforcement, or precipitated withdrawal.
Grasing, K; He, S; Li, N, 2005
)
3.21
"Selegiline is an irreversible inhibitor of monoamine oxidase (MAO) with psychostimulant and neuroprotective effects. "( Effects of high-dose selegiline on morphine reinforcement and precipitated withdrawal in dependent rats.
Grasing, K; He, S, 2005
)
2.09
"Selegiline (L-deprenyl) is a selective irreversible monoamine oxidase B inhibitor shown to be effective in the treatment of Parkinson's and Alzheimer's diseases. "( A comprehensive assessment of the safety of intravenous methamphetamine administration during treatment with selegiline.
Anderson, A; Bloch, DA; Chiang, N; De La Garza, R; Elkashef, A; Fong, T; Holmes, TH; Newton, TF, 2005
)
1.98
"Selegiline is a monamine oxidase type B (MAO-B) inhibitor that incorporates a propargyl ring within its molecular structure."( Rationale for considering that propargylamines might be neuroprotective in Parkinson's disease.
Olanow, CW, 2006
)
1.06
"Selegiline is an irreversible selective inhibitor of monoamine oxidase type B (MAO-B) which may affect cocaine addiction through several potential mechanisms."( Double-blind, placebo-controlled trial of selegiline transdermal system (STS) for the treatment of cocaine dependence.
Boardman, K; Chiang, N; Collins, J; Elkashef, A; Fudala, PJ; Gorgon, L; Jones, K; Kahn, R; Li, SH; Sather, M; Vocci, F, 2006
)
1.32
"Selegiline is an inhibitor of type B monoamine oxidase (MAO) with psychostimulant effects that can decrease morphine-reinforced and non-reinforced responding. "( L-methamphetamine and selective MAO inhibitors decrease morphine-reinforced and non-reinforced behavior in rats; Insights towards selegiline's mechanism of action.
Grasing, K; He, S, 2006
)
1.98
"Selegiline is an MAO-B inhibitor with antioxidant and neurotrophic properties."( A multicenter trial of selegiline transdermal system for HIV-associated cognitive impairment.
Clifford, DB; Ellis, RJ; Evans, SR; Hung, VL; Katzenstein, D; Kolson, D; Marra, CM; Millar, LL; Miller, EN; Remmel, R; Sacktor, N; Schifitto, G; Simpson, D; Singer, E; Smith, E; Valcour, V; Weihe, J; Zhang, J, 2007
)
1.37
"Selegiline is a selective and irreversible monoamine B inhibitor with the capacity to increase the level of several antioxidative enzymes in rat brain. "( Monoamine oxidase B inhibitor selegiline protects young and aged rat peripheral sympathetic neurons against 6-hydroxydopamine-induced neurotoxicity.
Haapalinna, A; Heinonen, E; Hervonen, A; Salonen, T; Suhonen, J, 1996
)
2.03
"Selegiline is a relatively selective inhibitor of monoamine oxidase type B that has been used in Parkinson's disease as an adjunct to levodopa and as putative neuroprotective therapy. "( Deprenyl in the treatment of Parkinson's disease: clinical effects and speculations on mechanism of action.
Olanow, CW, 1996
)
1.74
"Selegiline is a selective, irreversible inhibitor of monoamine oxidase type B. "( Selegiline in treatment of behavioral and cognitive symptoms of Alzheimer disease.
Fuller, MA; Tolbert, SR, 1996
)
3.18
"Selegiline, at low dose, is a selective monoamine oxidase inhibitor type B (MAOI-B)."( Selegiline in ADHD adults: plasma monoamines and monoamine metabolites.
Eisenhofer, G; Ernst, M; Jons, PH; Liebenauer, LL; Murphy, DL; Tebeka, D; Zametkin, AJ, 1997
)
2.46
"Selegiline is a selective monoamine oxidase inhibitor used in the treatment of Parkinson's disease. "( Retrospective study of selegiline-antidepressant drug interactions and a review of the literature.
Alexander, B; Ritter, JL, 1997
)
2.05
"Selegiline is an irreversible inhibitor of monoamine oxidase type B (MAO-B). "( Inhibition of platelet monoamine oxidase type B by selegiline.
Anttila, MI; Heinonen, EH; Lammintausta, RA; Nyman, LM; Pyykkö, KA; Vuorinen, JA, 1997
)
1.99
"Selegiline is a selective inhibitor of monoamine oxidase-B (MAO-B) at a dose of 10 mg/day and is given to patients with Parkinson's disease as an adjunct to levodopa therapy. "( Clinical pharmacokinetics and pharmacodynamics of selegiline. An update.
Mahmood, I, 1997
)
1.99
"Selegiline (SEL) is a selective, irreversible inhibitor of MAO-B, used in the treatment of Parkinson's disease, either alone or as an adjunct to L-DOPA. "( Integrated pharmacokinetic and metabolic modeling of selegiline and metabolites after transdermal administration.
Barrett, JS; DeWitt, KE; Morales, RJ; Rohatagi, S, 1997
)
1.99
"Selegiline is a monoamine oxidase-B inhibitor; once thought to affect the pathogenesis of idiopathic parkinsonism, it is now known to offer only symptomatic relief."( Early idiopathic parkinsonism: initiation and optimization of treatment.
Calne, DB, 1994
)
1.01
"Selegiline is a selective, irreversible inhibitor of MAO-B, used in the treatment of Parkinson's disease, either alone or as an adjunct to L-DOPA. "( Pharmacokinetic evaluation of a selegiline pulsatile oral delivery system.
Barrett, JS; DeWitt, KE; Lessard, D; Morales, RJ; Rohatagi, S, 1997
)
2.02
"Selegiline is an irreversible inhibitor of monoamine oxidase B with trophic and neuroprotective effects. "( Selegiline prevents long-term changes in dopamine efflux and stress immobility during the second and third weeks of abstinence following opiate withdrawal.
Ghosh, S; Grasing, K, 1998
)
3.19
"Selegiline (deprenyl) is a selective, irreversible cerebral monoamine oxidase type B inhibitor (MAO-B) that is used in the treatment of Parkinson's disease. "( Selegiline: an appraisal of the basis of its pharmacoeconomic and quality-of-life benefits in Parkinson's disease.
Bryson, HM; Chrisp, P; Milne, RJ, 1992
)
3.17
"Selegiline is a centrally acting sympatholytic agent with neuroprotective properties. "( Selegiline improves cardiac sympathetic terminal function and beta-adrenergic responsiveness in heart failure.
Dong, E; Kawai, H; Liang, CS; Shite, J; Stevens, SY, 2000
)
3.19
"Selegiline (l-deprenyl) is an irreversible monoamine oxidase B (MAO-B) inhibitor that is suggested to have neuroprotective and neuronal rescuing properties. "( Selegiline combined with enriched-environment housing attenuates spatial learning deficits following focal cerebral ischemia in rats.
Haapalinna, A; Jolkkonen, J; Puurunen, K; Sirviö, J; Sivenius, J, 2001
)
3.2
"Selegiline (L-deprenyl) is a selective monoamine oxidase B (MAO-B) inhibitor used in the treatment of Parkinson's disease. "( Selegiline treatment facilitates recovery after stroke.
Aaltonen, H; Heinonen, E; Kilkku, O; Reinikainen, K; Sarasoja, T; Sivenius, J, 2001
)
3.2
"Selegiline (1-deprenyl) is an irreversible inhibitor of monoamine oxidase (MAO) type B. "( A review of the pharmacology of selegiline.
Heinonen, EH; Lammintausta, R, 1991
)
2.01
"Selegiline (deprenyl) is a selective inhibitor of cerebral monoamine oxidase type B at the dosage (10 mg/day) used in patients with Parkinson's disease. "( Selegiline. A review of its pharmacology, symptomatic benefits and protective potential in Parkinson's disease.
Chrisp, P; Mammen, GJ; Sorkin, EM, 1991
)
3.17
"Selegiline is a relatively new antiparkinson's drug whose metabolites include methamphetamine and amphetamine. "( Postmortem tissue methamphetamine concentrations following selegiline administration.
Meeker, JE; Reynolds, PC,
)
1.82
"Selegiline is a selective, irreversible inhibitor of monoamine oxidase type B (MAO-B). "( Selegiline in the treatment of Parkinson's disease.
Heinonen, EH; Rinne, UK, 1989
)
3.16
"Selegiline is a useful adjuvant drug in the treatment of Parkinson's disease. "( Selegiline in the early and late phases of Parkinson's disease.
Csanda, E; Tárczy, M, 1987
)
3.16

Effects

Selegiline has a small but significant therapeutic effect in CFS which appears independent of an antidepressant effect. It has a long-term beneficial effect in Alzheimer's disease on memory modalities that reflect the function of the prefrontal areas.

Selegiline has neuroprotective rather than neurorescue or neurorestorative effects on MPTP-induced nigrostriatal dopaminergic neuronal degeneration, which is directly pertinent to its selective and irreversible inhibition of brain MAO-B activity. SeLegiline monotherapy has been clearly demonstrated to delay the development of disability in early, otherwise untreated Parkinson's disease patients.

ExcerptReferenceRelevance
"Selegiline has a small but significant therapeutic effect in CFS which appears independent of an antidepressant effect."( Single-blind, placebo phase-in trial of two escalating doses of selegiline in the chronic fatigue syndrome.
Bergen, M; Cheu, J; Dahl, K; Denny, T; Hill, N; Korn, L; Natelson, BH, 1998
)
1.98
"Selegiline has a long-term beneficial effect in Alzheimer's disease on memory modalities that reflect the function of the prefrontal areas of the brain, which are rich in dopamine receptors. "( Selegiline in the treatment of Alzheimer's disease: a long-term randomized placebo-controlled trial. Czech and Slovak Senile Dementia of Alzheimer Type Study Group.
Filip, V; Kolibás, E, 1999
)
3.19
"Selegiline has a favourable beneficial effect in reducing the mild forms of response fluctuations."( Selegiline in the early and late phases of Parkinson's disease.
Csanda, E; Tárczy, M, 1987
)
2.44
"Selegiline therapy has been previously described but not commonly used for PDH treatment."( Assessment of selegiline and trilostane combined therapy efficacy for canine pituitary-dependent hypercortisolism treatment: A pilot randomized clinical trial.
da Silva Mello, FP; da Silva, CC; de Carvalho, GLC; de Faria Valle, S; de Moura Martins, FS; Furtado, PV; Machado, L; Meirelles, L; Neto, WS; Pöppl, ÁG, 2022
)
1.8
"Selegiline has been found to have neuroprotective properties and may be useful for the expression of neurotrophins."( Effect of selegiline as a monomine oxidase B inhibitor on the expression of neurotrophin mRNA levels in a contusion rat model of spinal cord injury.
Abdanipour, A; Anarkooli, IJ; Mirzaei, M; Mohammadi, P, 2023
)
2.03
"Selegiline hydrochloride has shown promising results in the treatment of neurosensory disorders resulting from maxillary orthognathic surgery."( Effectiveness of Selegiline Hydrochlorate in Treating Neurosensory Disorders of the Lower Alveolar Nerve Resulting From Mandibular Sagittal Osteotomy: Preliminary Study.
Amorim Gomes, AC; da Silva Mesquita, B; de Souza Andrade, ES; do Egito Vasconcelos, BC, 2020
)
2.34
"Selegiline has been reviewed looking for neuroprotection, but studies have been unable to come to a definite positive neuroprotection conclusion."( Selegiline and rasagiline: twins or distant cousins?
Knudsen Gerber, DS, 2011
)
2.53
"Selegiline has been proposed as a treatment for cocaine addiction and studies in humans suggest that it attenuates cocaine's reinforcing effects. "( Selegiline potentiates cocaine-induced increases in rodent nucleus accumbens dopamine.
Azmoodeh, M; Dewey, SL; Fowler, JS; Gerasimov, M; Schiffer, WK; Volkow, ND, 2003
)
3.2
"Selegiline has been formulated in an acrylic polymer adhesive mixture to be employed as a constant release topical patch for daily transdermal administration. "( Daily transdermal administration of selegiline to guinea-pigs preferentially inhibits monoamine oxidase activity in brain when compared with intestinal and hepatic tissues.
Azzaro, AJ; Cole, D; Mawhinney, M, 2003
)
2.04
"Selegiline treatment has shortened significantly the reaction times and has improved mnesic capacities."( [Effectiveness and tolerability of selegiline in the treatment of pathological cerebral involutions].
Bettini, R; Gorini, M,
)
1.13
"Selegiline has been shown to be efficacious in Parkinson's disease, global ischemia, Gille de la Tourette syndrome, and narcolepsy."( Therapeutic efficacy of selegiline in neurodegenerative disorders and neurological diseases.
Brown-Borg, H; Carlson, EC; Ebadi, M; El ReFaey, H; Ren, J; Sharma, S; Shavali, S, 2006
)
1.36
"Selegiline has demonstrated efficacy as monotherapy in patients with early PD (Deprenyl and Tocopherol Antioxidative Therapy of Parkinsonism study), but evidence of selegiline efficacy as adjunctive treatment in levodopa-treated PD patients with motor fluctuations is equivocal."( Monamine oxidase inhibitors: current and emerging agents for Parkinson disease.
Chen, JJ; Fernandez, HH,
)
0.85
"Selegiline has moreover a detoxicating potential and the ability to block the transformation of some protoxins into an effective toxin."( [Selegiline in the treatment of Alzheimer's disease].
Obenberger, J; Roth, J, 1995
)
1.92
"Selegiline (L-deprenyl) has been shown to delay the need to initiate levodopa therapy in early PD, and selegiline has also been suggested to increase the survival of PD patients."( Nigral degeneration in Parkinson's disease.
Rinne, JO, 1993
)
1.01
"Selegiline (L-deprenyl) has been recommended as an antiparkinsonian drug to be used as an adjunct to therapy with L-dopa, if and when L-dopa starts to lose its effect. "( Selegiline in de novo parkinsonian patients: the Finnish study.
Heinonen, EH; Myllylä, VV; Sotaniemi, KA; Vuorinen, JA, 1993
)
3.17
"Selegiline, however, has been found to rescue neurons in MPP(+)-treated mice after they have sustained lethal damage independently of monoamine oxidase-B inhibition."( Selegiline is neuroprotective in primary brain cultures treated with 1-methyl-4-phenylpyridinium.
Chen, TS; Koutsilieri, E; Rausch, WD; Riederer, P, 1996
)
2.46
"As selegiline has been shown to reduce the number of sleep attacks in nacrolepsy, we tested whether hypersomnolence in myotonic dystrophy would respond to the same treatment."( Selegiline in the treatment of hypersomnolence in myotonic dystrophy: a pilot study.
Antonini, G; Fiorelli, M; Fiorini, M; Giubilei, F; Morino, S, 1997
)
2.25
"Selegiline (L-deprenyl) has shown neuroprotective effects in a variety of degenerative processes. "( Selegiline treatment after transient global ischemia in gerbils enhances the survival of CA1 pyramidal cells in the hippocampus.
Haapalinna, A; Kauppinen, R; Keinänen, R; Koistinaho, J; Lahtinen, H; Sivenius, J, 1997
)
3.18
"Selegiline also has pronounced symptomatic motor effects in advanced Parkinson's disease."( Autonomic effects of selegiline: possible cardiovascular toxicity in Parkinson's disease.
Boonkongchuen, P; Churchyard, A; Lees, AJ; Mathias, CJ, 1997
)
1.34
"Selegiline has a small but significant therapeutic effect in CFS which appears independent of an antidepressant effect."( Single-blind, placebo phase-in trial of two escalating doses of selegiline in the chronic fatigue syndrome.
Bergen, M; Cheu, J; Dahl, K; Denny, T; Hill, N; Korn, L; Natelson, BH, 1998
)
1.98
"Selegiline has been well tolerated when given alone."( Safety of selegiline (deprenyl) in the treatment of Parkinson's disease.
Heinonen, EH; Myllylä, V, 1998
)
1.42
"Selegiline has a long-term beneficial effect in Alzheimer's disease on memory modalities that reflect the function of the prefrontal areas of the brain, which are rich in dopamine receptors. "( Selegiline in the treatment of Alzheimer's disease: a long-term randomized placebo-controlled trial. Czech and Slovak Senile Dementia of Alzheimer Type Study Group.
Filip, V; Kolibás, E, 1999
)
3.19
"Selegiline has neuroprotective rather than neurorescue or neurorestorative effects on MPTP-induced nigrostriatal dopaminergic neuronal degeneration, which is directly pertinent to its selective and irreversible inhibition of brain MAO-B activity."( Neuroprotective rather than neurorescue or neurorestorative effect of selegiline against MPTP-induced dopaminergic toxicity.
Guan, HJ; Ji, XQ; Wang, RG; Wu, WR; Zhu, XZ, 1999
)
1.98
"Selegiline monotherapy has been clearly demonstrated to delay the development of disability in early, otherwise untreated Parkinson's disease patients. "( Does selegiline monotherapy in Parkinson's disease act by symptomatic or protective mechanisms?
Calne, D; Olanow, CW, 1992
)
2.24
"Selegiline has been used in the therapy of Parkinson's disease since 1986."( Selegiline--an overview of its role in the treatment of Parkinson's disease.
Szelenyi, I; Wessel, K, 1992
)
2.45
"Selegiline has a favourable beneficial effect in reducing the mild forms of response fluctuations."( Selegiline in the early and late phases of Parkinson's disease.
Csanda, E; Tárczy, M, 1987
)
2.44
"Selegiline also has mild L-dopa sparing effects (100-200 mg per day) and it may also increase alertness, drive and motivation (Lees et al., 1977)."( Current controversies in the use of selegiline hydrochloride.
Lees, AJ, 1987
)
1.27

Actions

ExcerptReferenceRelevance
"(6) Selegiline can cause a serotoninergic syndrome and arterial hypertension, so must not be combined with pethidine, tramadol, bupropion, sumatriptan, zolmitriptan or naratriptan."( Selegiline: a second look. Six years later: too risky in Parkinson's disease.
, 2002
)
2.24

Treatment

Selegiline or levodopa treatment has been suggested as a therapeutic method for Parkinson's disease (PD)

ExcerptReferenceRelevance
"Selegiline or levodopa treatment has been suggested as a therapeutic method for Parkinson's disease (PD) in many clinical trial reports. "( Comparison of selegiline and levodopa combination therapy versus levodopa monotherapy in the treatment of Parkinson's disease: a meta-analysis.
Chen, XB; Jiang, DQ; Jiang, LL; Li, MX; Zhou, XW, 2020
)
2.36
"Selegiline-treated smokers with the CHRNA5 rs680244 GG genotype had lower post-quit craving, and unlike placebo-treated GG-carrying smokers, did not experience a post-quit increase in depressive symptoms."( Response to Transdermal Selegiline Smoking Cessation Therapy and Markers in the 15q24 Chromosomal Region.
Ameli, N; Fortmann, SP; Killen, JD; Lazzeroni, LC; Murphy, GM; Ryan, HS; Sarginson, JE; Schatzberg, AF, 2015
)
1.45
"Selegiline treatment continued throughout behavioral testing."( Effects of HIV/TAT protein expression and chronic selegiline treatment on spatial memory, reversal learning and neurotransmitter levels in mice.
Kesby, JP; Markou, A; Semenova, S, 2016
)
1.41
"Selegiline treatment had no significant protective effect."( Neuroprotection by rasagiline in thiamine deficient rats.
Cohen, S; Dror, V; Eliash, S; Rehavi, M, 2009
)
1.07
"Selegiline treatment significantly increased BDNF levels in the anterior cingulate cortex (1.55 +/- 0.22, P < 0.05, Student's t-test)."( Regulation of brain-derived neurotrophic factor (BDNF) and cerebral dopamine neurotrophic factor (CDNF) by anti-parkinsonian drug therapy in vivo.
Castrén, E; Gyárfás, T; Knuuttila, J; Lindholm, P; Rantamäki, T, 2010
)
1.08
"Selegiline treatment prevented the increase of liver fat in the group fed with lipid-rich diet."( The effect of selegiline on total scavenger capacity and liver fat content: a preliminary study in an animal model.
Adler, I; Bekesi, G; Dinya, E; Lengyel, G; Magyar, K; Marczell, I; Nagy-Repas, P; Racz, K; Schaff, Z; Stark, J; Szombath, D; Tulassay, Z, 2012
)
1.46
"Selegiline treatment had independent effects as a predictor of death at 8 year follow-up with a hazard ratio of 2.54 (95% CI 1.51, 4.25) but had beneficial effects on disability with a hazard ratio of 0.363 (95% CI 0.132, 0.533) and depression with a hazard ratio of 0.372 (95% CI 0.12, 0.552)."( Disease progress and response to treatment as predictors of survival, disability, cognitive impairment and depression in Parkinson's disease.
Holford, NH; Nutt, JG; Vu, TC, 2012
)
1.1
"The selegiline treatment did not produce a significant increase, though it tended to such as effect, in a brain-derived neurotrophic factor (BDNF) level in the retina, when compared with the NMDA-treated control group."( Protective effects of selegiline and desmethylselegiline against N-methyl-D-aspartate-induced rat retinal damage.
Akaike, A; Honda, Y; Kashii, S; Katsuki, H; Kobayashi, Y; Kume, T; Muraoka, S; Takahata, K; Yoneda, F, 2003
)
1.11
"Selegiline treatment in chronic heart failure animals reduced plasma norepinephrine, cardiac oxidative stress and myocyte apoptosis, prevented the changes of Bcl-2 and Bcl-2 to Bax ratio, and improved left ventricular fractional shortening and dP/dt."( Selegiline attenuates cardiac oxidative stress and apoptosis in heart failure: association with improvement of cardiac function.
Liang, CS; Mao, W; Qin, F; Shite, J, 2003
)
2.48
"Selegiline treatment has shortened significantly the reaction times and has improved mnesic capacities."( [Effectiveness and tolerability of selegiline in the treatment of pathological cerebral involutions].
Bettini, R; Gorini, M,
)
1.13
"Selegiline treatment did not enhance any of the cardiovascular changes (heart rate, blood pressure) produced by methamphetamine administration."( A comprehensive assessment of the safety of intravenous methamphetamine administration during treatment with selegiline.
Anderson, A; Bloch, DA; Chiang, N; De La Garza, R; Elkashef, A; Fong, T; Holmes, TH; Newton, TF, 2005
)
1.26
"Selegiline treatment increased the number of motoneurons surviving axotomy from 24 to 52%, showing that selegiline can rescue neurons by partially compensating for the loss of target-derived trophic support."( Selegiline can mediate neuronal rescue rather than neuronal protection.
Tatton, WG, 1993
)
2.45
"Selegiline pretreatment protected SCG neurons and their postganglionic nerve fibers in SMG against these changes in a dose-dependent manner."( Monoamine oxidase B inhibitor selegiline protects young and aged rat peripheral sympathetic neurons against 6-hydroxydopamine-induced neurotoxicity.
Haapalinna, A; Heinonen, E; Hervonen, A; Salonen, T; Suhonen, J, 1996
)
1.3
"Selegiline, used in the treatment of Parkinson's disease, inhibits the intracerebral degradation of dopamine and the uptake of catecholamines. "( Bioequivalence evaluation of two preparations containing the highly variable compound selegiline (L-deprenyl).
Ludwig, G; Michaelis, K; Pabst, G; Reh, C; Waitzinger, J, 1996
)
1.96
"Selegiline treatment was not more effective than placebo."( Selegiline in adults with attention deficit hyperactivity disorder: clinical efficacy and safety.
Cohen, RM; Ernst, M; Jons, PH; Liebenauer, LL; Tebeka, D; Zametkin, AJ, 1996
)
2.46
"Selegiline-treated patients require less levodopa and have a delay in the progression of parkinsonian signs and symptoms."( Attempts to obtain neuroprotection in Parkinson's disease.
Olanow, CW, 1997
)
1.02
"Selegiline treatment alone had no significant influence on striatal FDOPA metabolism."( Striatal 6-[18F]fluorodopa accumulation after combined inhibition of peripheral catechol-O-methyltransferase and monoamine oxidase type B: differing response in relation to presynaptic dopaminergic dysfunction.
Bergman, JR; Haaparanta, MT; Oikonen, VJ; Rinne, JO; Rinne, UK; Ruotsalainen, UH; Ruottinen, HM; Solin, OH, 1997
)
1.02
"Selegiline treatment had no significant effect on the rate of clinical progression or outcome of ALS."( Selegiline is ineffective in a collaborative double-blind, placebo-controlled trial for treatment of amyotrophic lateral sclerosis.
Appel, SH; Appel, V; Diamond, B; Lai, EC; Lange, DJ; Murphy, PL; Younger, DS, 1998
)
3.19
"Selegiline treatment also altered glucose utilization (normalized against whole brain counts) in the two limbic regions, but not the thalamus."( Selegiline effects on cocaine-induced changes in medial temporal lobe metabolism and subjective ratings of euphoria.
Bartzokis, G; Beckson, M; Bridge, TP; Foster, JA; Ling, W; Mandelkern, M; Mintz, J; Newton, T, 1999
)
2.47
"Selegiline pretreatment prevented the depletion of noradrenaline (NA) induced by DSP-4 in the rat hippocampus."( Neuroprotective and neuronal rescue effects of selegiline: review.
Haberle, D; Magyar, K, 1999
)
1.28
"Selegiline treatment for 3, 7, 14, or 21 days decreased tyrosine hydroxylase (the enzyme that catalyzes the rate-limiting step in catecholamine biosynthesis) activity in the cell body regions (substantia nigra) of the nigrostriatal pathway."( Chronic selegiline administration transiently decreases tyrosine hydroxylase activity and mRNA in the rat nigrostriatal pathway.
Azzaro, AJ; Vrana, KE; Vrana, SL, 1992
)
1.44
"Selegiline treatment allowed a significant reduction of the necessary daily levodopa dose in both parts of the study and of the daily dosing frequency in the long-term investigation."( Selegiline and levodopa in early or moderately advanced Parkinson's disease: a double-blind controlled short- and long-term study.
Boesen, F; Dupont, E; Heinonen, E; Mikkelsen, B; Mogensen, P; Rasmussen, C; Sivertsen, B, 1989
)
2.44
"Treatment with selegiline significantly reduced total UPDRS score from week 4 (mean ± SD, -2.62 ± 3.83; P < 0.0001) to week 56 (-3.39 ± 9.27; P < 0.01)."( Long-Term Selegiline Monotherapy for the Treatment of Early Parkinson Disease.
Hattori, N; Kondo, T; Mizuno, Y; Nomoto, M; Origasa, H; Takahashi, R; Yamamoto, M; Yanagisawa, N,
)
0.87
"Treatment with selegiline (1 or 5 mg/kg p.o."( Cardiovascular baroreceptor activity and selective inhibition of monoamine oxidase.
Bar-Am, O; Finberg, JP; Friedman, R; Gross, A, 2012
)
0.72
"Pretreatment with selegiline or metallothionein suppressed 1-methyl-4-phenylpyridinium ion-, 6-hydroxydopamine-, and rotenone-induced increases in mitochondrial 8-hydroxy-2-deoxyguanosine accumulation."( Metallothionein attenuates 3-morpholinosydnonimine (SIN-1)-induced oxidative stress in dopaminergic neurons.
Ebadi, M; Sharma, SK, 2003
)
0.64
"Treatment with selegiline in doses up to 20 mg/d led to marked improvement of the gait disorder."( Treatment of primary progressive freezing of gait with high doses of selegiline.
Cersósimo, MG; Díaz, S; Lester, J; Micheli, FE; Zúñiga, C,
)
0.71
"Pretreatment with selegiline and desmethylselegiline increased inhibition (IC(50)) in microsomes by 3.3- and 6.1-fold, respectively."( Selegiline is a mechanism-based inactivator of CYP2A6 inhibiting nicotine metabolism in humans and mice.
Siu, EC; Tyndale, RF, 2008
)
2.11
"Treatment with selegiline, 10 mg per day, which blocks irreversibly monoaminooxidase type B, when administered on a long-term basis, revealed improvement of cognitive functions and of general functional fitness during objective examinations by means of a battery of psychometric tests."( [Selegiline in the treatment of Alzheimer's disease].
Obenberger, J; Roth, J, 1995
)
1.54
"Treatment with selegiline produced profound hypoglycemia in a 70-year-old man with Parkinson's disease. "( Hypoglycemia caused by selegiline, an antiparkinsonian drug: can such side effects be predicted?
Bransome, ED; Hendry, LB; Rowland, MJ, 1994
)
0.95
"Pretreatment with selegiline can protect neurons against a variety of neurotoxins, such as 1-methyl-4-phenyl-1,2,3,6 tetrahydropyridine (MPTP), 6-hydroxydopamine, N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine (DSP-4), methyl-beta-acetoxyethyl-2-chloroethylamine (AF64A), and 5,6-dihydroxyserotonin, which damage dopaminergic, adrenergic, cholinergic, and sertoninergic neurons, respectively."( Neuroprotective actions of selegiline.
Ebadi, M; El Refaey, H; Sharma, S; Shavali, S, 2002
)
0.94
"Treatment with selegiline might retard the death of nigral neurons, but further studies are needed to confirm the preliminary findings."( Nigral degeneration in Parkinson's disease in relation to clinical features.
Rinne, JO, 1991
)
0.62

Toxicity

The objective of this analysis is to present the safety profile of selegiline transdermal system (STS) in clinical practice after US Food and Drug Administration approval. The side effect of antidepressant monoamine oxidase inhibitors was well documented in 1959-1968 publications.

ExcerptReferenceRelevance
" Adverse effects are common, however."( Deprenyl in Parkinson's disease: mechanisms, neuroprotective effect, indications and adverse effects.
Grimes, D; Mohr, E; Vezina, P, 1992
)
0.28
" LD50 values of three of these compounds were assessed after intraperitoneal administration with a special emphasis on interactions with drugs increasing catecholaminergic neurotransmission."( Acute toxicity of three new selective COMT inhibitors in mice with special emphasis on interactions with drugs increasing catecholaminergic neurotransmission.
Männistö, PT; Törnwall, M, 1991
)
0.28
"The toxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), its oxidized metabolite, and two recently synthesized 2'-alkyl derivatives of MPTP (methyl and ethyl), found to be more toxic in vivo in mice, have been compared in two neuroblastoma hybrid cell lines (NCB-20 and 140-3) that express the B form of monoamine oxidase (MAO), as tissue culture models for the mode of action of MPTP in the central nervous system."( Toxicity of MPTP and structural analogs in clonal cell lines of neuronal origin expressing B type monoamine oxidase activity.
Buckman, TD, 1991
)
0.28
" MPTP was more toxic to hepatocytes than its major metabolite, 1-methyl-4-phenylpyridine (MPP+); this may, in part, be explained by the lesser permeability of the hepatocyte plasma membrane to the cation compared to its parent compound, MPTP."( The mechanism of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity: role of intracellular calcium.
Kass, GE; Nicotera, P; Orrenius, S; Wright, JM, 1988
)
0.27
"MPTP is oxidized to its toxic metabolite MPP+ by MAO B in both primate and rodent brains and this reaction can be inhibited by (-)-deprenyl."( The role of MAO in MPTP toxicity--a review.
Gibb, C; Glover, V; Sandler, M, 1986
)
0.27
" Thus formation of a toxic metabolite by the action of MAO B may be involved in DSP-4 induced neural damage."( Inhibition of MAO B, but not MAO A, blocks DSP-4 toxicity on central NE neurons.
Gibson, CJ, 1987
)
0.27
" MPP+ is toxic to 3,4-dihydroxyphenylethylamine (dopamine, DA) neurons in explant cultures of rat embryonic midbrain."( Deprenyl protects dopamine neurons from the neurotoxic effect of 1-methyl-4-phenylpyridinium ion.
Cohen, G; Mytilineou, C, 1985
)
0.27
"Prior studies concluded that 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP, a toxin causing parkinsonism) and its analogues are bioactivated by monoamine oxidase (MAO) to toxic pyridinium metabolites."( Suppression of hydroxyl radical formation by MAO inhibitors: a novel possible neuroprotective mechanism in dopaminergic neurotoxicity.
Chiueh, CC; Huang, SJ; Murphy, DL, 1994
)
0.29
" Although this side effect of antidepressant monoamine oxidase inhibitors was well documented in 1959-1968 publications, it was not known to the manufacturer of selegiline."( Hypoglycemia caused by selegiline, an antiparkinsonian drug: can such side effects be predicted?
Bransome, ED; Hendry, LB; Rowland, MJ, 1994
)
0.8
"25 x 10(-4) M or larger, is toxic for the human neuroblastoma cell NB69."( Ascorbic acid protects against levodopa-induced neurotoxicity on a catecholamine-rich human neuroblastoma cell line.
Fahn, S; García de Yébenes, J; Mena, MA; Pardo, B, 1993
)
0.29
"8 nmol) dose-dependently injured nigral neurons as reflected by reduced dopamine levels in the ipsilateral striatum four days after the infusion of this toxic metabolite of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)."( Neuronal protective and rescue effects of deprenyl against MPP+ dopaminergic toxicity.
Chiueh, CC; Murphy, DL; Wu, RM, 1995
)
0.29
" We have assessed the toxic effects of dopamine and L-DOPA toward catecholaminergic neuroblastoma SH-SY5Y cells and whether R(-)-deprenyl and several structurally related compounds possess antioxidant effects in this system."( R(-)-deprenyl potentiates dopamine-induced cytotoxicity toward catecholaminergic neuroblastoma SH-SY5Y cells.
Lai, CT; Yu, PH, 1997
)
0.3
"The aim of the present study was to assess the toxic potential of drugs of abuse and other neuropharmacological agents in the pathogenesis of AIDS dementia complex (ADC), the neurological complication of AIDS."( Regulation of glutathione and cell toxicity following exposure to neurotropic substances and human immunodeficiency virus-1 in vitro.
Demuth, M; Götz, ME; Koutsilieri, E; Riederer, P; Sauer, U; Sopper, S; ter Meulen, V, 1997
)
0.3
" As the first MAO-B inhibitor approved for the treatment of Parkinson's disease, concerns were raised about the safety of the drug based on the adverse effect profiles of older, nonselective MAO inhibitors."( Safety of selegiline (deprenyl) in the treatment of Parkinson's disease.
Heinonen, EH; Myllylä, V, 1998
)
0.7
" Side effect profiles were similar for STS and placebo with the exception of application-site reaction, which was observed in 31."( A double-blind, placebo-controlled trial of the safety and efficacy of selegiline transdermal system without dietary restrictions in patients with major depressive disorder.
Amsterdam, JD, 2003
)
0.55
" However, there have been reports of patients experiencing adverse events with related agents."( Safety of selegiline with cold medications.
Jacob, JE; Sage, JI; Wagner, ML, 2003
)
0.72
" If selegiline is used with these medications, watch for adverse events or replace selegiline with another drug."( Safety of selegiline with cold medications.
Jacob, JE; Sage, JI; Wagner, ML, 2003
)
1.28
"There is no evidence that sublingual selegiline reduces the risk of adverse effects associated with oral selegiline."( Sublingual selegiline: new formulation. New formulation: new risk of oral adverse effects.
, 2003
)
0.98
" Twenty-four drug-related adverse events were recorded of which four were regarded as serious."( Efficacy and safety of high-dose cabergoline in Parkinson's disease.
Ludolph, A; Odin, P; Oehlwein, C; Polzer, U; Renner, R; Schüler, P; Shing, M; Storch, A; Werner, G, 2006
)
0.33
" In general, adverse events were mild or moderate, and no subjects were discontinued due to adverse events or serious adverse events."( A comprehensive assessment of the safety of intravenous methamphetamine administration during treatment with selegiline.
Anderson, A; Bloch, DA; Chiang, N; De La Garza, R; Elkashef, A; Fong, T; Holmes, TH; Newton, TF, 2005
)
0.54
"5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects."( Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004
)
0.32
" In SH-SY5Y cells amitriptyline was severely toxic, while selegiline and paracetamol failed to show any toxic effect, and carbamazepine was only slightly toxic at the highest concentration."( The combined use of human neural and liver cell lines and mouse hepatocytes improves the predictability of the neurotoxicity of selected drugs.
Mannerström, M; Tähti, H; Toimela, T; Ylikomi, T, 2006
)
0.58
" Safety assessments included adverse events and oropharyngeal findings."( Safety and efficacy of newly formulated selegiline orally disintegrating tablets as an adjunct to levodopa in the management of 'off' episodes in patients with Parkinson's disease.
Bertoni, J; Kricorian, G; Leehey, M; Lew, MF; Pahwa, R, 2007
)
0.61
" Treatment-related adverse events occurred in 132 (52%) patients."( Safety and efficacy of newly formulated selegiline orally disintegrating tablets as an adjunct to levodopa in the management of 'off' episodes in patients with Parkinson's disease.
Bertoni, J; Kricorian, G; Leehey, M; Lew, MF; Pahwa, R, 2007
)
0.61
"A comprehensive review of safety from the clinical development program suggests that the STS is safe and well tolerated, with an improved safety margin compared with orally administered MAOIs."( The selegiline transdermal system in major depressive disorder: a systematic review of safety and tolerability.
Amsterdam, JD; Robinson, DS, 2008
)
0.9
" It is known that dopamine (DA) enhances this toxic effect."( Endogenous dopamine enhances the neurotoxicity of 3-nitropropionic acid in the striatum through the increase of mitochondrial respiratory inhibition and free radicals production.
Cano, J; de Pablos, RM; Herrera, AJ; Machado, A; Navarro, A; Santiago, M; Tomás-Camardiel, M; Villarán, RF, 2008
)
0.35
"To determine whether adding orally disintegrating selegiline (ODS) while decreasing dopamine agonist (DA) dosages would reduce DA-related adverse effects (AEs) of excessive daytime sleepiness (EDS), pedal edema, hallucinations, and impulse control disorders (ICDs) without compromising efficacy in Parkinson disease (PD) patients."( Orally disintegrating selegiline in Parkinson patients with dopamine agonist-related adverse effects.
Elmer, LW; Friedman, JH; Hauser, RA; Hermanowicz, N; Hersh, BP; Isaacson, SH; Lew, MF; Lyons, KE; Pahwa, R; Parashos, SA; Silver, DE; Struck, LK; Tetrud, JW,
)
0.7
"The objective of this analysis is to present the safety profile of selegiline transdermal system (STS) in clinical practice after US Food and Drug Administration approval by analyzing reported postmarketing adverse events (AEs)."( Safety of selegiline transdermal system in clinical practice: analysis of adverse events from postmarketing exposures.
Bodkin, JA; Pae, CU; Patkar, AA; Portland, KB; Thase, ME, 2012
)
1.02
"Deidentified data were obtained on AEs, regardless of causality, as collected and compiled in the pharmaceutical company's adverse event collection systems/databases after the launch of STS in the United States."( Safety of selegiline transdermal system in clinical practice: analysis of adverse events from postmarketing exposures.
Bodkin, JA; Pae, CU; Patkar, AA; Portland, KB; Thase, ME, 2012
)
0.78
" The MAO inhibitors clorgyline and deprenyl, and the SERT inhibitor fluoxetine, per se or in combination, were not able to mimic the toxic effects of MDMA in the P19-derived neurons or block the MDMA-induced cell toxicity."( Non-Serotonergic Neurotoxicity by MDMA (Ecstasy) in Neurons Derived from Mouse P19 Embryonal Carcinoma Cells.
Forsblad, A; Hashemian, S; Jacobsson, SO; Popova, D, 2016
)
0.43
" For each subgroup, changes from baseline in PD diary measures ("off" time and "on" time with and without troublesome dyskinesia), Unified Parkinson Disease Rating Scale Parts II + III scores, and adverse events were analyzed, comparing ER CD-LD with the active comparator."( Effect of Concomitant Medications on the Safety and Efficacy of Extended-Release Carbidopa-Levodopa (IPX066) in Patients With Advanced Parkinson Disease: A Post Hoc Analysis.
Gupta, S; Kell, S; Khanna, S; LeWitt, PA; Rubens, R; Verhagen Metman, L,
)
0.13
" For safety outcomes, rasagiline was associated with a higher incidence of adverse events than placebo and safinamide."( Comparative efficacy and safety of monoamine oxidase type B inhibitors plus channel blockers and monoamine oxidase type B inhibitors as adjuvant therapy to levodopa in the treatment of Parkinson's disease: a network meta-analysis of randomized controlled
Cai, G; Cai, H; Cui, Y; Feng, T; Lin, F; Su, D; Yan, R, 2023
)
0.91
" RRs of adverse events and all-cause discontinuation were secondary and acceptability outcomes, respectively."( Efficacy and safety of selegiline across different psychiatric disorders: A systematic review and meta-analysis of oral and transdermal formulations.
Birkenhager, TK; Caiazza, C; Cattaneo, CI; de Bartolomeis, A; Fornaro, M; Gillman, K; Iasevoli, F; Rossano, F; Ruhé, HG; Sobrino, A; Solini, N; Stahl, S; Van den Eynde, V; Vellucci, A; Zotti, N, 2023
)
1.22
" MAO-B inhibitors may differ in adverse events (AEs)."( Safety comparisons among monoamine oxidase inhibitors against Parkinson's disease using FDA adverse event reporting system.
Asano, H; Hatabu, A; Ikeda, K; Takagi, T; Tian, YS; Ueda, M, 2023
)
0.91

Pharmacokinetics

Unlike oral contraceptives, HRT is not likely to have clinically significant pharmacokinetic interaction with selegiline. There is some recent evidence to suggest rasagiline also has monoamine.

ExcerptReferenceRelevance
"" Pharmacokinetic studies revealed no effect of deprenyl on the plasma levodopa concentration vs."( L-deprenyl, levodopa pharmacokinetics, and response fluctuations in Parkinson's disease.
Cedarbaum, JM; Clark, M; Harts, A; Kutt, H; Silvestri, M, 1990
)
0.28
" Currently no pharmacokinetic data are available for selegiline in the literature, mainly due to lack of analytical methods that can measure concentrations below 10 ng mL-1 in plasma."( The pharmacokinetics and absolute bioavailability of selegiline in the dog.
Mahmood, I; Mason, WD; Peters, DK, 1994
)
0.79
" The mean plasma concentration-time curves on each occasion were essentially superimposable and there were no significant differences in any calculated pharmacokinetic parameter."( The effect of selegiline on the peripheral pharmacokinetics of levodopa in young volunteers.
Macklin, BS; O'Shea, N; Renwick, AG; Roberts, J; Waller, DG, 1995
)
0.65
" This study aimed at examining whether the plasma pharmacokinetic parameters of cabergoline and selegiline are modified when given in combination."( Lack of pharmacokinetic interaction between the selective dopamine agonist cabergoline and the MAO-B inhibitor selegiline.
Bosc, M; Deffond, D; Dordain, G; Dostert, P; Fiorentini, F; La Croix, R; Persiani, S; Strolin Benedetti, M; Vernay, D, 1995
)
0.72
" A half-life of approximately 70 min was observed following the administration of either dosage form."( Pharmacokinetics and relative bioavailability of selegiline in healthy volunteers.
Mahmood, I; Marinac, JS; Mason, WD; Willsie, S, 1995
)
0.55
"The objectives of this study were to assess potential pharmacokinetic and pharmacodynamic interactions between moclobemide and selegiline."( Pharmacokinetic-pharmacodynamic interactions between two selective monoamine oxidase inhibitors: moclobemide and selegiline.
Dingemanse, J; Kettler, R; Kneer, J; Korn, A; Koulu, M; Wallnöfer, A; Zürcher, G, 1996
)
0.71
" As plasma levels of selegiline are very low and the elimination half-life is very short being about 9 minutes, therefore, a very sensitive and selective method for determining the 3 main metabolites desmethylselegiline (DMS), methamphetamine (MA) and amphetamine (A) was developed."( Pharmacokinetics and bioequivalence of the main metabolites of selegiline: desmethylselegiline, methamphetamine and amphetamine after oral administration of selegiline.
Kikuta, C; Ludwig, G; Mascher, HJ; Millendorfer, A; Schiel, H, 1997
)
0.86
" A pharmacokinetic-pharmacodynamic analysis was then used to relate these pharmacokinetic data to the results of previous microdialysis studies in which increases in extracellular dopamine were measured in the caudate-putamen after l-MeAmp (3-18 mg/kg) and after deprenyl (10 mg/kg)."( l-methamphetamine pharmacokinetics and pharmacodynamics for assessment of in vivo deprenyl-derived l-methamphetamine.
Cho, AK; Kuczenski, R; Melega, WP; Schmitz, D; Segal, DS, 1999
)
0.3
" As it became evident that the use of oral steroids had a drastic effect on selegiline concentrations, the pharmacokinetic analyses were performed separately for oral contraceptive users and those not receiving any concomitant medication."( Dose linearity study of selegiline pharmacokinetics after oral administration: evidence for strong drug interaction with female sex steroids.
Anttila, M; Helminen, A; Huupponen, R; Karnani, H; Laine, K, 1999
)
0.84
"The total AUC and Cmax of selegiline were 10-to 20-fold higher in those subjects taking oral steroids compared with subjects with no concomitant medication; this finding was consistent and statistically significant at all the four dose levels."( Dose linearity study of selegiline pharmacokinetics after oral administration: evidence for strong drug interaction with female sex steroids.
Anttila, M; Helminen, A; Huupponen, R; Karnani, H; Laine, K, 1999
)
0.91
" The pharmacokinetic profiles of selegiline and the metabolites were examined from serum samples for 24 hours (i."( Multiple-dose pharmacokinetics of selegiline and desmethylselegiline suggest saturable tissue binding.
Anttila, M; Heinonen, E; Huupponen, R; Laine, K; Mäki-Ikola, O,
)
0.69
"Unlike oral contraceptives, HRT is not likely to have clinically significant pharmacokinetic interaction with selegiline."( Effect of concomitant hormone replacement therapy containing estradiol and levonorgestrel on the pharmacokinetics of selegiline.
Anttila, M; Laine, K; Nyman, L; Palovaara, S, 2002
)
0.74
" The elimination half-life of cabergoline estimated from urinary data of healthy subjects ranges between 63 and 109 hours."( Clinical pharmacokinetics of cabergoline.
Bonuccelli, U; Del Dotto, P, 2003
)
0.32
" Concentrations of serum selegiline and its main metabolites were determined and pharmacokinetic parameters calculated."( Marked effect of liver and kidney function on the pharmacokinetics of selegiline.
Anttila, M; Pelkonen, O; Rautio, A; Sotaniemi, EA, 2005
)
0.87
"The pharmacokinetic parameters of selegiline differed considerably between the patient groups and the control subjects."( Marked effect of liver and kidney function on the pharmacokinetics of selegiline.
Anttila, M; Pelkonen, O; Rautio, A; Sotaniemi, EA, 2005
)
0.84
" Using models for disease progression and pharmacodynamic models for drug effects we have characterized the changes in UPDRS over time to determine the influence of the various drug treatments."( Disease progression and pharmacodynamics in Parkinson disease - evidence for functional protection with levodopa and other treatments.
Chan, PL; Holford, NH; Kieburtz, K; Nutt, JG; Shoulson, I, 2006
)
0.33
" This article reports results from 3 studies examining the potential for cytochrome P450-dependent pharmacokinetic interactions between STS and 3 psychotropic medications that might be coadministered."( Selegiline transdermal system: an examination of the potential for CYP450-dependent pharmacokinetic interactions with 3 psychotropic medications.
Azzaro, AJ; Campbell, BJ; Kemper, E; VanDenBerg, C; Ziemniak, J, 2007
)
1.78
" Pharmacokinetic parameters obtained following selegiline transdermal system and pseudoephedrine or phenylpropanolamine were unremarkable."( Evaluation of the potential for pharmacodynamic and pharmacokinetic drug interactions between selegiline transdermal system and two sympathomimetic agents (pseudoephedrine and phenylpropanolamine) in healthy volunteers.
Azzaro, AJ; Blob, LF; Campbell, BJ; Kemper, EM; VanDenBerg, CM; Ziemniak, J, 2007
)
0.82
" The main pharmacokinetic parameters (C(max), t(max), t1/2beta, AUC(0-6), AUC(0-infinity)) have been calculated."( Pharmacokinetic studies of (-)-deprenyl and some of its metabolites in mouse.
Lengyel, J; Magyar, K; Szatmáry, I; Szebeni, G, 2007
)
0.34
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
0.35
" A new formulation, an orally disintegrating tablet (ODT), has recently been introduced to overcome these pharmacokinetic problems by avoiding its presystemic metabolism."( The pharmacokinetic evaluation of selegiline ODT for the treatment of Parkinson's disease.
Magyar, K; Szökő, E; Tábi, T; Vécsei, L, 2013
)
0.67
"The authors summarize the pharmacokinetic and clinical efficacy data of selegiline ODT and compare them with the more conventional oral selegiline."( The pharmacokinetic evaluation of selegiline ODT for the treatment of Parkinson's disease.
Magyar, K; Szökő, E; Tábi, T; Vécsei, L, 2013
)
0.9
"Selegiline ODT shows a clear pharmacokinetic advantage over the conventional form."( The pharmacokinetic evaluation of selegiline ODT for the treatment of Parkinson's disease.
Magyar, K; Szökő, E; Tábi, T; Vécsei, L, 2013
)
2.11
" There is some recent evidence to suggest rasagiline also has monoamine oxidase-A (MAO-A) inhibiting properties, as well as different clinical and pharmacodynamic properties when compared with selegiline, and clinical benefits when used in combination with a dopamine agonist monotherapy."( Pharmacokinetic/pharmacodynamic evaluation of rasagiline mesylate for Parkinson's disease.
Müller, T, 2014
)
0.59
" Oral fluid (OF) has been successfully used as an alternative matrix for blood testing in several pharmacokinetic studies."( Pharmacokinetics of selegiline, R-methamphetamine, R-amphetamine, and desmethylselegiline in oral fluid after a single oral administration of selegiline.
Chen, L; Duan, G; Shen, B; Shi, Y; Wang, S; Xiang, P; Yan, H; Yu, Y, 2019
)
0.84

Compound-Compound Interactions

Levodopa in combination with selegiline seemed to confer no clinical benefit over levodopa alone in treating early, mild Parkinson's disease. Low dose betahistine increased cochlear microcirculation significantly when combined with seLegiline.

ExcerptReferenceRelevance
"To compare effectiveness of levodopa and levodopa combined with selegiline in treating early, mild Parkinson's disease."( Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. Parkinson's Disease Research Group of the United Kingdom.
Lees, AJ, 1995
)
0.75
"Treatment with levodopa and dopa decarboxylase inhibitor (arm 1) or levodopa and decarboxylase inhibitor in combination with selegiline (arm 2)."( Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. Parkinson's Disease Research Group of the United Kingdom.
Lees, AJ, 1995
)
0.72
"Levodopa in combination with selegiline seemed to confer no clinical benefit over levodopa alone in treating early, mild Parkinson's disease."( Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. Parkinson's Disease Research Group of the United Kingdom.
Lees, AJ, 1995
)
0.8
" Recently, selegiline's package insert was revised to reflect the potential risk of adverse effects when it is used in combination with selective serotonin reuptake inhibitors and tricyclic antidepressants."( Retrospective study of selegiline-antidepressant drug interactions and a review of the literature.
Alexander, B; Ritter, JL, 1997
)
1
" This article details those medications that may interact significantly with the SSRIs, and provides clinical guidelines for minimising the likelihood of such complications."( Drug interactions of clinical significance with selective serotonin reuptake inhibitors.
Mitchell, PB, 1997
)
0.3
" Because striatal dopamine is metabolized by COMT and monoamine oxidase (MAO), central COMT inhibition alone or in combination with MAO inhibition might provide symptomatic benefit for patients not receiving levodopa."( A pilot evaluation of the tolerability, safety, and efficacy of tolcapone alone and in combination with oral selegiline in untreated Parkinson's disease patients. Tolcapone De Novo Study Group.
Dorflinger, EE; Hauser, RA; Molho, E; Pedder, S; Shale, H, 1998
)
0.51
" Selegiline administration combined with enriched-environment housing attenuated ischemia-induced spatial learning deficits in a water-maze task and enhanced performance of both the contralateral affected and ipsilateral nonaffected forelimbs in a staircase test."( Selegiline combined with enriched-environment housing attenuates spatial learning deficits following focal cerebral ischemia in rats.
Haapalinna, A; Jolkkonen, J; Puurunen, K; Sirviö, J; Sivenius, J, 2001
)
2.66
" These results suggest that PEA in combination with l-deprenyl prolonged the duration of the stereotypy (particularly, continuous sniffing) while reducing the striatal level of dopamine."( 2-Phenylethylamine in combination with l-deprenyl lowers the striatal level of dopamine and prolongs the duration of the stereotypy in mice.
Kitanaka, J; Kitanaka, N; Takemura, M; Tatsuta, T, 2005
)
0.33
" This study examined the potential for drug-drug interactions during treatment with selegiline transdermal system and pseudoephedrine or phenylpropanolamine."( Evaluation of the potential for pharmacodynamic and pharmacokinetic drug interactions between selegiline transdermal system and two sympathomimetic agents (pseudoephedrine and phenylpropanolamine) in healthy volunteers.
Azzaro, AJ; Blob, LF; Campbell, BJ; Kemper, EM; VanDenBerg, CM; Ziemniak, J, 2007
)
0.78
"The objective of the study was to evaluate the metabolism dependent inhibition of CYP2B6 catalyzed bupropion hydroxylation in human liver microsomes by monoamine oxidase (MAO) inhibitors and to predict the drug-drug interaction potential of monoamine oxidase inhibitors as perpetrators of drug interaction."( Evaluation of metabolism dependent inhibition of CYP2B6 mediated bupropion hydroxylation in human liver microsomes by monoamine oxidase inhibitors and prediction of potential as perpetrators of drug interaction.
Bhyrapuneni, G; Manoharan, A; Mohammed, AR; Nirogi, R; Palacharla, RC; Ponnamaneni, RK, 2015
)
0.42
"Low dose betahistine increased cochlear microcirculation significantly when combined with selegiline."( Low Dose Betahistine in Combination With Selegiline Increases Cochlear Blood Flow in Guinea Pigs.
Bertlich, M; Canis, M; Freytag, S; Ihler, F; Kloos, B; Lauer, SK; Spiegel, JL; Weiss, BG, 2023
)
1.4

Bioavailability

The oral disintegrating tablet formulation of selegiline allows pregastric absorption, minimizing first-pass metabolism. The absolute bioavailability of seLegiline is approximately 10%. The area under the concentration-time curve from time 0 to 24 hours (AUC0-24) of desmethylselegi was 33 times higher than that of se Legiline.

ExcerptReferenceRelevance
" 14C-Deprenyl is well absorbed after oral or subcutaneous administration and penetrates rapidly to the central nervous system."( Pharmacokinetic aspects of deprenyl effects.
Magyar, K; Tóthfalusi, L,
)
0.13
" The pharmacokinetics and relative bioavailability of selegiline were investigated in healthy volunteers following oral administration of 10 mg tablet or solution."( Pharmacokinetics and relative bioavailability of selegiline in healthy volunteers.
Mahmood, I; Marinac, JS; Mason, WD; Willsie, S, 1995
)
0.79
" An open, randomized, 2-way cross-over study was performed in 24 healthy male volunteers to determine bioavailability and pharmacokinetic parameters of 2 oral selegiline preparations after single dose administration."( Bioequivalence evaluation of two preparations containing the highly variable compound selegiline (L-deprenyl).
Ludwig, G; Michaelis, K; Pabst, G; Reh, C; Waitzinger, J, 1996
)
0.71
"An open-label, four-way crossover, single dose pharmacokinetic study comparing the bioavailability of 10 mg selegiline hydrochloride administered to healthy young males as a solution by the oral route (in the stomach) and by a nasoenteric tube to the following three sites: duodenum, jejunum and terminal ileum was conducted."( Absorption and presystemic metabolism of selegiline hydrochloride at different regions in the gastrointestinal tract in healthy males.
Barrett, JS; De Witt, KE; Ireland, J; Morales, RJ; Rajewski, G; Rohatagi, S; Szego, P, 1996
)
0.77
"The bioavailability of two selegiline HCl (CAS 14611-52-0) tablet products was compared in a single-blind, single-dose, randomised, two-way, cross-over study with 25 healthy volunteers."( Bioavailability of two selegiline hydrochloride tablet products.
Duursema, L; Groenewoud, G; Hundt, HK; Joubert, A; Middle, MV; Muir, AR; Müller, FO; Schall, R; Swart, KJ, 1996
)
0.9
"A bioavailability study of 2 different selegiline preparations were conducted in 20 healthy volunteers to test the bioequivalence."( Pharmacokinetics and bioequivalence of the main metabolites of selegiline: desmethylselegiline, methamphetamine and amphetamine after oral administration of selegiline.
Kikuta, C; Ludwig, G; Mascher, HJ; Millendorfer, A; Schiel, H, 1997
)
0.81
" Therefore, the ratio of MAO-B inhibitory potential of intravenously and orally given selegiline is approximately 7 to 1, which fits well with the low bioavailability of the drug after oral administration."( Inhibition of platelet monoamine oxidase type B by selegiline.
Anttila, MI; Heinonen, EH; Lammintausta, RA; Nyman, LM; Pyykkö, KA; Vuorinen, JA, 1997
)
0.77
" The area under the concentration-time curve from time 0 to 24 hours (AUC0-24) of desmethylselegiline was 33 times higher than that of selegiline, suggesting a better bioavailability of desmethylselegiline."( Desmethylselegiline, a metabolite of selegiline, is an irreversible inhibitor of monoamine oxidase type B in humans.
Anttila, MI; Heinonen, EH; Karnani, HL; Lammintausta, RA; Nyman, LM; Pyykkö, KA; Vuorinen, JA, 1997
)
0.93
" The absolute bioavailability of selegiline is approximately 10%."( Clinical pharmacokinetics and pharmacodynamics of selegiline. An update.
Mahmood, I, 1997
)
0.83
"Concomitant use of oral contraceptives caused a drastic (20-fold) increase in the oral bioavailability of selegiline."( Dose linearity study of selegiline pharmacokinetics after oral administration: evidence for strong drug interaction with female sex steroids.
Anttila, M; Helminen, A; Huupponen, R; Karnani, H; Laine, K, 1999
)
0.82
"The quantitative structure-bioavailability relationship of 232 structurally diverse drugs was studied to evaluate the feasibility of constructing a predictive model for the human oral bioavailability of prospective new medicinal agents."( QSAR model for drug human oral bioavailability.
Topliss, JG; Yoshida, F, 2000
)
0.31
" Biodisposition studies on domestic pigs including dose, area, surface dependence and comparative bioavailability with traditional dosage forms and application moods."( Transdermal formulations of deprenyl: guinea pig and pig models.
Fejér, E; Gaál, J; Magyar, K; Mezei, M; Szatmári, I; Szebeni, G; Székács, G; Wágner, O, 2000
)
0.31
" The absolute bioavailability of cabergoline is unknown."( Clinical pharmacokinetics of cabergoline.
Bonuccelli, U; Del Dotto, P, 2003
)
0.32
" Bioavailability was determined using AUC and peak plasma concentrations (C(max))."( A new formulation of selegiline: improved bioavailability and selectivity for MAO-B inhibition.
Brewer, F; Clarke, A; Corn, TH; Hartig, F; Johnson, ES; Mallard, N; Taylor, S, 2003
)
0.64
" Selegiline orally disintegrating tablet dissolves in the mouth within seconds and is rapidly absorbed directly into the systemic circulation, increasing parent drug bioavailability and lowering plasma metabolites compared with conventional oral formulations."( Selegiline orally disintegrating tablets for the treatment of Parkinson's disease.
Lew, MF, 2005
)
2.68
" The Zydis formulation allows pregastric absorption of selegiline, minimizing first-pass metabolism, and thereby increasing selegiline bioavailability and reducing the concentration of amphetamine metabolites."( Monamine oxidase inhibitors: current and emerging agents for Parkinson disease.
Chen, JJ; Fernandez, HH,
)
0.38
" The drug delivery system itself can affect the bioavailability of certain drugs, which might influence the efficacy and tolerability of medications, as well as improve the compliance and reduce the incidence of recurrence and relapse."( Selegiline transdermal system: current awareness and promise.
Han, C; Lee, C; Lim, HK; Neena, A; Pae, CU; Patkar, AA, 2007
)
1.78
" Monoamine oxidase type B (MAO-B) inhibitors can be used across the spectrum of disease severity, but selegiline (deprenyl), the prototype in this class, is characterised by low and erratic bioavailability of the parent drug and conversion to amphetamine metabolites that may increase the risk of adverse events."( Community and long-term care management of Parkinson's disease in the elderly: focus on monoamine oxidase type B inhibitors.
Chen, JJ; Fernandez, HH, 2007
)
0.55
" The current study was conducted during the selegiline transdermal system development program to characterize the single-dose pharmacokinetics and absolute bioavailability of selegiline administered by the 6-mg/24-h selegiline transdermal system in healthy volunteers."( Pharmacokinetics and absolute bioavailability of selegiline following treatment of healthy subjects with the selegiline transdermal system (6 mg/24 h): a comparison with oral selegiline capsules.
Azzaro, AJ; Campbell, BJ; Kemper, E; VanDenBerg, C; Ziemniak, J, 2007
)
0.86
" This new formulation provides higher drug bioavailability and a substantially reduced concentration of active metabolites."( Zydis selegiline in the management of Parkinson's disease.
Poston, KL; Waters, C, 2007
)
0.82
" (-)-Deprenyl is well absorbed after oral and parental treatment."( Pharmacokinetic studies of (-)-deprenyl and some of its metabolites in mouse.
Lengyel, J; Magyar, K; Szatmáry, I; Szebeni, G, 2007
)
0.34
" The oral disintegrating tablet formulation of selegiline allows pregastric absorption, minimizing first-pass metabolism, thereby increasing selegiline bioavailability and reducing the concentration of amphetamine metabolites."( Monoamine oxidase-B inhibition in the treatment of Parkinson's disease.
Chen, JJ; Fernandez, HH, 2007
)
0.6
"The present study was designed to investigate the involvement of monoaminergic system(s) in the antidepressant activity of curcumin and the effect of piperine, a bioavailability enhancer, on the bioavailability and biological effects of curcumin."( Antidepressant activity of curcumin: involvement of serotonin and dopamine system.
Bhutani, MK; Bishnoi, M; Kulkarni, SK, 2008
)
0.35
" The clinical value of conventional selegiline is, however, compromised by extensive first-pass metabolism, which reduces its bioavailability and leads to the production of possibly harmful methamfetamine metabolites."( Orally disintegrating selegiline for the treatment of Parkinson's disease.
Löhle, M; Storch, A, 2008
)
0.94
" Their role as possible antiaging strategies in healthy people in relation to neuroendocrine-immune responses and zinc ion bioavailability is reported and discussed."( Possible new antiaging strategies related to neuroendocrine-immune interactions.
Malavolta, M; Mocchegiani, E, 2008
)
0.35
"Oral bioavailability (F) is a product of fraction absorbed (Fa), fraction escaping gut-wall elimination (Fg), and fraction escaping hepatic elimination (Fh)."( Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV, 2010
)
0.36
" It is characterized by improved bioavailability allowing dose reduction and a lower exposure to amphetamine metabolites."( The pharmacokinetic evaluation of selegiline ODT for the treatment of Parkinson's disease.
Magyar, K; Szökő, E; Tábi, T; Vécsei, L, 2013
)
0.67
" Buccal absorption of selegiline can bypass its first-pass metabolism and improve bioavailability accompanied by greatly reduced metabolite formation, which is potentially of enhanced therapeutic value in patients with Parkinson's disease."( Development and evaluation of buccoadhesive tablet for selegiline hydrochloride based on thiolated polycarbophil.
Godse, RD; Nair, HA; Wasnik, MN, 2014
)
0.96
" The main problem associated with its oral administration is its low oral bioavailability (10%) due to its poor aqueous solubility and extensive first pass metabolism."( Design Expert(®) supported optimization and predictive analysis of selegiline nanoemulsion via the olfactory region with enhanced behavioural performance in Parkinson's disease.
Ali, J; Baboota, S; Kumar, S, 2016
)
0.67
"Selegiline hydrochloride (SL), is an anti-Parkinson's agent, has low-oral bioavailability due to its high first pass metabolism and scarce oral absorption."( Brain targeted delivery of mucoadhesive thermosensitive nasal gel of selegiline hydrochloride for treatment of Parkinson's disease.
Bajaj, A; Gaud, R; Meshram, P; Sridhar, V; Wairkar, S, 2018
)
2.16
"Selegiline, a well-known anti-Parkinson agent, is reported to be associated with poor oral bioavailability and safety."( Pharmacokinetics and pharmacodynamics of intranasally administered selegiline nanoparticles with improved brain delivery in Parkinson's disease.
Bajaj, A; Gaud, R; Sridhar, V; Wairkar, S, 2018
)
2.16
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
", Quercetin (QUR) for improving the bioavailability of the SEL in the brain via the oral route."( Lipid nanocarrier of selegiline augmented anti-Parkinson's effect via P-gp modulation using quercetin.
Ali, A; Ali, J; Ashhar, MU; Baboota, S; Qamar, Z; Qizilibash, FF; Sahoo, PK, 2021
)
0.94

Dosage Studied

Transdermal selegiline treatment allowed a significant reduction of the necessary daily levodopa dose in both parts of the study. Analysis of urine samples from four horses dosed with 50 mg of seLegiline confirmed that N-desmethylselegilines is the major urinary metabolite of se Legiline in horses.

ExcerptRelevanceReference
" However, if selective inhibition is to be maintained in vivo, correct dosage schedules are critically important, since all selective MAO inhibitors described up to now lack selectivity at high doses."( The molecular pharmacology of L-deprenyl.
Gerlach, M; Riederer, P; Youdim, MB, 1992
)
0.28
"Selegiline (deprenyl) is a selective inhibitor of cerebral monoamine oxidase type B at the dosage (10 mg/day) used in patients with Parkinson's disease."( Selegiline. A review of its pharmacology, symptomatic benefits and protective potential in Parkinson's disease.
Chrisp, P; Mammen, GJ; Sorkin, EM, 1991
)
3.17
" Selegiline (also known as deprenyl), is a selective irreversible monoamine oxidase type B inhibitor virtually devoid of the tyramine reaction at the recommended dosage of 10 mg/d."( Selegiline: initial or adjunctive therapy of Parkinson's disease?
Fuller, MA; Tolbert, SR, 1991
)
2.63
" This suggests that selegiline treatment may retard the death of nigral neurons, but alternative explanations, such as the reduction of levodopa dosage in selegiline-treated patients, are possible."( Selegiline (deprenyl) treatment and death of nigral neurons in Parkinson's disease.
Paljärvi, L; Rinne, JO; Rinne, UK; Röyttä, M; Rummukainen, J, 1991
)
2.05
" The method was applied to the measurement of the dose-response curve of a reversible MAO-B inhibitor (Ro 19-6327)."( Measurement of cerebral monoamine oxidase B activity using L-[11C]deprenyl and dynamic positron emission tomography.
Bench, CJ; Cremer, JE; Frackowiak, RS; Lammertsma, AA; Luthra, SK; Price, GW; Turton, D; Wood, ND, 1991
)
0.28
" When selegiline (10 mg/day) was added in the double-blind phase the mean lisuride dosage could be reduced by 22."( Lisuride plus selegiline in the treatment of early Parkinson's disease.
Bruggi, P; Horowski, R; Martignoni, E; Nappi, G; Pacchetti, C; Rainer, E; Runge, I, 1991
)
1.12
" The dosage of carbidopa/levodopa can usually be reduced, resulting in diminished side effects."( Selegiline for Parkinson's disease.
Calesnick, B, 1990
)
1.72
" The marked between-group differences demonstrate that, at the dosage used, selegiline was far more effective than L-acetylcarnitine with respect to the degree of improvement."( Selegiline versus L-acetylcarnitine in the treatment of Alzheimer-type dementia.
Campi, N; Scarzella, L; Todeschini, GP,
)
1.8
" The doses and pretreatment times of the inhibitors used were based on an earlier reported in vivo dose-response and time-course study."( Effect of selective monoamine oxidase A and B inhibitors on footshock induced aggression in paired rats.
Bhattacharya, SK; Datla, KP, 1990
)
0.28
" Lethality after MPP+ administration almost certainly does not involve the brain, since little or no MPP+ could be measured in brain after oral or subcutaneous dosing of MPP+."( Tissue concentrations of MPTP and MPP+ after administration of lethal and sublethal doses of MPTP to mice.
Fuller, RW; Hemrick-Luecke, SK, 1990
)
0.28
" Analysis of the results demonstrates that, at the dosage used, selegiline is more effective than oxiracetam in improving higher cognitive functions and reducing impairment in daily living."( Selegiline versus oxiracetam in patients with Alzheimer-type dementia.
Falsaperla, A; Monici Preti, PA; Oliani, C,
)
1.81
" Platelet MAO activity is a useful method of monitoring bioavailability, compliance, dose-response relationship and optimal dosage schedules for L-deprenyl in Parkinson patients."( Platelet monoamine oxidase in Parkinson patients: effect of L-deprenyl therapy.
Chung, E; Dvorozniak, MT; Lee, DH; Mendoza, M; van Woert, MH; Yahr, MD, 1989
)
0.28
" Thereafter, selegiline was added in a progressively increasing dosage up to a maximum of 10 mg/day during 4 months, with the aim of a) further improving the long-term results and b) reducing the doses of the new formula of L-DOPA."( Combination of selegiline and controlled release levodopa in the treatment of fluctuations of clinical disability in parkinsonian patients.
Aljanati, R; Buzo, R; Caamaño, JL; Chouza, C; De Medina, O; Fernandez, A; Romero, S; Scaramelli, A, 1989
)
1
" Selegiline treatment allowed a significant reduction of the necessary daily levodopa dose in both parts of the study and of the daily dosing frequency in the long-term investigation."( Selegiline and levodopa in early or moderately advanced Parkinson's disease: a double-blind controlled short- and long-term study.
Boesen, F; Dupont, E; Heinonen, E; Mikkelsen, B; Mogensen, P; Rasmussen, C; Sivertsen, B, 1989
)
2.63
" Its administration with levodopa, as initial therapy, allows for use of lower dosage and less side-effects of the latter agent."( Selegiline in the treatment of Parkinson's disease--long term experience.
Elizan, TS; Moros, D; Yahr, MD, 1989
)
1.72
" Repeated dosing for 14 days did not enhance MAO-A inhibition."( SR 95191, a selective inhibitor of type A monoamine oxidase with dopaminergic properties. II. Biochemical characterization of monoamine oxidase inhibition.
Bizière, K; Kan, JP; Mouget-Goniot, C; Steinberg, R; Worms, P, 1987
)
0.27
" Administration in daily dosage of 10 mgs produces an almost complete inhibition of the enzyme."( R-(-)-deprenyl and parkinsonism.
Yahr, MD, 1987
)
0.27
" Mean daily Sinemet dosage decreases were 17% in the deprenyl group and 7% in the placebo group."( Deprenyl in the treatment of symptom fluctuations in advanced Parkinson's disease.
Ahlskog, JE; Duvoisin, RC; Foo, SH; Golbe, LI; Gopinathan, G; Lieberman, AN; Muenter, MD; Neophytides, AN, 1988
)
0.27
"Blood pressure and heart rate responses to oral tyramine have been measured in healthy volunteers before and after administration of the selective monoamine oxidase B inhibitor selegiline at high dosage (30 mg/day)."( Enhanced pressor sensitivity to oral tyramine challenge following high dose selegiline treatment.
Glover, V; Goodwin, BL; Prasad, A; Sandler, M; Signy, M; Smith, SE, 1988
)
0.7
" When given in combination with d,l-5-HTP, there was a potentiation of the down-regulation capabilities of fenfluramine at several different dosage levels; however, maximal down-regulation was also limited to 40%."( Down-regulation of [3H]5-hydroxytryptamine binding sites in chick embryo brain by monoamine oxidase inhibitors or fenfluramine and potentiation by d,l-5-hydroxytryptophan.
DuMontier, G; Jeng, I; Soblosky, JS, 1985
)
0.27
"The purpose of this double-blind placebo controlled study was to estimate how much the levodopa dosage can be reduced, when deprenyl is used, without worsening the disease and to see whether deprenyl can reduce the "off-periods"."( Deprenyl (selegiline) combined with levodopa and a decarboxylase inhibitor in the treatment of Parkinson's disease.
Hajba, A; Presthus, J, 1983
)
0.67
" In the present study we determined the time-course and dose-response effects of 6-MeO-THbetaC for blockade of AGS."( Effects of 6-methoxy-1,2,3,4-tetrahydro-beta-carboline (6-MeO-THbetaC) on audiogenic seizures in DBA/2J mice.
Buckholtz, NS; Sparks, DL, 1980
)
0.26
" In vivo dose-response curves obtained with the common substrates DA and p-TA showed approximately 20% deamination by the B enzyme."( Specificity of endogenous substrates for types A and B monoamine oxidase in rat striatum.
Azzaro, AJ; Schoepp, DD, 1981
)
0.26
" Monoamine oxidase activity associated with the soluble fraction did not show the usual biphasic dose-response kinetics with clorgyline when kynuramine was used as the substrate."( Clorgyline and deprenyl insensitive monoamine oxidase in rat brain soluble fraction.
Baquer, NZ; Mayanil, K; Shekhar, C, 1982
)
0.26
" We hypothesized that selegiline, at a dosage of 60 mg/d, would be at least partially effective but that the higher doses would not maintain the monoamine oxidase B selectivity observed with the lower doses of selegiline."( High-dose selegiline in treatment-resistant older depressive patients.
Cohen, RM; Lawlor, BA; Mellow, AM; Molchan, S; Mueller, EA; Murphy, DL; Newhouse, PA; Sunderland, T; Tariot, PN, 1994
)
1.01
"3 years) entered a double-blind, randomized, crossover study of placebo vs 3 weeks of selegiline at a dosage of 60 mg/d."( High-dose selegiline in treatment-resistant older depressive patients.
Cohen, RM; Lawlor, BA; Mellow, AM; Molchan, S; Mueller, EA; Murphy, DL; Newhouse, PA; Sunderland, T; Tariot, PN, 1994
)
0.91
" We compared the influence of dosage of CNTF and (-)-deprenyl on FMn death, weight loss, and animal survival in rat pups that underwent facial nerve transection at the 14th postnatal day (P14)."( CNTF or (-)-deprenyl in immature rats: survival of axotomized facial motoneurons and weight loss.
Guo, Q; Holland, DP; Richardson, PM; Tatton, WG; Zhang, F, 1995
)
0.29
" The present study was designed to evaluate whether long-term treatment with L-deprenyl at a dosage not inhibiting the monoamine oxidase-B (MAO-B) (1."( Effect of long-term treatment with L-deprenyl on the age-dependent microanatomical changes in the rat hippocampus.
Amenta, F; Bongrani, S; Bronzetti, E; Cadel, S; Ricci, A; Valsecchi, B; Zeng, YC, 1995
)
0.29
"Deprenyl (DPN) and its metabolites, desmethyl deprenyl (desmethyl DPN), methamphetamine (MA) and amphetamine (AP), in the hair of rats and humans dosed with DPN were analyzed by selected ion monitoring of gas chromatograph-mass spectrometry (GC-MS-SIM)."( Hair analysis for drugs of abuse. IX. Comparison of deprenyl use and methamphetamine use by hair analysis.
Kikura, R; Nakahara, Y, 1995
)
0.29
" The slow turnover of brain MAO B suggests that the current clinical dose of L-deprenyl may be excessive and that the clinical efficacy of reduced dosing should be evaluated."( Slow recovery of human brain MAO B after L-deprenyl (Selegeline) withdrawal.
Alexoff, D; Fowler, JS; Logan, J; MacGregor, RR; Pappas, N; Schyler, D; Shea, C; Volkow, ND; Wang, GJ; Wolf, AP, 1994
)
0.29
"" Although l-deprenyl itself appears to have no abuse potential, it is theoretically possible that it might potentiate the actions and frequency of dosage and use of various drugs of abuse or dependence."( Therapy with l-deprenyl (selegiline) and relation to abuse liability.
Goldstein, B; Schneider, LS; Tariot, PN, 1994
)
0.59
" In addition, treatment for a longer term tended to reduce the optimal dosage in the same animal group."( (-)Deprenyl increases the life span as well as activities of superoxide dismutase and catalase but not of glutathione peroxidase in selective brain regions in Fischer rats.
Carrillo, MC; Ivy, GO; Kanai, S; Kitani, K, 1994
)
0.29
" Significant effects were observed for sex (females showed lower overall MAO-B activity in the liver), dose (MAO-A and B inhibition increased with dose, with females exhibiting greater sensitivity), route of administration (subcutaneous injection was more efficient than oral dosing), and dosing interval (MAO-B was significantly inhibited when dosing interval was increased to as long as 168 hours)."( Monoamine oxidase inhibition by L-deprenyl depends on both sex and route of administration in the rat.
Ivy, GO; Milgram, NW; Murphy, MP; Wu, PH, 1993
)
0.29
" This type of analysis may be of therapeutic value by indicating optimal dosage of quasi-selective MAO B inhibitors for the treatment of Parkinson's disease."( Suicide inhibition of monoamine oxidases A and B by (-)-deprenyl. A computer-aided solution for determining inhibition specificity.
Batke, J; Gaál, J, 1993
)
0.29
"To examine selegiline's dosing effects, we studied 16 Parkinson disease patients with motor fluctuations in a double-blind, crossover trial of selegiline at 0, 5, and 10 mg daily."( Effects of selegiline dosing on motor fluctuations in Parkinson's disease.
Hubble, JP; Koller, WC; Waters, C, 1993
)
1.07
"We previously reported that the optimal dosage of (-)deprenyl to increase superoxide dismutase (SOD) activities in striatum in rats differs 10 fold between young male and female rats (1)."( The optimal dosage of (-)deprenyl for increasing superoxide dismutase activities in several brain regions decreases with age in male Fischer 344 rats.
Carrillo, MC; Ivy, GO; Kanai, S; Kitani, K; Nokubo, M; Sato, Y, 1993
)
0.29
" Dosage adjustments, addition of a second medication to the drug regimen, and dietary modifications may help maximize response to symptomatic therapy."( Moderate Parkinson's disease. Strategies for maximizing treatment.
Silverstein, PM, 1996
)
0.29
" This initial hyperthermia appears to be protective since its prevention by dosing at a low ambient temperature enhances striatal dopamine (DA) depletion in CD-1 mice."( MPTP- and MPP(+)-induced effects on body temperature exhibit age- and strain-dependence in mice.
Ali, SF; Freyaldenhoven, TE; Hart, RW, 1995
)
0.29
" A half-life of approximately 70 min was observed following the administration of either dosage form."( Pharmacokinetics and relative bioavailability of selegiline in healthy volunteers.
Mahmood, I; Marinac, JS; Mason, WD; Willsie, S, 1995
)
0.55
" At present, treatment with selegiline in otherwise untreated parkinsonian patients allows to postpone the treatment with levodopa or to keep the levodopa dosage on a lower level."( DATATOP-study: significance of its results in the treatment of Parkinson's disease.
Schneider, E, 1995
)
0.59
" The pharmacokinetic parameters of moclobemide and its metabolites changed on multiple dosing but were not influenced to a relevant extent by concomitant administration of selegiline."( Pharmacokinetic-pharmacodynamic interactions between two selective monoamine oxidase inhibitors: moclobemide and selegiline.
Dingemanse, J; Kettler, R; Kneer, J; Korn, A; Koulu, M; Wallnöfer, A; Zürcher, G, 1996
)
0.7
" While both AMP and MET exposure was equivalent at all dosing sites, DMS exposure was less (approximately 18%) at the terminal ileum."( Absorption and presystemic metabolism of selegiline hydrochloride at different regions in the gastrointestinal tract in healthy males.
Barrett, JS; De Witt, KE; Ireland, J; Morales, RJ; Rajewski, G; Rohatagi, S; Szego, P, 1996
)
0.56
" AMP and MET metabolites were insensitive to dosing site consistent with their hepatic formation."( Absorption and presystemic metabolism of selegiline hydrochloride at different regions in the gastrointestinal tract in healthy males.
Barrett, JS; De Witt, KE; Ireland, J; Morales, RJ; Rajewski, G; Rohatagi, S; Szego, P, 1996
)
0.56
" For depression a higher dosage of deprenyl between 30 to 60 mg/day appears to be necessary for effective treatment."( The clinical potential of Deprenyl in neurologic and psychiatric disorders.
Kuhn, W; Müller, T, 1996
)
0.29
" MAO activity of LC neurons was inhibited by low concentrations of clorgyline with a monophasic dose-response curve but not with a biphasic curve."( Preferential localization of monoamine oxidase type A activity in neurons of the locus coeruleus and type B activity in neurons of the dorsal raphe nucleus of the rat: a detailed enzyme histochemical study.
Arai, R; Kimura, H; Maeda, T; Nagatsu, I, 1997
)
0.3
" The reduction in metabolite formation, relative exposure of selegiline in the dog at the NOEL compared to oral toxicology studies, and margin of safety provided, given that the expected clinical dose is less than the dosage of oral Eldepryl (0."( Toxicokinetic evaluation of a selegiline transdermal system in the dog.
Barrett, JS; DiSanto, AR; Larsen, EM; Morales, RJ; Palazzolo, MJ; Thomford, PJ, 1997
)
0.83
"A dose-ranging study of selegiline was performed in patients with Parkinson's disease to determine the minimal dosage of the drug able to inhibit > or = 95% of platelet monoamine oxidase (MAO) activity."( A dose-ranging study of selegiline in patients with Parkinson's disease: effect of platelet monoamine oxidase activity.
Andreu, N; Damase-Michel, C; Montastruc, JL; Rascol, O; Senard, JM, 1997
)
0.91
" Neuronal degeneration was observed in the substantia nigra pars compacta (SN), ventral tegmental area (VTA) and retrorubral field (RRF) of only animals dosed in the low temperature environment."( Systemic administration of MPTP induces thalamic neuronal degeneration in mice.
Ali, SF; Freyaldenhoven, TE; Schmued, LC, 1997
)
0.3
" The racemate of lipoic acid at high dosage (350 mg/kg body weight) reduced the life span significantly."( Influence of selegiline and lipoic acid on the life expectancy of immunosuppressed mice.
Ackermann, H; Freisleben, HJ; Lehr, F; Neeb, A, 1997
)
0.67
" This study aimed to clarify this matter and to investigate the dose-response of MAO inhibition caused by orally administered selegiline."( Inhibition of platelet monoamine oxidase type B by selegiline.
Anttila, MI; Heinonen, EH; Lammintausta, RA; Nyman, LM; Pyykkö, KA; Vuorinen, JA, 1997
)
0.75
" The sole recommended dosing regimen is 5 mg given in the morning and at noon with breakfast and lunch."( Pharmacokinetic evaluation of a selegiline pulsatile oral delivery system.
Barrett, JS; DeWitt, KE; Lessard, D; Morales, RJ; Rohatagi, S, 1997
)
0.58
" Following this test, dosage was increased to 10 mg/day and a third VMC test was given after 30 more days of treatment."( Deprenyl monotherapy improves visuo-motor control in early parkinsonism.
Giladi, N; Hocherman, S; Levin, G; Youdim, MB, 1998
)
0.3
" The great increase in levodopa responses by deprenyl suggests a likely therapeutic use of this dopamine precursor with a higher dosage of the MAO inhibitor, to reduce effectively the daily levodopa requirements in Parkinson's disease patients."( Modification of levodopa responses by deprenyl (selegiline): an electrophysiological and behavioral study in the rat relevant to Parkinson's disease.
Bernardi, G; Bonci, A; Federici, M; Mercuri, NB; Scarponi, M; Siniscalchi, A, 1998
)
0.56
" The inhibition of platelet MAO-B activity against multiple dosing of selegiline (2."( Is 10 milligrams selegiline essential as an adjunct therapy for the symptomatic treatment of Parkinson's disease?
Mahmood, I, 1998
)
0.87
" At the same time, the lower levodopa dosage in the selegiline group was accompanied by at least equal therapeutic efficacy (which is necessary for an unambiguous interpretation)."( SELEDO: a 5-year long-term trial on the effect of selegiline in early Parkinsonian patients treated with levodopa.
Conrad, B; Dichgans, J; Kraus, PH; Krauseneck, P; Pergande, G; Przuntek, H; Rinne, U; Schimrigk, K; Schnitker, J; Vogel, HP, 1999
)
0.81
" The present results suggest that concomitant use of selegiline with exogenous female sex steroids should be avoided or the dosage of selegiline should be reduced in order to minimize the risks of selegiline related adverse drug reactions."( Dose linearity study of selegiline pharmacokinetics after oral administration: evidence for strong drug interaction with female sex steroids.
Anttila, M; Helminen, A; Huupponen, R; Karnani, H; Laine, K, 1999
)
0.86
"These studies compared the dose-response effects of oral vs."( Oral versus transdermal selegiline: antidepressant-like activity in rats.
Azzaro, AJ; Gordon, MN; Morgan, DG; Muller, CD; Sherman, KA; Wecker, L, 1999
)
0.61
" In contrast, Selegiline given in a lower dosage (0."( Effects of Selegiline in a retroviral rat model for neurodegenerative disease.
Czub, M; Czub, S; Gerlach, M; Gosztonyi, G; Koutsilieri, E; Müller, JG; Riederer, P; Sopper, S; ter Meulen, V, 1999
)
1.05
" A significant improvement in NIP was found in both groups of patients, with no psychotic exacerbation or a change in the dosage of haloperidol."( A trial of L-deprenyl for the treatment of neuroleptic-induced parkinsonism.
Elizur, A; Levin, J; Rabey, JM; Rapoport, A; Schwartz, M; Stein, D; Stier, S, 1999
)
0.3
" The retardation or programmed release capability of the conventional dosage forms like oral and parenteral are limited and toxic and undesired side-effects may occur after their applications."( Transdermal formulations of deprenyl: guinea pig and pig models.
Fejér, E; Gaál, J; Magyar, K; Mezei, M; Szatmári, I; Szebeni, G; Székács, G; Wágner, O, 2000
)
0.31
", was ineffective, suggesting a bell-shaped dose-response relationship which has also been observed in other paradigms."( CGP 3466 protects dopaminergic neurons in lesion models of Parkinson's disease.
Hengerer, B; Spooren, WP; Waldmeier, PC, 2000
)
0.31
" Consumption was expressed in defined daily dosage (DDD) and the costs in euros."( [The evolution of use of anti-Parkinson drugs in Spain].
Castel, JM; Montané, E; Vallano Ferraz, A,
)
0.13
" Dose-response curves were established for the increase in BP induced by tyramine (5-200 mg/kg) administered orally via a naso-pharyngeal tube."( Limited potentiation of blood pressure response to oral tyramine by brain-selective monoamine oxidase A-B inhibitor, TV-3326 in conscious rabbits.
Gorodetsky, E; Gross, A; Wang, RH; Weinreb, O; Weinstock, M; Youdim, MB, 2002
)
0.31
" STS dose-response curves were generated by altering patch size (cm(2))."( Daily transdermal administration of selegiline to guinea-pigs preferentially inhibits monoamine oxidase activity in brain when compared with intestinal and hepatic tissues.
Azzaro, AJ; Cole, D; Mawhinney, M, 2003
)
0.59
" A total of 28 children with ADHD as defined by DSM IV were randomized to selegiline or methylphenidate dosed on an age and weight-adjusted basis at selegiline 5 mg/day (under 5 years) and 10 mg/day (over 5 years) (Group 1) and methylphenidate 1 mg/kg/day (Group 2) for a 4-week double-blind clinical trial."( Selegiline in the treatment of attention deficit hyperactivity disorder in children: a double blind and randomized trial.
Akhondzadeh, S; Amini, H; Arabgol, F; Davari-Ashtiani, R; Tavakolian, R, 2003
)
1.99
" This hypothesis is, for many clinicians, the rationale for postponing the employment of and reducing the applied dosage of L-DOPA and for beginning therapy with dopamine receptor agonists or the monoamine oxidase type B (MAO-B) inhibitor selegiline."( Arguments for the use of dopamine receptor agonists in clinical and preclinical Parkinson's disease.
Double, K; Gerlach, M; Reichmann, H; Riederer, P, 2003
)
0.5
" Additionally, analysis of urine samples from four horses dosed with 50 mg of selegiline confirmed that N-desmethylselegiline is the major urinary metabolite of selegiline in horses."( Detection, quantification, metabolism, and behavioral effects of selegiline in horses.
Boyles, J; Dirikolu, L; Harkins, JD; Hughes, C; Karpiesiuk, W; Lehner, AF; Tobin, T; Troppmann, A; Woods, WE, 2003
)
0.78
" Therefore, in the treatment of neurodegenerative diseases, reconsideration of the dosing schedule, by lowering the dose of deprenyl and choosing the most appropriate route of administration, would diminish undesired adverse effects, with unaltered neuroprotective potency."( Pharmacological aspects of (-)-deprenyl.
Kalász, H; Magyar, K; Pálfi, M; Szende, B; Szöko, E; Tábi, T, 2004
)
0.32
" These results suggest that selegiline dosage adjustments may be required in patients with altered liver and kidney function."( Marked effect of liver and kidney function on the pharmacokinetics of selegiline.
Anttila, M; Pelkonen, O; Rautio, A; Sotaniemi, EA, 2005
)
0.86
" A poorer response to levodopa was associated with increased mortality independent of disease severity or dosage of levodopa."( Survival in Parkinson disease: thirteen-year follow-up of the DATATOP cohort.
Lang, AE; Marras, C; McDermott, MP; Naglie, G; Rochon, PA; Rudolph, A; Tanner, CM, 2005
)
0.33
" Wearing-off can be treated by dietary manipulation, shortening the dosing interval, substituting sustained-release levodopa, adding amantadine, or monoamine oxidase type B inhibitors, and other options, including catechol-O-methyltransferase inhibitors and the approved dopamine agonists addressed in another chapter."( Other pharmacological treatments for motor complications and dyskinesias.
Waters, C, 2005
)
0.33
" Since (-)deprenyl directly modulates Deltapsi(M) and production of reactive oxygen species (ROS) by altering the respiratory function of mitochondria, we were interested in the dose-response relations of these effects."( Low dose (-)deprenyl is cytoprotective: it maintains mitochondrial membrane potential and eliminates oxygen radicals.
Bori, Z; Magyar, K; Nagy, Z; Simon, L; Szilágyi, G; Telek, G, 2005
)
0.33
" The minimum dosage of 6 mg/24 h was effective in two trials; this dosage did not require any dietary precautions."( Seligiline transdermal system in depression.
Goodnick, PJ, 2007
)
0.34
" The data described in the present study provides further evidence that functional deficits following an acute MPTP dosing schedule in mice can be quantified and are related to nigro-striatal dopamine function."( A beam-walking apparatus to assess behavioural impairments in MPTP-treated mice: pharmacological validation with R-(-)-deprenyl.
Brackenborough, KT; Chapman, H; Pangalos, MN; Perren, MJ; Quinn, LP; Upton, N; Vidgeon-Hart, M; Virley, DJ; Woodhams, PL, 2007
)
0.34
" Transdermal selegiline administration reduced metabolism and produced a high, sustained plasma selegiline concentration over the dosing period, with an absolute bioavailability of 73%."( Pharmacokinetics and absolute bioavailability of selegiline following treatment of healthy subjects with the selegiline transdermal system (6 mg/24 h): a comparison with oral selegiline capsules.
Azzaro, AJ; Campbell, BJ; Kemper, E; VanDenBerg, C; Ziemniak, J, 2007
)
0.96
" Most patients on long-term LD therapy eventually experience deterioration at the end of the LD dosing interval, with predictable "wearing off" and "on-off" fluctuations."( Selegiline orally disintegrating tablets in patients with Parkinson disease and "wearing off" symptoms.
Kricorian, G; Ondo, WG; Sethi, KD,
)
1.57
" The recent development of an orally disintegrating dosage form using Zydis technology allows pregastric drug absorption and, thus, greatly improving the pharmacodynamic and pharmacokinetic drug profiles."( Zydis selegiline in the management of Parkinson's disease.
Poston, KL; Waters, C, 2007
)
0.82
" This report suggests that serum prolactin levels can be a good biomarker for optimal dosage of hydroxylated precursors in long-term treatment monitoring."( Serum prolactin as a tool for the follow-up of treated DHPR-deficient patients.
Concolino, D; Moricca, MT; Muzzi, G; Pascale, MG; Rapsomaniki, M; Strisciuglio, P, 2008
)
0.35
"To investigate the role of potent MAO-B inhibitor deprenyl in fertilized females, we have evaluated the effect of chronic treatment with deprenyl at a high dosage on preimplantation embryo development and DNA damage in blood lymphocytes in Wistar rats."( Study of high deprenyl dose on the preimplantation embryo development and lymphocyte DNA in rat.
Kravcuková, P; Mareková, M; Mihalik, J; Schmidtová, K; Spakovská, T, 2008
)
0.35
"To investigate the role of potent MAO-B inhibitor deprenyl in fertilized females, we have evaluated the effect of chronic treatment with deprenyl at a low dosage on preimplantation embryo development in Wistar rats."( Antagonistic effect of low deprenyl dose on the preimplantation embryo development in rat.
Mihalik, J; Prokopcakova, L; Schmidtova, K; Spakovska, T, 2008
)
0.35
" In this unit, several MAO assay procedures are described, along with support protocols for equilibrating ion-exchange resin, preparing aldehyde dehydrogenase, preparing dose-response curves for determining the relative proportions of isoenzyme activities, determining concentrations of each isoenzyme, assessing new compounds as putative MAO inhibitors, and determining protein concentration of membrane-bound proteins."( Monoamine oxidase assays.
Davey, G; Motherway, M; Tipton, KF, 2001
)
0.31
" Patient adherence theoretically could be improved due to ease of use and once-daily dosing when compared to oral counterparts' need for multiple daily doses."( A critical appraisal of the selegiline transdermal system for major depressive disorder.
Bied, AM; Kim, J; Schwartz, TL, 2015
)
0.71
" They reacted to the devaluation of food in a manner consistent with a dose-response relationship."( Rats bred for helplessness exhibit positive reinforcement learning deficits which are not alleviated by an antidepressant dose of the MAO-B inhibitor deprenyl.
Henn, FA; Huston, JP; Petri, D; Schulz, D, 2016
)
0.43
" On the other hand, it is crucial to choose a proper dose, since lower dose was more competent compared to a dosage that was one hundred times higher."( The effect of R-(-)-deprenyl administration on antioxidant enzymes in rat testis.
Danielisová, V; Domoráková, I; Hodorová, I; Horváthová, F; Mihalik, J; Rybárová, S; Solár, P, 2016
)
0.43
" 99%), metabolized by monoamine oxidases (MAO), the benefits of a high-dosage betahistine monotherapy were compared with those of a lower dosage of betahistine in combination with the MAO-B inhibitor (MAO-B) selegiline on the frequency of acute attacks of vertigo in patients with Menière's disease (MD)."( Menière's disease: combined pharmacotherapy with betahistine and the MAO-B inhibitor selegiline-an observational study.
Kraus, L; Rujescu, D; Schautzer, F; Strupp, M, 2018
)
0.89
"9 years; six females) had initially been treated with a high dosage of betahistine dihydrochloride for at least 1 year."( Menière's disease: combined pharmacotherapy with betahistine and the MAO-B inhibitor selegiline-an observational study.
Kraus, L; Rujescu, D; Schautzer, F; Strupp, M, 2018
)
0.7
"The initial dosage for the long-term "titration" of the attacks of vertigo was 9-80 24-mg tablets/day (mean 37."( Menière's disease: combined pharmacotherapy with betahistine and the MAO-B inhibitor selegiline-an observational study.
Kraus, L; Rujescu, D; Schautzer, F; Strupp, M, 2018
)
0.7
"The achievement of the same clinical effect with a significantly lower (about 1/5) dosage of betahistine can be explained by the inhibition of the MAO-B by selegiline leading to higher serum concentrations of betahistine."( Menière's disease: combined pharmacotherapy with betahistine and the MAO-B inhibitor selegiline-an observational study.
Kraus, L; Rujescu, D; Schautzer, F; Strupp, M, 2018
)
0.9
" In one study, tics limited further dosage increases of methylphenidate."( Pharmacological treatment for attention deficit hyperactivity disorder (ADHD) in children with comorbid tic disorders.
Osland, ST; Pringsheim, T; Steeves, TD, 2018
)
0.48
" There was no significant difference in trilostane dosage at D180 between groups."( Assessment of selegiline and trilostane combined therapy efficacy for canine pituitary-dependent hypercortisolism treatment: A pilot randomized clinical trial.
da Silva Mello, FP; da Silva, CC; de Carvalho, GLC; de Faria Valle, S; de Moura Martins, FS; Furtado, PV; Machado, L; Meirelles, L; Neto, WS; Pöppl, ÁG, 2022
)
1.08
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
geroprotectorAny compound that supports healthy aging, slows the biological aging process, or extends lifespan.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
selegiline
terminal acetylenic compoundAn acetylenic compound which a carbon of the C#C moiety is attached to a hydrogen atom.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (23)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Ferritin light chainEquus caballus (horse)Potency22.38725.623417.292931.6228AID485281
regulator of G-protein signaling 4Homo sapiens (human)Potency0.08440.531815.435837.6858AID504845
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency7.94330.035520.977089.1251AID504332
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
AcetylcholinesteraseElectrophorus electricus (electric eel)IC50 (µMol)500.00000.00000.94539.9400AID1152907
Cytochrome P450 2B1Rattus norvegicus (Norway rat)Ki1.05000.08002.31005.8000AID624688
CholinesteraseHomo sapiens (human)IC50 (µMol)250.00270.00001.559910.0000AID1322902; AID1556701
Cytochrome P450 3A4Homo sapiens (human)IC50 (µMol)0.00390.00011.753610.0000AID1383066
Alpha-2A adrenergic receptorHomo sapiens (human)IC50 (µMol)1.79800.00001.44217.3470AID625201
Alpha-2A adrenergic receptorHomo sapiens (human)Ki0.67400.00010.807410.0000AID625201
Alpha-2B adrenergic receptorHomo sapiens (human)IC50 (µMol)0.37600.00001.23808.1590AID625202
Alpha-2B adrenergic receptorHomo sapiens (human)Ki0.17200.00020.725710.0000AID625202
Amine oxidase [flavin-containing] BRattus norvegicus (Norway rat)IC50 (µMol)0.21270.00040.764912.5000AID102893; AID102894; AID102895; AID102896; AID102897; AID125399; AID125403; AID125405; AID126691; AID127347; AID1586574; AID1631764; AID747670
Amine oxidase [flavin-containing] BRattus norvegicus (Norway rat)Ki0.45240.00081.09276.0000AID1192621; AID1192622; AID590316
Amine oxidase [flavin-containing] A Rattus norvegicus (Norway rat)IC50 (µMol)0.90460.00071.979812.5000AID102738; AID102739; AID125399; AID125403; AID125405; AID125708; AID127347; AID1586572
Amine oxidase [flavin-containing] A Rattus norvegicus (Norway rat)Ki16.19000.00190.55334.8000AID1192621; AID238291; AID590300
Amine oxidase [flavin-containing] AHomo sapiens (human)IC50 (µMol)53.76550.00002.37899.7700AID1140811; AID1176890; AID1195740; AID1231601; AID1241471; AID1252747; AID1301269; AID1320874; AID1322903; AID1368627; AID1378854; AID1383065; AID1397341; AID1406147; AID1416660; AID1421879; AID1444065; AID1458405; AID1460876; AID1493743; AID1519692; AID1524509; AID1528913; AID1556700; AID1586573; AID1602879; AID1636269; AID1798967; AID1851411; AID1891688; AID314094; AID349909; AID361935; AID409942; AID416572; AID449664; AID461711; AID468863; AID478544; AID497342; AID501517; AID509549; AID514141; AID515170; AID528278; AID589434; AID593111; AID599357; AID604279; AID610969; AID619466; AID622913; AID625150; AID629007; AID637705; AID639308; AID693560; AID706469; AID733504; AID743813; AID767289
Amine oxidase [flavin-containing] AHomo sapiens (human)Ki14.82800.00192.379710.0000AID1286741; AID1413448; AID1708793; AID1801003; AID1801059; AID590315; AID604264; AID776660
Amine oxidase [flavin-containing] A Bos taurus (cattle)IC50 (µMol)38.01890.00290.10380.3802AID277618; AID367003
Amine oxidase [flavin-containing] A Bos taurus (cattle)Ki9.02830.00251.35733.8000AID125547; AID1797405; AID279953; AID387972; AID710372
AcetylcholinesteraseHomo sapiens (human)IC50 (µMol)500.00000.00000.933210.0000AID1322906
Adenosine receptor A1Rattus norvegicus (Norway rat)IC50 (µMol)0.00670.00020.552110.0000AID747670
Amine oxidase [flavin-containing] BHomo sapiens (human)IC50 (µMol)1.50740.00001.89149.5700AID1057042; AID1057559; AID1057562; AID1140812; AID1176892; AID1190174; AID1195741; AID1231602; AID1241472; AID1245395; AID1252748; AID1282045; AID1301267; AID1320875; AID1322904; AID1351085; AID1368626; AID1378855; AID1383066; AID1383067; AID1397342; AID1406148; AID1409012; AID1412303; AID1416662; AID1421880; AID1444066; AID1456237; AID1458404; AID1459559; AID1460878; AID1484649; AID1493744; AID1498905; AID1502984; AID1512063; AID1514372; AID1519691; AID1524508; AID1528914; AID1532341; AID1533829; AID1556701; AID1586575; AID1602880; AID1636270; AID1701088; AID1759294; AID1767578; AID1798967; AID1851412; AID1891689; AID1900900; AID314095; AID340615; AID349912; AID361936; AID409943; AID416573; AID461712; AID468865; AID478547; AID497343; AID501518; AID509550; AID514142; AID515171; AID528279; AID551666; AID566355; AID589435; AID593110; AID599359; AID604281; AID610970; AID619468; AID622915; AID626694; AID629008; AID637760; AID639310; AID658202; AID672471; AID693561; AID706470; AID717662; AID723213; AID733502; AID733943; AID743812; AID747669; AID751623; AID767288; AID768157; AID773440; AID779070
Amine oxidase [flavin-containing] BHomo sapiens (human)Ki1.63050.00061.777110.0000AID1054590; AID1192621; AID1192622; AID1286742; AID1413449; AID1528928; AID1528930; AID1708794; AID1801003; AID1801059; AID238322; AID254307; AID590317; AID604265; AID776659
Type-1 angiotensin II receptorSus scrofa (pig)IC50 (µMol)0.04800.04800.04800.0480AID340615
Alpha-synucleinHomo sapiens (human)IC50 (µMol)0.27000.19003.82049.8000AID1695731
C-X-C chemokine receptor type 3Homo sapiens (human)IC50 (µMol)67.25000.00500.35886.5600AID449664
Amine oxidase [flavin-containing] BBos taurus (cattle)IC50 (µMol)1.00001.00001.00001.0000AID277619; AID367273
Amine oxidase [flavin-containing] BBos taurus (cattle)Ki1.44170.05401.83906.0000AID125550; AID1797405; AID279954; AID387973; AID710371
Sigma intracellular receptor 2Rattus norvegicus (Norway rat)IC50 (µMol)0.01700.01431.37567.5000AID1406148
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Amine oxidase [flavin-containing] BHomo sapiens (human)Kd0.05890.00900.11930.2754AID1192631
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Amine oxidase [flavin-containing] BRattus norvegicus (Norway rat)Activity0.00110.00080.00120.0014AID125378
Amine oxidase [flavin-containing] A Rattus norvegicus (Norway rat)Activity0.00110.00080.00110.0014AID125378
Amine oxidase [flavin-containing] AMus musculus (house mouse)Activity0.00100.00060.00110.0014AID125378; AID125698
Amine oxidase [flavin-containing] BMus musculus (house mouse)Activity0.00090.00050.00100.0014AID125378; AID126675
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (193)

Processvia Protein(s)Taxonomy
xenobiotic metabolic processCholinesteraseHomo sapiens (human)
learningCholinesteraseHomo sapiens (human)
negative regulation of cell population proliferationCholinesteraseHomo sapiens (human)
neuroblast differentiationCholinesteraseHomo sapiens (human)
peptide hormone processingCholinesteraseHomo sapiens (human)
response to alkaloidCholinesteraseHomo sapiens (human)
cocaine metabolic processCholinesteraseHomo sapiens (human)
negative regulation of synaptic transmissionCholinesteraseHomo sapiens (human)
response to glucocorticoidCholinesteraseHomo sapiens (human)
response to folic acidCholinesteraseHomo sapiens (human)
choline metabolic processCholinesteraseHomo sapiens (human)
acetylcholine catabolic processCholinesteraseHomo sapiens (human)
lipid hydroxylationCytochrome P450 3A4Homo sapiens (human)
lipid metabolic processCytochrome P450 3A4Homo sapiens (human)
steroid catabolic processCytochrome P450 3A4Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 3A4Homo sapiens (human)
steroid metabolic processCytochrome P450 3A4Homo sapiens (human)
cholesterol metabolic processCytochrome P450 3A4Homo sapiens (human)
androgen metabolic processCytochrome P450 3A4Homo sapiens (human)
estrogen metabolic processCytochrome P450 3A4Homo sapiens (human)
alkaloid catabolic processCytochrome P450 3A4Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 3A4Homo sapiens (human)
calcitriol biosynthetic process from calciolCytochrome P450 3A4Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 3A4Homo sapiens (human)
vitamin D metabolic processCytochrome P450 3A4Homo sapiens (human)
vitamin D catabolic processCytochrome P450 3A4Homo sapiens (human)
retinol metabolic processCytochrome P450 3A4Homo sapiens (human)
retinoic acid metabolic processCytochrome P450 3A4Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 3A4Homo sapiens (human)
aflatoxin metabolic processCytochrome P450 3A4Homo sapiens (human)
oxidative demethylationCytochrome P450 3A4Homo sapiens (human)
positive regulation of cytokine productionAlpha-2A adrenergic receptorHomo sapiens (human)
DNA replicationAlpha-2A adrenergic receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
Ras protein signal transductionAlpha-2A adrenergic receptorHomo sapiens (human)
Rho protein signal transductionAlpha-2A adrenergic receptorHomo sapiens (human)
female pregnancyAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of cell population proliferationAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of norepinephrine secretionAlpha-2A adrenergic receptorHomo sapiens (human)
regulation of vasoconstrictionAlpha-2A adrenergic receptorHomo sapiens (human)
actin cytoskeleton organizationAlpha-2A adrenergic receptorHomo sapiens (human)
platelet activationAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of cell migrationAlpha-2A adrenergic receptorHomo sapiens (human)
activation of protein kinase activityAlpha-2A adrenergic receptorHomo sapiens (human)
activation of protein kinase B activityAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of epinephrine secretionAlpha-2A adrenergic receptorHomo sapiens (human)
cellular response to hormone stimulusAlpha-2A adrenergic receptorHomo sapiens (human)
receptor transactivationAlpha-2A adrenergic receptorHomo sapiens (human)
vasodilationAlpha-2A adrenergic receptorHomo sapiens (human)
glucose homeostasisAlpha-2A adrenergic receptorHomo sapiens (human)
fear responseAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of potassium ion transportAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of MAP kinase activityAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of epidermal growth factor receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of calcium ion-dependent exocytosisAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of insulin secretionAlpha-2A adrenergic receptorHomo sapiens (human)
intestinal absorptionAlpha-2A adrenergic receptorHomo sapiens (human)
thermoceptionAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of lipid catabolic processAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of membrane protein ectodomain proteolysisAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of calcium ion transportAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of insulin secretion involved in cellular response to glucose stimulusAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of uterine smooth muscle contractionAlpha-2A adrenergic receptorHomo sapiens (human)
adrenergic receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
adenylate cyclase-inhibiting adrenergic receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
phospholipase C-activating adrenergic receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of wound healingAlpha-2A adrenergic receptorHomo sapiens (human)
presynaptic modulation of chemical synaptic transmissionAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of calcium ion transmembrane transporter activityAlpha-2A adrenergic receptorHomo sapiens (human)
MAPK cascadeAlpha-2B adrenergic receptorHomo sapiens (human)
angiogenesisAlpha-2B adrenergic receptorHomo sapiens (human)
regulation of vascular associated smooth muscle contractionAlpha-2B adrenergic receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayAlpha-2B adrenergic receptorHomo sapiens (human)
cell-cell signalingAlpha-2B adrenergic receptorHomo sapiens (human)
female pregnancyAlpha-2B adrenergic receptorHomo sapiens (human)
negative regulation of norepinephrine secretionAlpha-2B adrenergic receptorHomo sapiens (human)
platelet activationAlpha-2B adrenergic receptorHomo sapiens (human)
activation of protein kinase B activityAlpha-2B adrenergic receptorHomo sapiens (human)
negative regulation of epinephrine secretionAlpha-2B adrenergic receptorHomo sapiens (human)
receptor transactivationAlpha-2B adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeAlpha-2B adrenergic receptorHomo sapiens (human)
positive regulation of neuron differentiationAlpha-2B adrenergic receptorHomo sapiens (human)
positive regulation of blood pressureAlpha-2B adrenergic receptorHomo sapiens (human)
positive regulation of uterine smooth muscle contractionAlpha-2B adrenergic receptorHomo sapiens (human)
adrenergic receptor signaling pathwayAlpha-2B adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayAlpha-2B adrenergic receptorHomo sapiens (human)
biogenic amine metabolic processAmine oxidase [flavin-containing] AHomo sapiens (human)
positive regulation of signal transductionAmine oxidase [flavin-containing] AHomo sapiens (human)
dopamine catabolic processAmine oxidase [flavin-containing] AHomo sapiens (human)
catecholamine metabolic processAmine oxidase [flavin-containing] A Bos taurus (cattle)
acetylcholine catabolic process in synaptic cleftAcetylcholinesteraseHomo sapiens (human)
regulation of receptor recyclingAcetylcholinesteraseHomo sapiens (human)
osteoblast developmentAcetylcholinesteraseHomo sapiens (human)
acetylcholine catabolic processAcetylcholinesteraseHomo sapiens (human)
cell adhesionAcetylcholinesteraseHomo sapiens (human)
nervous system developmentAcetylcholinesteraseHomo sapiens (human)
synapse assemblyAcetylcholinesteraseHomo sapiens (human)
receptor internalizationAcetylcholinesteraseHomo sapiens (human)
negative regulation of synaptic transmission, cholinergicAcetylcholinesteraseHomo sapiens (human)
amyloid precursor protein metabolic processAcetylcholinesteraseHomo sapiens (human)
positive regulation of protein secretionAcetylcholinesteraseHomo sapiens (human)
retina development in camera-type eyeAcetylcholinesteraseHomo sapiens (human)
acetylcholine receptor signaling pathwayAcetylcholinesteraseHomo sapiens (human)
positive regulation of cold-induced thermogenesisAcetylcholinesteraseHomo sapiens (human)
response to xenobiotic stimulusAmine oxidase [flavin-containing] BHomo sapiens (human)
response to toxic substanceAmine oxidase [flavin-containing] BHomo sapiens (human)
response to aluminum ionAmine oxidase [flavin-containing] BHomo sapiens (human)
response to selenium ionAmine oxidase [flavin-containing] BHomo sapiens (human)
negative regulation of serotonin secretionAmine oxidase [flavin-containing] BHomo sapiens (human)
phenylethylamine catabolic processAmine oxidase [flavin-containing] BHomo sapiens (human)
substantia nigra developmentAmine oxidase [flavin-containing] BHomo sapiens (human)
response to lipopolysaccharideAmine oxidase [flavin-containing] BHomo sapiens (human)
dopamine catabolic processAmine oxidase [flavin-containing] BHomo sapiens (human)
response to ethanolAmine oxidase [flavin-containing] BHomo sapiens (human)
positive regulation of dopamine metabolic processAmine oxidase [flavin-containing] BHomo sapiens (human)
hydrogen peroxide biosynthetic processAmine oxidase [flavin-containing] BHomo sapiens (human)
response to corticosteroneAmine oxidase [flavin-containing] BHomo sapiens (human)
calcium ion homeostasisAlpha-synucleinHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIAlpha-synucleinHomo sapiens (human)
microglial cell activationAlpha-synucleinHomo sapiens (human)
positive regulation of receptor recyclingAlpha-synucleinHomo sapiens (human)
positive regulation of neurotransmitter secretionAlpha-synucleinHomo sapiens (human)
negative regulation of protein kinase activityAlpha-synucleinHomo sapiens (human)
fatty acid metabolic processAlpha-synucleinHomo sapiens (human)
neutral lipid metabolic processAlpha-synucleinHomo sapiens (human)
phospholipid metabolic processAlpha-synucleinHomo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic processAlpha-synucleinHomo sapiens (human)
mitochondrial membrane organizationAlpha-synucleinHomo sapiens (human)
adult locomotory behaviorAlpha-synucleinHomo sapiens (human)
response to xenobiotic stimulusAlpha-synucleinHomo sapiens (human)
response to iron(II) ionAlpha-synucleinHomo sapiens (human)
regulation of phospholipase activityAlpha-synucleinHomo sapiens (human)
negative regulation of platelet-derived growth factor receptor signaling pathwayAlpha-synucleinHomo sapiens (human)
regulation of glutamate secretionAlpha-synucleinHomo sapiens (human)
regulation of dopamine secretionAlpha-synucleinHomo sapiens (human)
synaptic vesicle exocytosisAlpha-synucleinHomo sapiens (human)
synaptic vesicle primingAlpha-synucleinHomo sapiens (human)
regulation of transmembrane transporter activityAlpha-synucleinHomo sapiens (human)
negative regulation of microtubule polymerizationAlpha-synucleinHomo sapiens (human)
receptor internalizationAlpha-synucleinHomo sapiens (human)
protein destabilizationAlpha-synucleinHomo sapiens (human)
response to magnesium ionAlpha-synucleinHomo sapiens (human)
negative regulation of transporter activityAlpha-synucleinHomo sapiens (human)
response to lipopolysaccharideAlpha-synucleinHomo sapiens (human)
negative regulation of monooxygenase activityAlpha-synucleinHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylationAlpha-synucleinHomo sapiens (human)
response to type II interferonAlpha-synucleinHomo sapiens (human)
cellular response to oxidative stressAlpha-synucleinHomo sapiens (human)
SNARE complex assemblyAlpha-synucleinHomo sapiens (human)
positive regulation of SNARE complex assemblyAlpha-synucleinHomo sapiens (human)
regulation of locomotionAlpha-synucleinHomo sapiens (human)
dopamine biosynthetic processAlpha-synucleinHomo sapiens (human)
mitochondrial ATP synthesis coupled electron transportAlpha-synucleinHomo sapiens (human)
regulation of macrophage activationAlpha-synucleinHomo sapiens (human)
positive regulation of apoptotic processAlpha-synucleinHomo sapiens (human)
negative regulation of apoptotic processAlpha-synucleinHomo sapiens (human)
negative regulation of cysteine-type endopeptidase activity involved in apoptotic processAlpha-synucleinHomo sapiens (human)
negative regulation of neuron apoptotic processAlpha-synucleinHomo sapiens (human)
positive regulation of endocytosisAlpha-synucleinHomo sapiens (human)
negative regulation of exocytosisAlpha-synucleinHomo sapiens (human)
positive regulation of exocytosisAlpha-synucleinHomo sapiens (human)
regulation of long-term neuronal synaptic plasticityAlpha-synucleinHomo sapiens (human)
synaptic vesicle endocytosisAlpha-synucleinHomo sapiens (human)
synaptic vesicle transportAlpha-synucleinHomo sapiens (human)
positive regulation of inflammatory responseAlpha-synucleinHomo sapiens (human)
regulation of acyl-CoA biosynthetic processAlpha-synucleinHomo sapiens (human)
protein tetramerizationAlpha-synucleinHomo sapiens (human)
positive regulation of release of sequestered calcium ion into cytosolAlpha-synucleinHomo sapiens (human)
neuron apoptotic processAlpha-synucleinHomo sapiens (human)
dopamine uptake involved in synaptic transmissionAlpha-synucleinHomo sapiens (human)
negative regulation of dopamine uptake involved in synaptic transmissionAlpha-synucleinHomo sapiens (human)
negative regulation of serotonin uptakeAlpha-synucleinHomo sapiens (human)
regulation of norepinephrine uptakeAlpha-synucleinHomo sapiens (human)
negative regulation of norepinephrine uptakeAlpha-synucleinHomo sapiens (human)
excitatory postsynaptic potentialAlpha-synucleinHomo sapiens (human)
long-term synaptic potentiationAlpha-synucleinHomo sapiens (human)
positive regulation of inositol phosphate biosynthetic processAlpha-synucleinHomo sapiens (human)
negative regulation of thrombin-activated receptor signaling pathwayAlpha-synucleinHomo sapiens (human)
response to interleukin-1Alpha-synucleinHomo sapiens (human)
cellular response to copper ionAlpha-synucleinHomo sapiens (human)
cellular response to epinephrine stimulusAlpha-synucleinHomo sapiens (human)
positive regulation of protein serine/threonine kinase activityAlpha-synucleinHomo sapiens (human)
supramolecular fiber organizationAlpha-synucleinHomo sapiens (human)
negative regulation of mitochondrial electron transport, NADH to ubiquinoneAlpha-synucleinHomo sapiens (human)
positive regulation of glutathione peroxidase activityAlpha-synucleinHomo sapiens (human)
positive regulation of hydrogen peroxide catabolic processAlpha-synucleinHomo sapiens (human)
regulation of synaptic vesicle recyclingAlpha-synucleinHomo sapiens (human)
regulation of reactive oxygen species biosynthetic processAlpha-synucleinHomo sapiens (human)
positive regulation of protein localization to cell peripheryAlpha-synucleinHomo sapiens (human)
negative regulation of chaperone-mediated autophagyAlpha-synucleinHomo sapiens (human)
regulation of presynapse assemblyAlpha-synucleinHomo sapiens (human)
amyloid fibril formationAlpha-synucleinHomo sapiens (human)
synapse organizationAlpha-synucleinHomo sapiens (human)
chemical synaptic transmissionAlpha-synucleinHomo sapiens (human)
angiogenesisC-X-C chemokine receptor type 3Homo sapiens (human)
regulation of leukocyte migrationC-X-C chemokine receptor type 3Homo sapiens (human)
apoptotic processC-X-C chemokine receptor type 3Homo sapiens (human)
chemotaxisC-X-C chemokine receptor type 3Homo sapiens (human)
inflammatory responseC-X-C chemokine receptor type 3Homo sapiens (human)
cell adhesionC-X-C chemokine receptor type 3Homo sapiens (human)
cell surface receptor signaling pathwayC-X-C chemokine receptor type 3Homo sapiens (human)
regulation of cell adhesionC-X-C chemokine receptor type 3Homo sapiens (human)
chemokine-mediated signaling pathwayC-X-C chemokine receptor type 3Homo sapiens (human)
positive regulation of cytosolic calcium ion concentrationC-X-C chemokine receptor type 3Homo sapiens (human)
calcium-mediated signalingC-X-C chemokine receptor type 3Homo sapiens (human)
immune responseC-X-C chemokine receptor type 3Homo sapiens (human)
cell chemotaxisC-X-C chemokine receptor type 3Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (79)

Processvia Protein(s)Taxonomy
amyloid-beta bindingCholinesteraseHomo sapiens (human)
catalytic activityCholinesteraseHomo sapiens (human)
acetylcholinesterase activityCholinesteraseHomo sapiens (human)
cholinesterase activityCholinesteraseHomo sapiens (human)
protein bindingCholinesteraseHomo sapiens (human)
hydrolase activity, acting on ester bondsCholinesteraseHomo sapiens (human)
enzyme bindingCholinesteraseHomo sapiens (human)
choline bindingCholinesteraseHomo sapiens (human)
identical protein bindingCholinesteraseHomo sapiens (human)
monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
steroid bindingCytochrome P450 3A4Homo sapiens (human)
iron ion bindingCytochrome P450 3A4Homo sapiens (human)
protein bindingCytochrome P450 3A4Homo sapiens (human)
steroid hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
retinoic acid 4-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
oxidoreductase activityCytochrome P450 3A4Homo sapiens (human)
oxygen bindingCytochrome P450 3A4Homo sapiens (human)
enzyme bindingCytochrome P450 3A4Homo sapiens (human)
heme bindingCytochrome P450 3A4Homo sapiens (human)
vitamin D3 25-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
caffeine oxidase activityCytochrome P450 3A4Homo sapiens (human)
quinine 3-monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
testosterone 6-beta-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
1-alpha,25-dihydroxyvitamin D3 23-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 8,9 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 11,12 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 14,15 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
aromatase activityCytochrome P450 3A4Homo sapiens (human)
vitamin D 24-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
estrogen 16-alpha-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
estrogen 2-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
1,8-cineole 2-exo-monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
alpha2-adrenergic receptor activityAlpha-2A adrenergic receptorHomo sapiens (human)
protein bindingAlpha-2A adrenergic receptorHomo sapiens (human)
protein kinase bindingAlpha-2A adrenergic receptorHomo sapiens (human)
alpha-1B adrenergic receptor bindingAlpha-2A adrenergic receptorHomo sapiens (human)
alpha-2C adrenergic receptor bindingAlpha-2A adrenergic receptorHomo sapiens (human)
thioesterase bindingAlpha-2A adrenergic receptorHomo sapiens (human)
heterotrimeric G-protein bindingAlpha-2A adrenergic receptorHomo sapiens (human)
protein homodimerization activityAlpha-2A adrenergic receptorHomo sapiens (human)
protein heterodimerization activityAlpha-2A adrenergic receptorHomo sapiens (human)
epinephrine bindingAlpha-2A adrenergic receptorHomo sapiens (human)
norepinephrine bindingAlpha-2A adrenergic receptorHomo sapiens (human)
guanyl-nucleotide exchange factor activityAlpha-2A adrenergic receptorHomo sapiens (human)
alpha2-adrenergic receptor activityAlpha-2B adrenergic receptorHomo sapiens (human)
protein bindingAlpha-2B adrenergic receptorHomo sapiens (human)
epinephrine bindingAlpha-2B adrenergic receptorHomo sapiens (human)
protein bindingAmine oxidase [flavin-containing] AHomo sapiens (human)
primary amine oxidase activityAmine oxidase [flavin-containing] AHomo sapiens (human)
aliphatic amine oxidase activityAmine oxidase [flavin-containing] AHomo sapiens (human)
monoamine oxidase activityAmine oxidase [flavin-containing] AHomo sapiens (human)
flavin adenine dinucleotide bindingAmine oxidase [flavin-containing] AHomo sapiens (human)
primary amine oxidase activityAmine oxidase [flavin-containing] A Bos taurus (cattle)
aliphatic amine oxidase activityAmine oxidase [flavin-containing] A Bos taurus (cattle)
monoamine oxidase activityAmine oxidase [flavin-containing] A Bos taurus (cattle)
amyloid-beta bindingAcetylcholinesteraseHomo sapiens (human)
acetylcholinesterase activityAcetylcholinesteraseHomo sapiens (human)
cholinesterase activityAcetylcholinesteraseHomo sapiens (human)
protein bindingAcetylcholinesteraseHomo sapiens (human)
collagen bindingAcetylcholinesteraseHomo sapiens (human)
hydrolase activityAcetylcholinesteraseHomo sapiens (human)
serine hydrolase activityAcetylcholinesteraseHomo sapiens (human)
acetylcholine bindingAcetylcholinesteraseHomo sapiens (human)
protein homodimerization activityAcetylcholinesteraseHomo sapiens (human)
laminin bindingAcetylcholinesteraseHomo sapiens (human)
protein bindingAmine oxidase [flavin-containing] BHomo sapiens (human)
primary amine oxidase activityAmine oxidase [flavin-containing] BHomo sapiens (human)
electron transfer activityAmine oxidase [flavin-containing] BHomo sapiens (human)
identical protein bindingAmine oxidase [flavin-containing] BHomo sapiens (human)
aliphatic amine oxidase activityAmine oxidase [flavin-containing] BHomo sapiens (human)
monoamine oxidase activityAmine oxidase [flavin-containing] BHomo sapiens (human)
flavin adenine dinucleotide bindingAmine oxidase [flavin-containing] BHomo sapiens (human)
fatty acid bindingAlpha-synucleinHomo sapiens (human)
phospholipase D inhibitor activityAlpha-synucleinHomo sapiens (human)
SNARE bindingAlpha-synucleinHomo sapiens (human)
magnesium ion bindingAlpha-synucleinHomo sapiens (human)
transcription cis-regulatory region bindingAlpha-synucleinHomo sapiens (human)
actin bindingAlpha-synucleinHomo sapiens (human)
protein kinase inhibitor activityAlpha-synucleinHomo sapiens (human)
copper ion bindingAlpha-synucleinHomo sapiens (human)
calcium ion bindingAlpha-synucleinHomo sapiens (human)
protein bindingAlpha-synucleinHomo sapiens (human)
phospholipid bindingAlpha-synucleinHomo sapiens (human)
ferrous iron bindingAlpha-synucleinHomo sapiens (human)
zinc ion bindingAlpha-synucleinHomo sapiens (human)
lipid bindingAlpha-synucleinHomo sapiens (human)
oxidoreductase activityAlpha-synucleinHomo sapiens (human)
kinesin bindingAlpha-synucleinHomo sapiens (human)
Hsp70 protein bindingAlpha-synucleinHomo sapiens (human)
histone bindingAlpha-synucleinHomo sapiens (human)
identical protein bindingAlpha-synucleinHomo sapiens (human)
alpha-tubulin bindingAlpha-synucleinHomo sapiens (human)
cysteine-type endopeptidase inhibitor activity involved in apoptotic processAlpha-synucleinHomo sapiens (human)
tau protein bindingAlpha-synucleinHomo sapiens (human)
phosphoprotein bindingAlpha-synucleinHomo sapiens (human)
molecular adaptor activityAlpha-synucleinHomo sapiens (human)
dynein complex bindingAlpha-synucleinHomo sapiens (human)
cuprous ion bindingAlpha-synucleinHomo sapiens (human)
chemokine receptor activityC-X-C chemokine receptor type 3Homo sapiens (human)
protein bindingC-X-C chemokine receptor type 3Homo sapiens (human)
C-X-C chemokine receptor activityC-X-C chemokine receptor type 3Homo sapiens (human)
chemokine bindingC-X-C chemokine receptor type 3Homo sapiens (human)
C-C chemokine receptor activityC-X-C chemokine receptor type 3Homo sapiens (human)
C-C chemokine bindingC-X-C chemokine receptor type 3Homo sapiens (human)
primary amine oxidase activityAmine oxidase [flavin-containing] BBos taurus (cattle)
aliphatic amine oxidase activityAmine oxidase [flavin-containing] BBos taurus (cattle)
monoamine oxidase activityAmine oxidase [flavin-containing] BBos taurus (cattle)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (45)

Processvia Protein(s)Taxonomy
extracellular regionCholinesteraseHomo sapiens (human)
nuclear envelope lumenCholinesteraseHomo sapiens (human)
endoplasmic reticulum lumenCholinesteraseHomo sapiens (human)
blood microparticleCholinesteraseHomo sapiens (human)
plasma membraneCholinesteraseHomo sapiens (human)
extracellular spaceCholinesteraseHomo sapiens (human)
cytoplasmCytochrome P450 3A4Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 3A4Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 3A4Homo sapiens (human)
cytoplasmAlpha-2A adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-2A adrenergic receptorHomo sapiens (human)
basolateral plasma membraneAlpha-2A adrenergic receptorHomo sapiens (human)
neuronal cell bodyAlpha-2A adrenergic receptorHomo sapiens (human)
axon terminusAlpha-2A adrenergic receptorHomo sapiens (human)
presynaptic active zone membraneAlpha-2A adrenergic receptorHomo sapiens (human)
dopaminergic synapseAlpha-2A adrenergic receptorHomo sapiens (human)
postsynaptic density membraneAlpha-2A adrenergic receptorHomo sapiens (human)
glutamatergic synapseAlpha-2A adrenergic receptorHomo sapiens (human)
GABA-ergic synapseAlpha-2A adrenergic receptorHomo sapiens (human)
receptor complexAlpha-2A adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-2A adrenergic receptorHomo sapiens (human)
cytosolAlpha-2B adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-2B adrenergic receptorHomo sapiens (human)
cell surfaceAlpha-2B adrenergic receptorHomo sapiens (human)
intracellular membrane-bounded organelleAlpha-2B adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-2B adrenergic receptorHomo sapiens (human)
mitochondrionAmine oxidase [flavin-containing] AHomo sapiens (human)
mitochondrial outer membraneAmine oxidase [flavin-containing] AHomo sapiens (human)
cytosolAmine oxidase [flavin-containing] AHomo sapiens (human)
mitochondrionAmine oxidase [flavin-containing] AHomo sapiens (human)
mitochondrial outer membraneAmine oxidase [flavin-containing] A Bos taurus (cattle)
extracellular regionAcetylcholinesteraseHomo sapiens (human)
basement membraneAcetylcholinesteraseHomo sapiens (human)
extracellular spaceAcetylcholinesteraseHomo sapiens (human)
nucleusAcetylcholinesteraseHomo sapiens (human)
Golgi apparatusAcetylcholinesteraseHomo sapiens (human)
plasma membraneAcetylcholinesteraseHomo sapiens (human)
cell surfaceAcetylcholinesteraseHomo sapiens (human)
membraneAcetylcholinesteraseHomo sapiens (human)
neuromuscular junctionAcetylcholinesteraseHomo sapiens (human)
synaptic cleftAcetylcholinesteraseHomo sapiens (human)
synapseAcetylcholinesteraseHomo sapiens (human)
perinuclear region of cytoplasmAcetylcholinesteraseHomo sapiens (human)
side of membraneAcetylcholinesteraseHomo sapiens (human)
mitochondrionAmine oxidase [flavin-containing] BHomo sapiens (human)
mitochondrial envelopeAmine oxidase [flavin-containing] BHomo sapiens (human)
mitochondrial outer membraneAmine oxidase [flavin-containing] BHomo sapiens (human)
dendriteAmine oxidase [flavin-containing] BHomo sapiens (human)
neuronal cell bodyAmine oxidase [flavin-containing] BHomo sapiens (human)
mitochondrionAmine oxidase [flavin-containing] BHomo sapiens (human)
platelet alpha granule membraneAlpha-synucleinHomo sapiens (human)
extracellular regionAlpha-synucleinHomo sapiens (human)
extracellular spaceAlpha-synucleinHomo sapiens (human)
nucleusAlpha-synucleinHomo sapiens (human)
cytoplasmAlpha-synucleinHomo sapiens (human)
mitochondrionAlpha-synucleinHomo sapiens (human)
lysosomeAlpha-synucleinHomo sapiens (human)
cytosolAlpha-synucleinHomo sapiens (human)
plasma membraneAlpha-synucleinHomo sapiens (human)
cell cortexAlpha-synucleinHomo sapiens (human)
actin cytoskeletonAlpha-synucleinHomo sapiens (human)
membraneAlpha-synucleinHomo sapiens (human)
inclusion bodyAlpha-synucleinHomo sapiens (human)
axonAlpha-synucleinHomo sapiens (human)
growth coneAlpha-synucleinHomo sapiens (human)
synaptic vesicle membraneAlpha-synucleinHomo sapiens (human)
perinuclear region of cytoplasmAlpha-synucleinHomo sapiens (human)
postsynapseAlpha-synucleinHomo sapiens (human)
supramolecular fiberAlpha-synucleinHomo sapiens (human)
protein-containing complexAlpha-synucleinHomo sapiens (human)
cytoplasmAlpha-synucleinHomo sapiens (human)
axon terminusAlpha-synucleinHomo sapiens (human)
neuronal cell bodyAlpha-synucleinHomo sapiens (human)
cell surfaceC-X-C chemokine receptor type 3Homo sapiens (human)
cytoplasmC-X-C chemokine receptor type 3Homo sapiens (human)
plasma membraneC-X-C chemokine receptor type 3Homo sapiens (human)
external side of plasma membraneC-X-C chemokine receptor type 3Homo sapiens (human)
mitochondrionAmine oxidase [flavin-containing] BBos taurus (cattle)
mitochondrial outer membraneAmine oxidase [flavin-containing] BBos taurus (cattle)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (626)

Assay IDTitleYearJournalArticle
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID102895Compound was evaluated for the time-dependence inhibition of MAO-B at 30 minutes pre-incubation periods1993Journal of medicinal chemistry, Apr-30, Volume: 36, Issue:9
5-[4-(benzyloxy)phenyl]-1,3,4-oxadiazol-2(3H)-one derivatives and related analogues: new reversible, highly potent, and selective monamine oxidase type B inhibitors.
AID588216FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID346979Inhibition of MAO-B in rat liver homogenate after 60 mins by residual activity plot2009Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2
New pyrazoline bearing 4(3H)-quinazolinone inhibitors of monoamine oxidase: synthesis, biological evaluation, and structural determinants of MAO-A and MAO-B selectivity.
AID514142Inhibition of human recombinant MAOB expressed in baculovirus infected BTI-TN-5B1-4 insect cells assessed as hydrogen peroxide production from p-tyramine by amplex red assay2010Bioorganic & medicinal chemistry, Jul-15, Volume: 18, Issue:14
Synthesis, semipreparative HPLC separation, biological evaluation, and 3D-QSAR of hydrazothiazole derivatives as human monoamine oxidase B inhibitors.
AID1701088Inhibition of recombinant human MAO-B expressed in Sf9 cells using benzylamine as substrate preincubated for 15 mins followed by substrate addition for 60 mins by Luminex assay2020Journal of medicinal chemistry, 12-10, Volume: 63, Issue:23
Computational Fragment-Based Design Facilitates Discovery of Potent and Selective Monoamine Oxidase-B (MAO-B) Inhibitor.
AID127017Ex vivo inhibitory activity against rat brain monoamine oxidase (MAO) type B at a dose of 5 mg/kg administered orally at 1 hr1995Journal of medicinal chemistry, Nov-24, Volume: 38, Issue:24
Selective and potent monoamine oxidase type B inhibitors: 2-substituted 5-aryltetrazole derivatives.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1397360Apparent half-life of the terminal disposition phase in C57BL/6 mouse brain at 10.8 mg/kg, iv administered as single dose measured 24 hrs by UPLC-MS/MS analysis2018Journal of medicinal chemistry, 08-23, Volume: 61, Issue:16
Development of Novel Monoamine Oxidase-B (MAO-B) Inhibitors with Reduced Blood-Brain Barrier Permeability for the Potential Management of Noncentral Nervous System (CNS) Diseases.
AID387972Inhibition of bovine brain mitochondrial MAO-A by fluorometric assay2008Bioorganic & medicinal chemistry, Nov-15, Volume: 16, Issue:22
Synthesis, structure-activity relationships and molecular modeling studies of new indole inhibitors of monoamine oxidases A and B.
AID1278140Reversible inhibition of recombinant human MAO-B assessed as enzyme activity recovered pretreated with compound for 15 mins followed by addition of 50 uM kynuramine as substrate measured after 24 hrs by dialysis2016Bioorganic & medicinal chemistry letters, Feb-15, Volume: 26, Issue:4
Inhibition of monoamine oxidase by benzoxathiolone analogues.
AID743816Neurotoxicity in CD1 mouse assessed as decrease in straightening at 10 mg/kg, ip measured for 1 hr relative to control2013European journal of medicinal chemistry, May, Volume: 63Novel (coumarin-3-yl)carbamates as selective MAO-B inhibitors: synthesis, in vitro and in vivo assays, theoretical evaluation of ADME properties and docking study.
AID1261183Irreversible inhibition of human MAO-B expressed in baculovirus infected BT1 cells microsome fraction assessed as enzyme activity recovered at 10 times of IC50 concentration preincubated for 30 mins followed by dilution to 0.1 times of IC50 concentration 2015Bioorganic & medicinal chemistry letters, Nov-15, Volume: 25, Issue:22
Monoamine oxidase inhibitory activities of heterocyclic chalcones.
AID1409015Reversible inhibition of recombinant human MAO-B using kynuramine as substrate assessed as recovery of enzyme activity preincubated for 15 mins followed by dialysis for 24 hrs and subsequent addition of substrate measured after 20 mins by fluorescence spe2018Bioorganic & medicinal chemistry, 11-01, Volume: 26, Issue:20
Synthesis and evaluation of 2-substituted 4(3H)-quinazolinone thioether derivatives as monoamine oxidase inhibitors.
AID1406145Inhibition of human 5-lipoxygenase using arachidonic acid as substrate pretreated for 10 mins followed by substrate and ATP addition and measured after 20 mins by H2DCFDA probe based fluorescence assay2018European journal of medicinal chemistry, Aug-05, Volume: 156Neurogenic and neuroprotective donepezil-flavonoid hybrids with sigma-1 affinity and inhibition of key enzymes in Alzheimer's disease.
AID461715Inhibition of human recombinant MAOB expressed in BTI-TN-5B1-4 cells at 20 nM before washing by centrifugation-ultrafiltration method2010Bioorganic & medicinal chemistry, Feb, Volume: 18, Issue:3
A new series of flavones, thioflavones, and flavanones as selective monoamine oxidase-B inhibitors.
AID1493743Inhibition of recombinant human MAO-A using kynuramine as substrate after 20 mins by fluorescence assay2018European journal of medicinal chemistry, Jan-01, Volume: 143Design, synthesis and biochemical evaluation of novel multi-target inhibitors as potential anti-Parkinson agents.
AID1152914Inhibition of MAO-A in rat liver homogenate using [14C]-5HT as substrate preincubated for 30 mins followed by substrate addition measured after 20 mins by liquid scintillation counting analysis2014European journal of medicinal chemistry, Jun-10, Volume: 80Donepezil + propargylamine + 8-hydroxyquinoline hybrids as new multifunctional metal-chelators, ChE and MAO inhibitors for the potential treatment of Alzheimer's disease.
AID743813Inhibition of human recombinant microsomal MAO-A expressed in baculovirus infected BTI-TN-5B1-4 cells using p-tyramine as substrate assessed as production of H2O2 incubated for 15 mins followed by substrate addition measured over 15 mins by fluorimetric a2013European journal of medicinal chemistry, May, Volume: 63Novel (coumarin-3-yl)carbamates as selective MAO-B inhibitors: synthesis, in vitro and in vivo assays, theoretical evaluation of ADME properties and docking study.
AID410879Inhibition of MAOB in rat liver homogenates preincubated for 60 mins2008Bioorganic & medicinal chemistry letters, Dec-15, Volume: 18, Issue:24
Pyrazoline-based mycobactin analogues as MAO-inhibitors.
AID1195745Selectivity ratio of IC50 for human MAO-A expressed in baculovirus infected BTI insect cells to IC50 for human MAO-B expressed in baculovirus infected BTI insect cells2014Journal of medicinal chemistry, Dec-26, Volume: 57, Issue:24
N-Methyl-N-((1-methyl-5-(3-(1-(2-methylbenzyl)piperidin-4-yl)propoxy)-1H-indol-2-yl)methyl)prop-2-yn-1-amine, a new cholinesterase and monoamine oxidase dual inhibitor.
AID1416660Inhibition of recombinant human MAO-A expressed in baculovirus infected insect cells assessed as reduction in H2O2 production using p-tyramine as substrate pretreated for 15 mins followed by substrate addition and measured over 15 mins by Amplex red reage2017MedChemComm, Sep-01, Volume: 8, Issue:9
MAO inhibitory activity of bromo-2-phenylbenzofurans: synthesis,
AID1767578Inhibition of MAO-B (unknown origin) by fluorometric assay2021European journal of medicinal chemistry, Oct-15, Volume: 222Halting colorectal cancer metastasis via novel dual nanomolar MMP-9/MAO-A quinoxaline-based inhibitors; design, synthesis, and evaluation.
AID768158Inhibition of human recombinant MAO-B using benzylamine hydrochloride as substrate assessed as H2O2 synthesis at 10 uM after 1 hr by fluorescence assay2013Bioorganic & medicinal chemistry, Sep-01, Volume: 21, Issue:17
Oxazolopyridines and thiazolopyridines as monoamine oxidase B inhibitors for the treatment of Parkinson's disease.
AID1141990Inhibition of voltage gated calcium channel in Wistar rat brain synaptoneurosomes homogenate assessed as intracellular calcium at 100 uM after 30 mins incubation by Fura-2/AM assay2014European journal of medicinal chemistry, Jun-10, Volume: 80Polycyclic propargylamine and acetylene derivatives as multifunctional neuroprotective agents.
AID26304Partition coefficient (logD6.5)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID1383066Inhibition of human MAO-B expressed in baculovirus infected insect cell membranes using kynuramine as substrate preincubated for 30 mins followed by substrate addition measured after 15 to 20 mins by discontinuous fluorimetric method
AID1397346Efflux ratio of apparent permeability in MDCK2-MDR1 cells at 10 uM after 1 hr in absence of P-gp inhibitor verapamil by UPLC-MS/MS analysis2018Journal of medicinal chemistry, 08-23, Volume: 61, Issue:16
Development of Novel Monoamine Oxidase-B (MAO-B) Inhibitors with Reduced Blood-Brain Barrier Permeability for the Potential Management of Noncentral Nervous System (CNS) Diseases.
AID1406147Inhibition of recombinant human MAO-A expressed in baculovirus infected BTI insect cells using p-tyramine as substrate pretreated for 15 mins followed by substrate addition by horse-radish peroxidase/amplex red-based fluorescence method2018European journal of medicinal chemistry, Aug-05, Volume: 156Neurogenic and neuroprotective donepezil-flavonoid hybrids with sigma-1 affinity and inhibition of key enzymes in Alzheimer's disease.
AID314095Inhibition of MAOB2008Journal of medicinal chemistry, Feb-14, Volume: 51, Issue:3
Multi-target-directed ligands to combat neurodegenerative diseases.
AID367003Inhibition of bovine mitochondrial MAOA2008European journal of medicinal chemistry, Oct, Volume: 43, Issue:10
Synthesis, molecular modeling studies and selective inhibitory activity against MAO of N1-propanoyl-3,5-diphenyl-4,5-dihydro-(1H)-pyrazole derivatives.
AID622915Inhibition of human recombinant MAO-B expressed in insect BT1-TN-5B1-4 cells assessed as production of hydrogen peroxide from p-tyramine up to 15 mins by amplex red-based fluorometric assay2011Journal of medicinal chemistry, Oct-27, Volume: 54, Issue:20
Synthesis and study of a series of 3-arylcoumarins as potent and selective monoamine oxidase B inhibitors.
AID1891689Inhibition of human recombinant MAOB using kynuramine substrate incubated for 20 mins by fluorescence spectrophotometry2022Bioorganic & medicinal chemistry letters, 07-01, Volume: 67The evaluation of N-propargylamine-2-aminotetralin as an inhibitor of monoamine oxidase.
AID1891695Inhibition of human recombinant MAOB assessed as enzyme activity recovery level using kynuramine substrate incubated for 15 mins followed by 24 hrs dialysis by fluorescence spectrophotometry2022Bioorganic & medicinal chemistry letters, 07-01, Volume: 67The evaluation of N-propargylamine-2-aminotetralin as an inhibitor of monoamine oxidase.
AID277620Selectivity index, pIC50 for MAO-A/pIC50 for MAO-B2007Journal of medicinal chemistry, Feb-08, Volume: 50, Issue:3
Monoamine oxidase isoform-dependent tautomeric influence in the recognition of 3,5-diaryl pyrazole inhibitors.
AID395325Lipophilicity, log P by microemulsion electrokinetic chromatography2009Journal of medicinal chemistry, Mar-26, Volume: 52, Issue:6
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.
AID29811Oral bioavailability in human2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID1057559Inhibition of human recombinant MAO-B expressed in insect cells by Amplex Red assay2013Bioorganic & medicinal chemistry, Dec-15, Volume: 21, Issue:24
Chromenylchalcones with inhibitory effects on monoamine oxidase B.
AID277618Inhibition of MAO-A in bovine brain mitochondria by fluorimetric method2007Journal of medicinal chemistry, Feb-08, Volume: 50, Issue:3
Monoamine oxidase isoform-dependent tautomeric influence in the recognition of 3,5-diaryl pyrazole inhibitors.
AID279954Inhibition of bovine brain mitochondria MAOB by fluorometric assay2007Journal of medicinal chemistry, Mar-08, Volume: 50, Issue:5
New pyrrole inhibitors of monoamine oxidase: synthesis, biological evaluation, and structural determinants of MAO-A and MAO-B selectivity.
AID1413454Irreversible inhibition of recombinant human MAO-A at 5 time Ki value preincubated for 15 mins followed by dilution of enzyme-inhibitor mixture for 24 hrs and subsequent p-tyramine substrate addition by dialysis method
AID514201Irreversible inhibition of human recombinant MAOB expressed in baculovirus infected BTI-TN-5B1-4 insect cells assessed as hydrogen peroxide production from p-tyramine at 20 nM measured after repeated washing by centrifugation-ultrafiltration method2010Bioorganic & medicinal chemistry, Jul-15, Volume: 18, Issue:14
Synthesis, semipreparative HPLC separation, biological evaluation, and 3D-QSAR of hydrazothiazole derivatives as human monoamine oxidase B inhibitors.
AID1551712Anti-neuroinflammatory activity in po dosed MPTP-induced C57BL/6 mouse model of Parkinson's disease assessed as increase in tyrosine hydroxylase expression in mid brain at 10 mg/kg, po pretreated for 30 mins followed by MPTP challenge for 7 days and subse2019European journal of medicinal chemistry, Jul-01, Volume: 173Discovery of coumarin Mannich base derivatives as multifunctional agents against monoamine oxidase B and neuroinflammation for the treatment of Parkinson's disease.
AID765364Reversible inhibition of human recombinant MAO-B expressed in insect cell microsomes assessed as recovery of enzyme activity incubated at 10 times IC50 for 30 mins measured after 100 fold dilution relative to control2013Bioorganic & medicinal chemistry letters, Sep-01, Volume: 23, Issue:17
Selected furanochalcones as inhibitors of monoamine oxidase.
AID1636271Selectivity index, ratio of IC50 for human recombinant MAO-A to IC50 for human recombinant MAO-B2016Bioorganic & medicinal chemistry, 10-15, Volume: 24, Issue:20
Design, synthesis and biological evaluation of N-methyl-N-[(1,2,3-triazol-4-yl)alkyl]propargylamines as novel monoamine oxidase B inhibitors.
AID515170Inhibition of human recombinant MAOA expressed in baculovirus infected BTI insect cells assessed as hydrogen peroxide production after 15 mins by Amplex red assay2010European journal of medicinal chemistry, Oct, Volume: 45, Issue:10
Synthesis of new 3-aryl-4,5-dihydropyrazole-1-carbothioamide derivatives. An investigation on their ability to inhibit monoamine oxidase.
AID747670Inhibition of MAO-B in mitochondria-enriched Sprague-Dawley rat liver fractions using p-tyramine as substrate incubated for 30 mins prior to substrate addition measured for 45 mins by amplex red reagent-based microplate fluorescence reader analysis2013Journal of medicinal chemistry, Jun-13, Volume: 56, Issue:11
Dual targeting of adenosine A(2A) receptors and monoamine oxidase B by 4H-3,1-benzothiazin-4-ones.
AID437350Inhibition of MAOB at 100 nM after 60 mins using benylamine as substrate relative to control2009European journal of medicinal chemistry, Oct, Volume: 44, Issue:10
Facile synthesis and in vitro properties of 1-alkyl- and 1-alkyl-N-propargyl-1,2,3,4-tetrahydroisoquinoline derivatives on PC12 cells.
AID589435Inhibition of human recombinant MAO-B expressed in BTI-TN-5B1-4 cells assessed as H2O2 production using para-tyramine substrate by fluorimetric method2011European journal of medicinal chemistry, Apr, Volume: 46, Issue:4
Synthesis, human monoamine oxidase inhibitory activity and molecular docking studies of 3-heteroarylcoumarin derivatives.
AID619471Selectivity ratio of IC50 for human recombinant MAO-A to IC50 for human recombinant MAO-B2011European journal of medicinal chemistry, Oct, Volume: 46, Issue:10
Synthesis and selective human monoamine oxidase inhibition of 3-carbonyl, 3-acyl, and 3-carboxyhydrazido coumarin derivatives.
AID1397359Apparent half-life of the terminal disposition phase in C57BL/6 mouse plasma at 10.8 mg/kg, iv administered as single dose measured 24 hrs by UPLC-MS/MS analysis2018Journal of medicinal chemistry, 08-23, Volume: 61, Issue:16
Development of Novel Monoamine Oxidase-B (MAO-B) Inhibitors with Reduced Blood-Brain Barrier Permeability for the Potential Management of Noncentral Nervous System (CNS) Diseases.
AID22293Delta logD (logD6.5 - logD7.4)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID1301267Inhibition of human recombinant microsomal MAO-B expressed in baculovirus infected BTI-TN-5B1-4 cells using p-tyramine as substrate assessed as reduction in H2O2 production preincubated for 15 mins followed by substrate addition measured for 15 mins Ample2016European journal of medicinal chemistry, Jul-19, Volume: 117(E)-3-Heteroarylidenechroman-4-ones as potent and selective monoamine oxidase-B inhibitors.
AID126675The ability of the compound(25 umol/kg/day) to inactivate monoamine oxidase B (MAO-B) was tested on brain mitochondrial membranes of mice, for 3 day.1996Journal of medicinal chemistry, Nov-22, Volume: 39, Issue:24
Synthesis and selective monoamine oxidase B-inhibiting properties of 1-methyl-1,2,3,6-tetrahydropyrid-4-yl carbamate derivatives: potential prodrugs of (R)- and (S)-nordeprenyl.
AID1586575Inhibition of human recombinant MAO-B expressed in baculovirus infected BTI-TN-5B1-4 insect cells using p-tyramine as substrate preincubated for 15 mins and measured after 45 mins by resorufin-based fluorescence assay2019European journal of medicinal chemistry, Jan-15, Volume: 162(Pyrrolo-pyridin-5-yl)benzamides: BBB permeable monoamine oxidase B inhibitors with neuroprotective effect on cortical neurons.
AID501518Inhibition of human MAOB expressed in BTI insect cells2010Bioorganic & medicinal chemistry letters, Sep-01, Volume: 20, Issue:17
New halogenated 3-phenylcoumarins as potent and selective MAO-B inhibitors.
AID619468Inhibition of human recombinant MAO-B expressed in baculovirus infected BTI-TN-5B1-4 cells assessed as production of hydrogen peroxide from p-tyramine after 15 mins by microplate fluorescence assay2011European journal of medicinal chemistry, Oct, Volume: 46, Issue:10
Synthesis and selective human monoamine oxidase inhibition of 3-carbonyl, 3-acyl, and 3-carboxyhydrazido coumarin derivatives.
AID1406148Inhibition of recombinant human MAO-B expressed in baculovirus infected BTI insect cells using p-tyramine as substrate pretreated for 15 mins followed by substrate addition by horse-radish peroxidase/amplex red-based fluorescence method2018European journal of medicinal chemistry, Aug-05, Volume: 156Neurogenic and neuroprotective donepezil-flavonoid hybrids with sigma-1 affinity and inhibition of key enzymes in Alzheimer's disease.
AID361935Inhibition of human recombinant MAOA2008Journal of medicinal chemistry, Aug-28, Volume: 51, Issue:16
Synthesis, stereochemical identification, and selective inhibitory activity against human monoamine oxidase-B of 2-methylcyclohexylidene-(4-arylthiazol-2-yl)hydrazones.
AID678712Inhibition of human CYP1A2 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using ethoxyresorufin as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID1140813Selectivity index, ratio of IC50 for human recombinant MAO-A expressed in baculovirus-infected BTI-TN-5B1-4 cell microsomes to IC50 for human recombinant MAO-B expressed in baculovirus-infected BTI-TN-5B1-4 cell microsomes2014Bioorganic & medicinal chemistry, May-15, Volume: 22, Issue:10
Identification of the stereochemical requirements in the 4-aryl-2-cycloalkylidenhydrazinylthiazole scaffold for the design of selective human monoamine oxidase B inhibitors.
AID127019Ex vivo inhibitory activity against rat brain monoamine oxidase (MAO) type B at a dose of 5 mg/kg administered orally at 24 hr1995Journal of medicinal chemistry, Nov-24, Volume: 38, Issue:24
Selective and potent monoamine oxidase type B inhibitors: 2-substituted 5-aryltetrazole derivatives.
AID743808Neurotoxicity in CD1 mouse assessed as decrease in motor activity at 10 mg/kg, ip measured for 1 hr relative to control2013European journal of medicinal chemistry, May, Volume: 63Novel (coumarin-3-yl)carbamates as selective MAO-B inhibitors: synthesis, in vitro and in vivo assays, theoretical evaluation of ADME properties and docking study.
AID540211Fraction unbound in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1767579Selectivity for MAO-B (unknown origin) to MAO-A (unknown origin)2021European journal of medicinal chemistry, Oct-15, Volume: 222Halting colorectal cancer metastasis via novel dual nanomolar MMP-9/MAO-A quinoxaline-based inhibitors; design, synthesis, and evaluation.
AID1397363AUClast in C57BL/6 mouse brain at 10.8 mg/kg, iv administered as single dose measured 24 hrs by UPLC-MS/MS analysis2018Journal of medicinal chemistry, 08-23, Volume: 61, Issue:16
Development of Novel Monoamine Oxidase-B (MAO-B) Inhibitors with Reduced Blood-Brain Barrier Permeability for the Potential Management of Noncentral Nervous System (CNS) Diseases.
AID1192628Selectivity for MAO-B in rat whole brain homogenate over MAO-A in rat whole brain homogenate2015Bioorganic & medicinal chemistry, Feb-15, Volume: 23, Issue:4
Reversible and irreversible small molecule inhibitors of monoamine oxidase B (MAO-B) investigated by biophysical techniques.
AID610969Inhibition of human MAO-A assessed as inhibition of p-tyramine oxidation to p-hydroxyphenyl-acetaldehyde after 15 mins by fluorimetric method2011Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
Chromone, a privileged scaffold for the development of monoamine oxidase inhibitors.
AID1195740Inhibition of human MAO-A expressed in baculovirus infected BTI insect cells preincubated for 15 mins2014Journal of medicinal chemistry, Dec-26, Volume: 57, Issue:24
N-Methyl-N-((1-methyl-5-(3-(1-(2-methylbenzyl)piperidin-4-yl)propoxy)-1H-indol-2-yl)methyl)prop-2-yn-1-amine, a new cholinesterase and monoamine oxidase dual inhibitor.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID1519692Inhibition of human microsomal MAO-A expressed in baculovirus infected BTI-TN-5B1-4 cells assessed as reduction in 4-hydroxyquinoline formation using kynuramine as substrate preincubated with substrate for 10 mins followed by enzyme addition by spectropho2020European journal of medicinal chemistry, Jan-01, Volume: 185Design of novel monoamine oxidase-B inhibitors based on piperine scaffold: Structure-activity-toxicity, drug-likeness and efflux transport studies.
AID456468Inhibition of MAO in mouse cortex at 10 uM by tube luminometry2010Bioorganic & medicinal chemistry, Jan-01, Volume: 18, Issue:1
New oxapolycyclic cage amines with NMDA receptor antagonist and trypanocidal activities.
AID551669Selectivity ratio of IC50 for human recombinant MAOA to IC50 for human recombinant MAOB2011Bioorganic & medicinal chemistry letters, Jan-15, Volume: 21, Issue:2
Chromone 3-phenylcarboxamides as potent and selective MAO-B inhibitors.
AID588219FDA HLAED, gamma-glutamyl transferase (GGT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1900900Inhibition of MAO-B (unknown origin)2022European journal of medicinal chemistry, Feb-05, Volume: 229Synthesis of novel thiazolyl hydrazone derivatives as potent dual monoamine oxidase-aromatase inhibitors.
AID599360Selectivity index, ratio of IC50 for human recombinant MAOA to IC50 for human recombinant MAOB2009Bioorganic & medicinal chemistry letters, Jun-15, Volume: 19, Issue:12
A new series of 3-phenylcoumarins as potent and selective MAO-B inhibitors.
AID361939Ratio of IC50 for human recombinant MAOA to IC50 for human recombinant MAOB2008Journal of medicinal chemistry, Aug-28, Volume: 51, Issue:16
Synthesis, stereochemical identification, and selective inhibitory activity against human monoamine oxidase-B of 2-methylcyclohexylidene-(4-arylthiazol-2-yl)hydrazones.
AID743805Potentiation of L-dopa/carbidopa activity in reserpine-treated CD1 mouse assessed as increase in movement at 10 mg/kg, ip administered 22 hrs post reserpine challenge followed by L-dopa/carbidopa adminstration at 30 mins measured after 1 hr relative to co2013European journal of medicinal chemistry, May, Volume: 63Novel (coumarin-3-yl)carbamates as selective MAO-B inhibitors: synthesis, in vitro and in vivo assays, theoretical evaluation of ADME properties and docking study.
AID1320878Antioxidant activity assessed as AAPH free radical scavenging activity by measuring trolox equivalent by oxygen radical absorbance capacity method2016European journal of medicinal chemistry, Oct-04, Volume: 121New cinnamic - N-benzylpiperidine and cinnamic - N,N-dibenzyl(N-methyl)amine hybrids as Alzheimer-directed multitarget drugs with antioxidant, cholinergic, neuroprotective and neurogenic properties.
AID528278Inhibition of human recombinant MAO-A expressed in baculovirus infected BT1 cells2010Bioorganic & medicinal chemistry letters, Nov-15, Volume: 20, Issue:22
Synthesis and molecular modelling studies of prenylated pyrazolines as MAO-B inhibitors.
AID1397343Efflux ratio of apparent permeability in MDCK cells at 10 uM after 1 hr in presence of P-gp inhibitor verapamil by UPLC-MS/MS analysis2018Journal of medicinal chemistry, 08-23, Volume: 61, Issue:16
Development of Novel Monoamine Oxidase-B (MAO-B) Inhibitors with Reduced Blood-Brain Barrier Permeability for the Potential Management of Noncentral Nervous System (CNS) Diseases.
AID127021Ex vivo inhibitory activity against rat brain monoamine oxidase (MAO) type B at a dose of 5 mg/kg administered orally at 8 hr1995Journal of medicinal chemistry, Nov-24, Volume: 38, Issue:24
Selective and potent monoamine oxidase type B inhibitors: 2-substituted 5-aryltetrazole derivatives.
AID127347Inhibitory activity against rat brain mitochondrial Monoamine oxidase1985Journal of medicinal chemistry, Feb, Volume: 28, Issue:2
Enzyme-activated irreversible inhibitors of monoamine oxidase: phenylallylamine structure-activity relationships.
AID102739In vitro inhibitory activity on rat brain by monoamine oxidase A (MAO-A)1993Journal of medicinal chemistry, Apr-30, Volume: 36, Issue:9
5-[4-(benzyloxy)phenyl]-1,3,4-oxadiazol-2(3H)-one derivatives and related analogues: new reversible, highly potent, and selective monamine oxidase type B inhibitors.
AID672471Inhibition of human recombinant MAO-B using kynuramine as substrate preincubated with compound for 15 mins measured after 20 mins by fluorometric analysis2012Bioorganic & medicinal chemistry letters, Aug-01, Volume: 22, Issue:15
Synthesis and evaluation of aplysinopsin analogs as inhibitors of human monoamine oxidase A and B.
AID593111Inhibition of human recombinant MAO-A expressed in baculovirus infected BTI-TN-5B1-4 insect sells assessed as hydrogen peroxide production by fluorimetric method2011Journal of medicinal chemistry, Apr-14, Volume: 54, Issue:7
Homoisoflavonoids: natural scaffolds with potent and selective monoamine oxidase-B inhibition properties.
AID1068746In vivo inhibition of MAO-A in Sprague-Dawley rat assessed as 3,4-dihydroxyphenylacetic acid level in brain striatum at 53 umol/kg, sc after 1 hr by HPLC/EC analysis relative to control2014European journal of medicinal chemistry, Feb-12, Volume: 73A novel series of 6-substituted 3-(pyrrolidin-1-ylmethyl)chromen-2-ones as selective monoamine oxidase (MAO) A inhibitors.
AID1528930Irreversible inhibition of recombinant human MAOB expressed in Pichia pastoris using varying levels of kynuramine as substrate measured after 5 mins by Michaelis-Menten equation analysis
AID444053Renal clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID114157Antidepressant activity was evaluated by measuring its ability to antagonize reserpine-induced ptosis in mice1988Journal of medicinal chemistry, Jun, Volume: 31, Issue:6
2,4-Dihydro-3H-1,2,4-triazole-3-thiones as potential antidepressant agents.
AID1378858Selectivity index, ratio of IC50 for human recombinant MAO-A expressed in baculovirus infected BTI-TN5B1-4 cells to IC50 for human recombinant MAO-B expressed in baculovirus infected BTI-TN5B1-4 cells2017European journal of medicinal chemistry, Oct-20, Volume: 139Synthesis and structure-activity relationship study of novel 3-heteroarylcoumarins based on pyridazine scaffold as selective MAO-B inhibitors.
AID126188Ex vivo inhibitory activity against rat brain monoamine oxidase (MAO) type A at a dose of 5 mg/kg administered orally at 8 hr1995Journal of medicinal chemistry, Nov-24, Volume: 38, Issue:24
Selective and potent monoamine oxidase type B inhibitors: 2-substituted 5-aryltetrazole derivatives.
AID593112Selectivity index, ratio of IC50 for human MAO-A to IC50 for human MAO-B2011Journal of medicinal chemistry, Apr-14, Volume: 54, Issue:7
Homoisoflavonoids: natural scaffolds with potent and selective monoamine oxidase-B inhibition properties.
AID444051Total clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1261185Irreversible inhibition of human MAO-B expressed in baculovirus infected BT1 cells microsome fraction assessed as residual enzyme activity at 4 times of IC50 concentration preincubated for 15 mins followed by dialysis for 24 hrs by fluorescence spectromet2015Bioorganic & medicinal chemistry letters, Nov-15, Volume: 25, Issue:22
Monoamine oxidase inhibitory activities of heterocyclic chalcones.
AID678714Inhibition of human CYP2C19 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 3-butyryl-7-methoxycoumarin as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID590317Competitive inhibition of human recombinant MAO-B after 60 mins using p-tyramine as substrate by spectrophotometry2011Bioorganic & medicinal chemistry letters, Apr-01, Volume: 21, Issue:7
Development of selective and reversible pyrazoline based MAO-B inhibitors: virtual screening, synthesis and biological evaluation.
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID349912Inhibition of human recombinant MAO-B assessed as hydrogen peroxide production2009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
Chalcones: a valid scaffold for monoamine oxidases inhibitors.
AID1416662Inhibition of recombinant human MAO-B expressed in baculovirus infected insect cells assessed as reduction in H2O2 production using p-tyramine as substrate pretreated for 15 mins followed by substrate addition and measured over 15 mins by Amplex red reage2017MedChemComm, Sep-01, Volume: 8, Issue:9
MAO inhibitory activity of bromo-2-phenylbenzofurans: synthesis,
AID1192634Inhibition of human recombinant soluble MAO-B assessed as change in melting temperature at 10 uM after 20 mins by SYPRO orange staining-based fluorescence assay2015Bioorganic & medicinal chemistry, Feb-15, Volume: 23, Issue:4
Reversible and irreversible small molecule inhibitors of monoamine oxidase B (MAO-B) investigated by biophysical techniques.
AID637760Inhibition of human recombinant MAO-B expressed in baculovirus infected BTI-TN-5B1-4 insect cells assessed as inhibition of hydrogen peroxide production from p-tryptamine after 15 mins by fluorimetric method2012European journal of medicinal chemistry, Feb, Volume: 48Synthesis and biological assessment of novel 2-thiazolylhydrazones and computational analysis of their recognition by monoamine oxidase B.
AID1421879Inhibition of human recombinant microsomal MAOA expressed in baculovirus infected BTI-TN-5B1- 4 cells using p-tyramine as substrate assessed as decrease in H2O2 production by amplex red-based fluorescence assay2018European journal of medicinal chemistry, Oct-05, Volume: 158Multi-target-directed ligands for Alzheimer's disease: Discovery of chromone-based monoamine oxidase/cholinesterase inhibitors.
AID588218FDA HLAED, lactate dehydrogenase (LDH) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1195741Inhibition of human MAO-B expressed in baculovirus infected BTI insect cells preincubated for 15 mins2014Journal of medicinal chemistry, Dec-26, Volume: 57, Issue:24
N-Methyl-N-((1-methyl-5-(3-(1-(2-methylbenzyl)piperidin-4-yl)propoxy)-1H-indol-2-yl)methyl)prop-2-yn-1-amine, a new cholinesterase and monoamine oxidase dual inhibitor.
AID1528932Irreversible inhibition of recombinant human MAOB expressed in Pichia pastoris assessed as inactivation rate constant using varying levels of kynuramine as substrate measured after 5 mins by Michaelis-Menten equation analysis
AID1194966Irreversible inhibition of human recombinant MAOB pre-incubated for 15 mins subsequently dialysed for 24 hrs followed by two fold dilution with kynuramine substrate assessed as enzyme catalytic activity by measuring 4-hydroxyquinoline level after 20 mins 2015Bioorganic & medicinal chemistry letters, May-01, Volume: 25, Issue:9
The synthesis and evaluation of sesamol and benzodioxane derivatives as inhibitors of monoamine oxidase.
AID361936Inhibition of human recombinant MAOB2008Journal of medicinal chemistry, Aug-28, Volume: 51, Issue:16
Synthesis, stereochemical identification, and selective inhibitory activity against human monoamine oxidase-B of 2-methylcyclohexylidene-(4-arylthiazol-2-yl)hydrazones.
AID468863Inhibition of human recombinant MAOA2010European journal of medicinal chemistry, Feb, Volume: 45, Issue:2
Synthesis and inhibitory activity against human monoamine oxidase of N1-thiocarbamoyl-3,5-di(hetero)aryl-4,5-dihydro-(1H)-pyrazole derivatives.
AID367273Inhibition of bovine mitochondrial MAOB2008European journal of medicinal chemistry, Oct, Volume: 43, Issue:10
Synthesis, molecular modeling studies and selective inhibitory activity against MAO of N1-propanoyl-3,5-diphenyl-4,5-dihydro-(1H)-pyrazole derivatives.
AID747668Selectivity ratio of IC50 for MAO-B in mitochondria-enriched Sprague-Dawley rat liver fractions to IC50 for recombinant human MAO-B2013Journal of medicinal chemistry, Jun-13, Volume: 56, Issue:11
Dual targeting of adenosine A(2A) receptors and monoamine oxidase B by 4H-3,1-benzothiazin-4-ones.
AID669059Displacement of [3H]-Ro 41-1049 from MAO-A receptor in rat cerebral cortex2012Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7
Synthesis and evaluation of a set of para-substituted 4-phenylpiperidines and 4-phenylpiperazines as monoamine oxidase (MAO) inhibitors.
AID437349Inhibition of MAOB at 100 nM after 60 mins using tyramine as substrate relative to control2009European journal of medicinal chemistry, Oct, Volume: 44, Issue:10
Facile synthesis and in vitro properties of 1-alkyl- and 1-alkyl-N-propargyl-1,2,3,4-tetrahydroisoquinoline derivatives on PC12 cells.
AID1413452Suicide inhibition of recombinant human MAO-A assessed as reduction in H2O2 production preincubated for 30 mins followed by p-tyramine substrate addition measured after 30 mins by Lineweaver-Burk plot analysis
AID743815Neurotoxicity in CD1 mouse assessed as decrease in movement at 10 mg/kg, ip measured for 1 hr relative to control2013European journal of medicinal chemistry, May, Volume: 63Novel (coumarin-3-yl)carbamates as selective MAO-B inhibitors: synthesis, in vitro and in vivo assays, theoretical evaluation of ADME properties and docking study.
AID1556702Selectivity index, ratio of IC50 for human recombinant MAO-A expressed in baculovirus infected BTI-TN-5B1-4 cells to IC50 for human recombinant MAO-B expressed in baculovirus infected BTI-TN-5B1-4 cells2019European journal of medicinal chemistry, Oct-01, Volume: 179Carboxamides vs. methanimines: Crystal structures, binding interactions, photophysical studies, and biological evaluation of (indazole-5-yl)methanimines as monoamine oxidase B and acetylcholinesterase inhibitors.
AID346980Inhibition of MAO-A in rat liver homogenate after 60 mins by residual activity plot2009Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2
New pyrazoline bearing 4(3H)-quinazolinone inhibitors of monoamine oxidase: synthesis, biological evaluation, and structural determinants of MAO-A and MAO-B selectivity.
AID733499Selectivity index, ratio of IC50 for recombinant human MAO-A expressed in baculovirus infected BT1-TN-5B1-4 cells to recombinant human MAO-B expressed in baculovirus infected BT1-TN-5B1-4 cells2013European journal of medicinal chemistry, Jan, Volume: 591,5-Diphenylpenta-2,4-dien-1-ones as potent and selective monoamine oxidase-B inhibitors.
AID125403In vitro inhibition of Monoamine oxidase at rat hyphalamic mitochondrial 5-HT by displacing 2.5 uM of [14C]5-HT.1983Journal of medicinal chemistry, Jul, Volume: 26, Issue:7
Synthesis and monoamine oxidase inhibitory activities of alpha-allenic amines in vivo and in vitro. Different activities of two enantiomeric allenes.
AID478550Selectivity index, ratio of IC50 for human recombinant MAO-B to IC50 for human recombinant MAO-A2010Bioorganic & medicinal chemistry letters, May-01, Volume: 20, Issue:9
Chromone-2- and -3-carboxylic acids inhibit differently monoamine oxidases A and B.
AID102580Compound was evaluated for the reversibility test for the percentage inhibition of MAO B at 6.25 nM before the test at 12.5 nM1993Journal of medicinal chemistry, Apr-30, Volume: 36, Issue:9
5-[4-(benzyloxy)phenyl]-1,3,4-oxadiazol-2(3H)-one derivatives and related analogues: new reversible, highly potent, and selective monamine oxidase type B inhibitors.
AID346978Inhibition of MAO-B in rat liver homogenate after 60 mins by Lineweaver-Burke plot2009Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2
New pyrazoline bearing 4(3H)-quinazolinone inhibitors of monoamine oxidase: synthesis, biological evaluation, and structural determinants of MAO-A and MAO-B selectivity.
AID387973Inhibition of bovine brain mitochondrial MAO-B by fluorometric assay2008Bioorganic & medicinal chemistry, Nov-15, Volume: 16, Issue:22
Synthesis, structure-activity relationships and molecular modeling studies of new indole inhibitors of monoamine oxidases A and B.
AID588215FDA HLAED, alkaline phosphatase increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1397431Acute toxicity in C57BL/6 mouse assessed as lethargy at 10.8 mg/kg, sc after 1 hr post-injection2018Journal of medicinal chemistry, 08-23, Volume: 61, Issue:16
Development of Novel Monoamine Oxidase-B (MAO-B) Inhibitors with Reduced Blood-Brain Barrier Permeability for the Potential Management of Noncentral Nervous System (CNS) Diseases.
AID1245395Inhibition of recombinant human MAOB using benzylamine as substrate after 30 mins by Amplex red based spectrophotometric analysis2015Bioorganic & medicinal chemistry, Oct-01, Volume: 23, Issue:19
Synthesis of a series of unsaturated ketone derivatives as selective and reversible monoamine oxidase inhibitors.
AID1524508Inhibition of recombinant human MAOB expressed in baculovirus infected BTI insect cells using p-tyramine as substrate preincubated for 30 mins followed by substrate addition and measured over 15 mins by Amplex red reagent/horseradish peroxidase coupled fl2019Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9
Discovery of novel 2,3-dihydro-1H-inden-1-amine derivatives as selective monoamine oxidase B inhibitors.
AID678718Metabolic stability in human liver microsomes assessed as high signal/noise ratio (S/N of >100) by measuring GSH adduct formation at 100 uM after 90 mins by HPLC-MS analysis2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID136946Compound was evaluated for MAO-B activity after 1 day of chronic peritoneal administration in mouse fore brain at dose of 0.2 mg/kg1992Journal of medicinal chemistry, Oct-02, Volume: 35, Issue:20
Aliphatic propargylamines: potent, selective, irreversible monoamine oxidase B inhibitors.
AID1241458Inhibition of electric eel AChE using acetylthiocholine iodide substrate by Ellman assay2015Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
Evaluation of Homobivalent Carbolines as Designed Multiple Ligands for the Treatment of Neurodegenerative Disorders.
AID1141992Inhibition of MAO-B in baboon liver mitochondrial fraction using MPTP substrate at 300 uM2014European journal of medicinal chemistry, Jun-10, Volume: 80Polycyclic propargylamine and acetylene derivatives as multifunctional neuroprotective agents.
AID604270Competitive inhibition of human MAO-B expressed in BTI insect cells using p-tyramine as substrate after 60 mins2011Bioorganic & medicinal chemistry letters, Jul-15, Volume: 21, Issue:14
Pyrazoline based MAO inhibitors: synthesis, biological evaluation and SAR studies.
AID1152915Inhibition of MAO-B in rat liver homogenate using [14C]-phenylethylamine as substrate preincubated for 30 mins followed by substrate addition measured after 4 mins by liquid scintillation counting analysis2014European journal of medicinal chemistry, Jun-10, Volume: 80Donepezil + propargylamine + 8-hydroxyquinoline hybrids as new multifunctional metal-chelators, ChE and MAO inhibitors for the potential treatment of Alzheimer's disease.
AID515175Selectivity index, ratio of IC50 for human recombinant MAOA to IC50 for human recombinant MAOB2010European journal of medicinal chemistry, Oct, Volume: 45, Issue:10
Synthesis of new 3-aryl-4,5-dihydropyrazole-1-carbothioamide derivatives. An investigation on their ability to inhibit monoamine oxidase.
AID425653Renal clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID125373Monoamine oxidase B inhibition 24 hours after the intraperitoneal injection into mice at 150 uM/kg1983Journal of medicinal chemistry, Jul, Volume: 26, Issue:7
Synthesis and monoamine oxidase inhibitory activities of alpha-allenic amines in vivo and in vitro. Different activities of two enantiomeric allenes.
AID1498905Inhibition of human MAO-B using p-tyramine as substrate after 15 mins by amplex red reagent based assay2018Bioorganic & medicinal chemistry, 07-30, Volume: 26, Issue:13
Developing hybrid molecule therapeutics for diverse enzyme inhibitory action: Active role of coumarin-based structural leads in drug discovery.
AID298032Acid dissociation constant, pKa of the compound2007Journal of medicinal chemistry, Sep-20, Volume: 50, Issue:19
High-throughput screening of drug-brain tissue binding and in silico prediction for assessment of central nervous system drug delivery.
AID635344Selectivity ratio of Ki for rat MAO-A to Ki for rat MAO-B2011Bioorganic & medicinal chemistry, Dec-15, Volume: 19, Issue:24
Molecular insights into human monoamine oxidase (MAO) inhibition by 1,4-naphthoquinone: evidences for menadione (vitamin K3) acting as a competitive and reversible inhibitor of MAO.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID767289Inhibition of human recombinant microsomal MAO-A expressed in baculovirus-infected insect BTI-TN-5B1-4 cells assessed as p-tyramine conversion to H2O2 by fluorescence assay2013Bioorganic & medicinal chemistry letters, Sep-15, Volume: 23, Issue:18
Design, synthesis, and in vitro hMAO-B inhibitory evaluation of some 1-methyl-3,5-diphenyl-4,5-dihydro-1H-pyrazoles.
AID593170Inhibition of human recombinant MAO-B expressed in baculovirus infected BTI-TN-5B1-4 insect sells assessed as hydrogen peroxide production at 20 nM by fluorimetric method2011Journal of medicinal chemistry, Apr-14, Volume: 54, Issue:7
Homoisoflavonoids: natural scaffolds with potent and selective monoamine oxidase-B inhibition properties.
AID1231601Inhibition of human recombinant MAO-A using p-tyramine as substrate incubated for 15 mins prior to substrate addition measured after 20 mins by fluorescence plate reader analysis2015Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13
Synthesis and evaluation of selegiline derivatives as monoamine oxidase inhibitor, antioxidant and metal chelator against Alzheimer's disease.
AID1851418Irreversible inhibition of human MAO-B assessed as enzyme residual activity using p-tyramine as substrate measured after dialysis by dialysis method2022Bioorganic & medicinal chemistry letters, 10-15, Volume: 74Synthesis and human monoamine oxidase inhibitory activity of novel C2-, C3- and C4-substituted phthalonitriles.
AID1397342Inhibition of human recombinant MAO-B expressed in baculovirus infected BTI-TN-5B1-4 insect cells using benzylamine as substrate preincubated for 1 hr followed by substrate addition and measured after 30 mins by resazurin dye-based fluorescence assay2018Journal of medicinal chemistry, 08-23, Volume: 61, Issue:16
Development of Novel Monoamine Oxidase-B (MAO-B) Inhibitors with Reduced Blood-Brain Barrier Permeability for the Potential Management of Noncentral Nervous System (CNS) Diseases.
AID444055Fraction absorbed in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID102896Compound was evaluated for the time-dependence inhibition of MAO-B at 60 minutes preincubation periods1993Journal of medicinal chemistry, Apr-30, Volume: 36, Issue:9
5-[4-(benzyloxy)phenyl]-1,3,4-oxadiazol-2(3H)-one derivatives and related analogues: new reversible, highly potent, and selective monamine oxidase type B inhibitors.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID1140811Inhibition of human recombinant MAO-A expressed in baculovirus-infected BTI-TN-5B1-4 cell microsomes assessed as decrease in H2O2 production using p-tyramine as substrate preincubated for 15 mins by Amplex Red reagent based fluorimetric method2014Bioorganic & medicinal chemistry, May-15, Volume: 22, Issue:10
Identification of the stereochemical requirements in the 4-aryl-2-cycloalkylidenhydrazinylthiazole scaffold for the design of selective human monoamine oxidase B inhibitors.
AID395328Lipophilicity, log P of the compound2009Journal of medicinal chemistry, Mar-26, Volume: 52, Issue:6
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.
AID1192622Inhibition of human recombinant soluble MAO-B expressed in Pichia pastoris incubated for 30 mins prior to substrate addition measured after 60 mins by MAO-Glo assay2015Bioorganic & medicinal chemistry, Feb-15, Volume: 23, Issue:4
Reversible and irreversible small molecule inhibitors of monoamine oxidase B (MAO-B) investigated by biophysical techniques.
AID1556701Inhibition of human recombinant MAO-B expressed in baculovirus infected BTI-TN-5B1-4 insect cells assessed as decrease in H2O2 production using p-tyramine as substrate incubated for 20 mins by horse-radish peroxidase/amplex red-based fluorescence method2019European journal of medicinal chemistry, Oct-01, Volume: 179Carboxamides vs. methanimines: Crystal structures, binding interactions, photophysical studies, and biological evaluation of (indazole-5-yl)methanimines as monoamine oxidase B and acetylcholinesterase inhibitors.
AID1586590Irreversible inhibition of human recombinant MAO-B expressed in baculovirus infected BTI-TN-5B1-4 insect cells at IC80 using p-tyramine as substrate incubated for 20 mins followed by increase in substrate concentration up to 1 mM and measured after 300 mi2019European journal of medicinal chemistry, Jan-15, Volume: 162(Pyrrolo-pyridin-5-yl)benzamides: BBB permeable monoamine oxidase B inhibitors with neuroprotective effect on cortical neurons.
AID733504Inhibition of recombinant human MAO-A expressed in baculovirus infected BT1-TN-5B1-4 cells assessed as inhibition of production of hydrogen peroxide from p-tyramine after 15 mins by Amplex Red assay2013European journal of medicinal chemistry, Jan, Volume: 591,5-Diphenylpenta-2,4-dien-1-ones as potent and selective monoamine oxidase-B inhibitors.
AID624688Mechanism based inhibition of rat cytochrome P450 CYP2B1 measured by 7-EFC O-deethylation activity2005Current drug metabolism, Oct, Volume: 6, Issue:5
Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity.
AID743814Neurotoxicity in CD1 mouse assessed as decrease in velocity at 10 mg/kg, ip measured for 1 hr relative to control2013European journal of medicinal chemistry, May, Volume: 63Novel (coumarin-3-yl)carbamates as selective MAO-B inhibitors: synthesis, in vitro and in vivo assays, theoretical evaluation of ADME properties and docking study.
AID1141989Antiapoptotic activity against serum deprivation-induced human SK-N-BE(2) cells assessed as viable cells at 10 uM after 36 hrs incubation by DePsipher agent relative to control2014European journal of medicinal chemistry, Jun-10, Volume: 80Polycyclic propargylamine and acetylene derivatives as multifunctional neuroprotective agents.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID710371Inhibition of bovine brain MAOB using kinuramine as substrate preincubated for 30 mins prior to substrate addition measured after 30 mins by fluorometric assay2012Journal of medicinal chemistry, Dec-13, Volume: 55, Issue:23
Synthesis of new 7-oxycoumarin derivatives as potent and selective monoamine oxidase A inhibitors.
AID1252749Selectivity ratio of IC50 for recombinant human MAOB to IC50 for recombinant human MAOA2015European journal of medicinal chemistry, Oct-20, Volume: 103Novel 2H-chromen-2-one derivatives of resveratrol: Design, synthesis, modeling and use as human monoamine oxidase inhibitors.
AID590316Competitive inhibition of rat liver MAO-B after 60 mins using p-tyramine as substrate by spectrophotometry2011Bioorganic & medicinal chemistry letters, Apr-01, Volume: 21, Issue:7
Development of selective and reversible pyrazoline based MAO-B inhibitors: virtual screening, synthesis and biological evaluation.
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID130604MAO activities in the mouse brain after intraperitoneal administration of compound towards 5-HT (5 x 10e-4 M) substrate1992Journal of medicinal chemistry, Oct-02, Volume: 35, Issue:20
Aliphatic propargylamines: potent, selective, irreversible monoamine oxidase B inhibitors.
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID125547Inhibitory activity against monoamine oxidase A in isolated bovine brain mitochondria2003Journal of medicinal chemistry, Mar-13, Volume: 46, Issue:6
Simple, potent, and selective pyrrole inhibitors of monoamine oxidase types A and B.
AID1190176Inhibition of human recombinant MAO-A using p-tyramine as substrate assessed as production of H2O2 incubated for 15 mins prior to substrate addition at 60 uM measured after 20 mins by microplate fluorescence reader analysis2015Bioorganic & medicinal chemistry, Feb-01, Volume: 23, Issue:3
Design and synthesis of novel 2-pyrazoline-1-ethanone derivatives as selective MAO inhibitors.
AID733502Inhibition of recombinant human MAO-B expressed in baculovirus infected BT1-TN-5B1-4 cells assessed as inhibition of production of hydrogen peroxide from p-tyramine after 15 mins by Amplex Red assay2013European journal of medicinal chemistry, Jan, Volume: 591,5-Diphenylpenta-2,4-dien-1-ones as potent and selective monoamine oxidase-B inhibitors.
AID588214FDA HLAED, liver enzyme composite activity2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1245398Inhibition of recombinant human MAOB using benzylamine as substrate at 2 uM after 30 mins by Amplex red based spectrophotometric analysis2015Bioorganic & medicinal chemistry, Oct-01, Volume: 23, Issue:19
Synthesis of a series of unsaturated ketone derivatives as selective and reversible monoamine oxidase inhibitors.
AID1176898Reversible inhibition of human recombinant MAOA expressed in BTI-TN-5B1-4 cells assessed as AUF/t ratio at 20 nM by effective dilution method relative to untreated control2015Bioorganic & medicinal chemistry letters, Feb-01, Volume: 25, Issue:3
Potent and selective MAO-B inhibitory activity: amino- versus nitro-3-arylcoumarin derivatives.
AID1192623Inhibition of MAO-A in rat whole brain homogenate in presence of selegiline2015Bioorganic & medicinal chemistry, Feb-15, Volume: 23, Issue:4
Reversible and irreversible small molecule inhibitors of monoamine oxidase B (MAO-B) investigated by biophysical techniques.
AID1708801Irreversible inhibition of human MAO-A assessed as residual enzyme activity at 4 fold IC50 incubated for 15 mins and measured 24 hrs post dialysis relative to control2021Journal of medicinal chemistry, 02-25, Volume: 64, Issue:4
New 2-Pyrazoline and Hydrazone Derivatives as Potent and Selective Monoamine Oxidase A Inhibitors.
AID501517Inhibition of human MAOA expressed in BTI insect cells2010Bioorganic & medicinal chemistry letters, Sep-01, Volume: 20, Issue:17
New halogenated 3-phenylcoumarins as potent and selective MAO-B inhibitors.
AID773443Reversible inhibition of recombinant human MAO-B using kynuramine as substrate assessed as residual activity at 10 times IC50 preincubated for 30 mins followed by 100 fold dilution measured after 20 mins by fluorescence spectrophotometry relative to contr2013Bioorganic & medicinal chemistry letters, Oct-15, Volume: 23, Issue:20
Inhibition of monoamine oxidase by 3,4-dihydro-2(1H)-quinolinone derivatives.
AID468869Reversible inhibition of human recombinant MAOB before washing with sodium phosphate buffer at 20 nM by centrifugation-ultrafiltration method2010European journal of medicinal chemistry, Feb, Volume: 45, Issue:2
Synthesis and inhibitory activity against human monoamine oxidase of N1-thiocarbamoyl-3,5-di(hetero)aryl-4,5-dihydro-(1H)-pyrazole derivatives.
AID409943Inhibition of human recombinant MAOB by fluorimetric method2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID619466Inhibition of human recombinant MAO-A expressed in baculovirus infected BTI-TN-5B1-4 cells assessed as production of hydrogen peroxide from p-tyramine after 15 mins by microplate fluorescence assay2011European journal of medicinal chemistry, Oct, Volume: 46, Issue:10
Synthesis and selective human monoamine oxidase inhibition of 3-carbonyl, 3-acyl, and 3-carboxyhydrazido coumarin derivatives.
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID114156Antidepressant activity was evaluated by measuring its ability to antagonize RO 4-1284-induced hypothermia in mice1988Journal of medicinal chemistry, Jun, Volume: 31, Issue:6
2,4-Dihydro-3H-1,2,4-triazole-3-thiones as potential antidepressant agents.
AID1190174Inhibition of human recombinant MAO-B using p-tyramine as substrate assessed as production of H2O2 incubated for 15 mins prior to substrate addition measured after 20 mins by microplate fluorescence reader analysis2015Bioorganic & medicinal chemistry, Feb-01, Volume: 23, Issue:3
Design and synthesis of novel 2-pyrazoline-1-ethanone derivatives as selective MAO inhibitors.
AID1851414Selectivity index, ratio of IC50 for inhibition of human MAO-A to IC50 for inhibition of human MAO-B2022Bioorganic & medicinal chemistry letters, 10-15, Volume: 74Synthesis and human monoamine oxidase inhibitory activity of novel C2-, C3- and C4-substituted phthalonitriles.
AID501520Selectivity ratio of IC50 for human MAOA to IC50 for human MAOB2010Bioorganic & medicinal chemistry letters, Sep-01, Volume: 20, Issue:17
New halogenated 3-phenylcoumarins as potent and selective MAO-B inhibitors.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID669065Increase in 3-MT level in Sprague-Dawley rat striatum at 5.3 umol/kg, sc measured after 1 hr compound administration2012Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7
Synthesis and evaluation of a set of para-substituted 4-phenylpiperidines and 4-phenylpiperazines as monoamine oxidase (MAO) inhibitors.
AID409942Inhibition of human recombinant MAOA by fluorimetric method2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID444057Fraction escaping hepatic elimination in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1413448Inhibition of recombinant human MAO-A assessed as reduction in H2O2 production preincubated for 30 mins followed by p-tyramine substrate addition measured after 30 mins by amplex red reagent based fluorescence assay
AID1412303Inhibition of human recombinant MAOB using kynuramine as substrate preincubated for 10 mins followed by substrate addition at 10 secs intervals measured after 20 mins by fluorescence assay
AID1416664Selectivity index, ratio of IC50 for recombinant human MAO-A expressed in baculovirus infected insect cells to IC50 for recombinant human MAO-B expressed in baculovirus infected insect cells2017MedChemComm, Sep-01, Volume: 8, Issue:9
MAO inhibitory activity of bromo-2-phenylbenzofurans: synthesis,
AID1519690Selectivity index, ratio of IC50 for human microsomal MAO-A expressed in baculovirus infected BTN-TN-5B1-4 cells to IC50 for human microsomal MAO-B expressed in baculovirus infected BTN-TN-5B1-4 cells using kynuramine as substrate2020European journal of medicinal chemistry, Jan-01, Volume: 185Design of novel monoamine oxidase-B inhibitors based on piperine scaffold: Structure-activity-toxicity, drug-likeness and efflux transport studies.
AID1551710Anti-parkinson's activity in MPTP-induced C57BL/6 mouse model of Parkinson's disease assessed as restoration of motor ability by measuring increase in latency to fall at 10 mg/kg, po pretreated for 30 mins followed by MPTP challenge for 7 days and subsequ2019European journal of medicinal chemistry, Jul-01, Volume: 173Discovery of coumarin Mannich base derivatives as multifunctional agents against monoamine oxidase B and neuroinflammation for the treatment of Parkinson's disease.
AID395327Dissociation constant, pKa by capillary electrophoresis2009Journal of medicinal chemistry, Mar-26, Volume: 52, Issue:6
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.
AID1459558Inhibition of recombinant human MAO-A assessed as reduction in 4-hydroxyquinolone production using kynuramine as substrate after 20 mins by fluorescence assay2017European journal of medicinal chemistry, Jan-05, Volume: 125Synthesis and evaluation of 7-substituted coumarin derivatives as multimodal monoamine oxidase-B and cholinesterase inhibitors for the treatment of Alzheimer's disease.
AID461713Selectivity for human MAOB over human MAOA2010Bioorganic & medicinal chemistry, Feb, Volume: 18, Issue:3
A new series of flavones, thioflavones, and flavanones as selective monoamine oxidase-B inhibitors.
AID1602881Selectivity index, ratio of IC50 for human recombinant MAO-A expressed in insect cells to IC50 for human recombinant MAO-B expressed in insect cells2019Bioorganic & medicinal chemistry letters, 04-15, Volume: 29, Issue:8
Design, synthesis and biological evaluation of novel human monoamine oxidase B inhibitors based on a fragment in an X-ray crystal structure.
AID1397347Metabolic stability in human plasma assessed as parent compound remaining at 5 uM after 4 hrs by UPLC-MS/MS analysis2018Journal of medicinal chemistry, 08-23, Volume: 61, Issue:16
Development of Novel Monoamine Oxidase-B (MAO-B) Inhibitors with Reduced Blood-Brain Barrier Permeability for the Potential Management of Noncentral Nervous System (CNS) Diseases.
AID1851412Inhibition of human MAO-B assessed as inhibition of H2O2 production using p-tyramine as substrate2022Bioorganic & medicinal chemistry letters, 10-15, Volume: 74Synthesis and human monoamine oxidase inhibitory activity of novel C2-, C3- and C4-substituted phthalonitriles.
AID416577Selectivity index, ratio of IC50 for human recombinant MAOA to IC50 for human recombinant MAOB2009Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7
Synthesis, molecular modeling, and selective inhibitory activity against human monoamine oxidases of 3-carboxamido-7-substituted coumarins.
AID452242Inhibition of MAO-B in rat liver homogenate by spectrophotometry-based Holt method2010Bioorganic & medicinal chemistry letters, Jan-01, Volume: 20, Issue:1
Towards development of selective and reversible pyrazoline based MAO-inhibitors: Synthesis, biological evaluation and docking studies.
AID468868Selectivity, ratio of IC50 for human recombinant MAOA to human recombinant MAOB2010European journal of medicinal chemistry, Feb, Volume: 45, Issue:2
Synthesis and inhibitory activity against human monoamine oxidase of N1-thiocarbamoyl-3,5-di(hetero)aryl-4,5-dihydro-(1H)-pyrazole derivatives.
AID1383068Selectivity index, ratio of IC50 for human MAO-A expressed in baculovirus infected insect cell membranes without preincubation with enzyme to IC50 for human MAO-B expressed in baculovirus infected insect cell membranes without preincubation with enzyme
AID1458405Inhibition of human recombinant microsomal MAOA expressed in baculovirus infected BTI-TN-5B1- 4 cells using p-tyramine as substrate assessed as decrease in H2O2 production after 15 mins by amplex red-based fluorescence assay2017Journal of medicinal chemistry, 08-24, Volume: 60, Issue:16
Coumarin versus Chromone Monoamine Oxidase B Inhibitors: Quo Vadis?
AID747669Inhibition of recombinant human MAO-B expressed in baculovirus-infected insect cells using p-tyramine as substrate incubated for 30 mins prior to substrate addition measured for 45 mins by amplex red reagent-based microplate fluorescence reader analysis2013Journal of medicinal chemistry, Jun-13, Volume: 56, Issue:11
Dual targeting of adenosine A(2A) receptors and monoamine oxidase B by 4H-3,1-benzothiazin-4-ones.
AID1484652Irreversible inhibition of recombinant human MAO-B expressed in baculovirus infected BTI insect cell microsomes assessed as residual activity using kynuramine as substrate at 0.079 uM preincubated for 15 mins with subsequent dialysis for 24 hrs followed b2017European journal of medicinal chemistry, Jul-28, Volume: 135The evaluation of 1,4-benzoquinones as inhibitors of human monoamine oxidase.
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID497525Inhibition of human MAOB at 20 nM by centrifugation-ultrafiltration method2010Bioorganic & medicinal chemistry, Aug-01, Volume: 18, Issue:15
Investigations on the 2-thiazolylhydrazyne scaffold: synthesis and molecular modeling of selective human monoamine oxidase inhibitors.
AID1192626Inhibition of MAO-B in rat whole brain homogenate2015Bioorganic & medicinal chemistry, Feb-15, Volume: 23, Issue:4
Reversible and irreversible small molecule inhibitors of monoamine oxidase B (MAO-B) investigated by biophysical techniques.
AID1301269Inhibition of human recombinant microsomal MAO-A expressed in baculovirus infected BTI-TN-5B1-4 cells using p-tyramine as substrate assessed as reduction in H2O2 production preincubated for 15 mins followed by substrate addition measured for 15 mins Ample2016European journal of medicinal chemistry, Jul-19, Volume: 117(E)-3-Heteroarylidenechroman-4-ones as potent and selective monoamine oxidase-B inhibitors.
AID1286746Suicide inhibition of recombinant human MAO-A using p-tyramine as substrate preincubated for 15 mins followed by substrate addition by Lineweaver-Burk plot analysis2016ACS medicinal chemistry letters, Jan-14, Volume: 7, Issue:1
Monoamine Oxidase Inhibitory Activity of Novel Pyrazoline Analogues: Curcumin Based Design and Synthesis.
AID635338Selectivity ratio of Ki for human recombinant MAO-A to Ki for human recombinant MAO-B2011Bioorganic & medicinal chemistry, Dec-15, Volume: 19, Issue:24
Molecular insights into human monoamine oxidase (MAO) inhibition by 1,4-naphthoquinone: evidences for menadione (vitamin K3) acting as a competitive and reversible inhibitor of MAO.
AID7963The absolute striatal uptake of the carbon-11 labeled compound at 60 min was determined in baboon1990Journal of medicinal chemistry, Jul, Volume: 33, Issue:7
Synthesis of (R)-(-)- and (S)-(+)-4-fluorodeprenyl and (R)-(-)- and (S)-(+)-[N-11C-methyl]-4-fluorodeprenyl and positron emission tomography studies in baboon brain.
AID706469Inhibition of human recombinant MAOA assessed as H2O2 production by Amplex Red reagent-based assay2012Journal of medicinal chemistry, Oct-11, Volume: 55, Issue:19
Multitarget-directed benzylideneindanone derivatives: anti-β-amyloid (Aβ) aggregation, antioxidant, metal chelation, and monoamine oxidase B (MAO-B) inhibition properties against Alzheimer's disease.
AID604265Inhibition of human MAO-B expressed in BTI insect cells using p-tyramine as substrate after 60 mins2011Bioorganic & medicinal chemistry letters, Jul-15, Volume: 21, Issue:14
Pyrazoline based MAO inhibitors: synthesis, biological evaluation and SAR studies.
AID444052Hepatic clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID658202Inhibition of human recombinant MAO-B expressed in insect cells assessed as kynuramine hydrobromide oxidation after 20 mins by spectrophotometric analysis2012Bioorganic & medicinal chemistry, May-01, Volume: 20, Issue:9
Synthesis and evaluation of [¹⁸F]fluororasagiline, a novel positron emission tomography (PET) radioligand for monoamine oxidase B (MAO-B).
AID657238Inhibition of MAO-B in Sprague-Dawley rat brain homogenate using kynuramine as substrate preincubated for 10 mins measured by fluorimetric assay2012Bioorganic & medicinal chemistry letters, May-01, Volume: 22, Issue:9
Synthesis and inhibitory effect of piperine derivates on monoamine oxidase.
AID593110Inhibition of human recombinant MAO-B expressed in baculovirus infected BTI-TN-5B1-4 insect sells assessed as hydrogen peroxide production by fluorimetric method2011Journal of medicinal chemistry, Apr-14, Volume: 54, Issue:7
Homoisoflavonoids: natural scaffolds with potent and selective monoamine oxidase-B inhibition properties.
AID590315Competitive inhibition of human recombinant MAO-A after 60 mins using p-tyramine as substrate by spectrophotometry2011Bioorganic & medicinal chemistry letters, Apr-01, Volume: 21, Issue:7
Development of selective and reversible pyrazoline based MAO-B inhibitors: virtual screening, synthesis and biological evaluation.
AID230685Ratio of activities of MAO-B / MAO-A1996Journal of medicinal chemistry, Nov-22, Volume: 39, Issue:24
Synthesis and selective monoamine oxidase B-inhibiting properties of 1-methyl-1,2,3,6-tetrahydropyrid-4-yl carbamate derivatives: potential prodrugs of (R)- and (S)-nordeprenyl.
AID1322903Inhibition of human recombinant MAOA using p-tyramine as substrate preincubated for 30 mins followed by substrate addition measured for 1 hr by horse-radish peroxidase/amplex red-based fluorometric method2016European journal of medicinal chemistry, Oct-04, Volume: 121Donepezil-like multifunctional agents: Design, synthesis, molecular modeling and biological evaluation.
AID361942Inhibition of human recombinant MAOB before repeated washing at 20 nM2008Journal of medicinal chemistry, Aug-28, Volume: 51, Issue:16
Synthesis, stereochemical identification, and selective inhibitory activity against human monoamine oxidase-B of 2-methylcyclohexylidene-(4-arylthiazol-2-yl)hydrazones.
AID126186Ex vivo inhibitory activity against rat brain monoamine oxidase (MAO) type A at a dose of 5 mg/kg administered orally at 24 hr1995Journal of medicinal chemistry, Nov-24, Volume: 38, Issue:24
Selective and potent monoamine oxidase type B inhibitors: 2-substituted 5-aryltetrazole derivatives.
AID478544Inhibition of human recombinant MAO-A assessed as inhibition of production of hydrogen peroxide after 15 mins by Amplex Red fluorimetric method2010Bioorganic & medicinal chemistry letters, May-01, Volume: 20, Issue:9
Chromone-2- and -3-carboxylic acids inhibit differently monoamine oxidases A and B.
AID551666Inhibition of human recombinant MAOB expressed in baculovirus-infected BTI insect cells after 15 mins by fluorimetric assay2011Bioorganic & medicinal chemistry letters, Jan-15, Volume: 21, Issue:2
Chromone 3-phenylcarboxamides as potent and selective MAO-B inhibitors.
AID349920Inhibition of human recombinant MAO-A assessed as hydrogen peroxide production at 1 mM2009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
Chalcones: a valid scaffold for monoamine oxidases inhibitors.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID1586573Inhibition of human recombinant MAO-A expressed in baculovirus infected BTI-TN-5B1-4 insect cells using p-tyramine as substrate preincubated for 15 mins and measured after 45 mins by resorufin-based fluorescence assay2019European journal of medicinal chemistry, Jan-15, Volume: 162(Pyrrolo-pyridin-5-yl)benzamides: BBB permeable monoamine oxidase B inhibitors with neuroprotective effect on cortical neurons.
AID125550Inhibitory activity against monoamine oxidase B in isolated bovine brain mitochondria2003Journal of medicinal chemistry, Mar-13, Volume: 46, Issue:6
Simple, potent, and selective pyrrole inhibitors of monoamine oxidase types A and B.
AID1286741Inhibition of recombinant human MAO-A using p-tyramine as substrate assessed as H2O2 production preincubated for 15 mins followed by substrate addition measured for 15 mins by amplex red assay2016ACS medicinal chemistry letters, Jan-14, Volume: 7, Issue:1
Monoamine Oxidase Inhibitory Activity of Novel Pyrazoline Analogues: Curcumin Based Design and Synthesis.
AID588220Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset2008Toxicology mechanisms and methods, , Volume: 18, Issue:2-3
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
AID706470Inhibition of human recombinant MAOB assessed as H2O2 production by Amplex Red reagent-based assay2012Journal of medicinal chemistry, Oct-11, Volume: 55, Issue:19
Multitarget-directed benzylideneindanone derivatives: anti-β-amyloid (Aβ) aggregation, antioxidant, metal chelation, and monoamine oxidase B (MAO-B) inhibition properties against Alzheimer's disease.
AID693560Inhibition of human MAO-A expressed in baculovirus infected BTI-TN-5B1-4 cells using p-tyramine as substrate incubated for 15 mins prior to substrate addition measured for 15 mins by Amplex red assay2012European journal of medicinal chemistry, Dec, Volume: 58Recent advances in the development of selective human MAO-B inhibitors: (hetero)arylidene-(4-substituted-thiazol-2-yl)hydrazines.
AID449967Competitive inhibition of MAOA in rat liver homogenate by spectrophotometrically2009Bioorganic & medicinal chemistry, Sep-15, Volume: 17, Issue:18
Synthesis and molecular modeling of some novel hexahydroindazole derivatives as potent monoamine oxidase inhibitors.
AID751623Inhibition of human recombinant monoamine oxidase-B assessed as kynuramine conversion to 6-hydroxyquinoline after 20 mins by fluorescence spectrophotometric analysis2013Bioorganic & medicinal chemistry letters, Mar-01, Volume: 23, Issue:5
Inhibition of monoamine oxidase by phthalide analogues.
AID1708793Inhibition of recombinant human MAO-A expressed in baculovirus infected BTI insect cells using p-tyramine as substrate incubated for 30 mins by Amplex red reagent based fluorescence analysis2021Journal of medicinal chemistry, 02-25, Volume: 64, Issue:4
New 2-Pyrazoline and Hydrazone Derivatives as Potent and Selective Monoamine Oxidase A Inhibitors.
AID1397344Efflux ratio of apparent permeability in MDCK cells at 10 uM after 1 hr in absence of P-gp inhibitor verapamil by UPLC-MS/MS analysis2018Journal of medicinal chemistry, 08-23, Volume: 61, Issue:16
Development of Novel Monoamine Oxidase-B (MAO-B) Inhibitors with Reduced Blood-Brain Barrier Permeability for the Potential Management of Noncentral Nervous System (CNS) Diseases.
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1068734In vivo inhibition of MAO-A in Sprague-Dawley rat assessed as 5-hydroxyindoleacetic acid in brain striatum at 53 umol/kg, sc after 1 hr by HPLC/EC analysis relative to control2014European journal of medicinal chemistry, Feb-12, Volume: 73A novel series of 6-substituted 3-(pyrrolidin-1-ylmethyl)chromen-2-ones as selective monoamine oxidase (MAO) A inhibitors.
AID637705Inhibition of human recombinant MAO-A expressed in baculovirus infected BTI-TN-5B1-4 insect cells assessed as inhibition of hydrogen peroxide production from p-tryptamine after 15 mins by fluorimetric method2012European journal of medicinal chemistry, Feb, Volume: 48Synthesis and biological assessment of novel 2-thiazolylhydrazones and computational analysis of their recognition by monoamine oxidase B.
AID340615Inhibition of MAOB2008Journal of medicinal chemistry, Jul-24, Volume: 51, Issue:14
Identification of a potent, selective, and orally active leukotriene a4 hydrolase inhibitor with anti-inflammatory activity.
AID669066Increase in 3-MT level in Sprague-Dawley rat striatum at 53 umol/kg, sc measured after 1 hr compound administration2012Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7
Synthesis and evaluation of a set of para-substituted 4-phenylpiperidines and 4-phenylpiperazines as monoamine oxidase (MAO) inhibitors.
AID1369565Inhibition of human MAO-B transfected in HEK293 cells using tyramine as substrate assessed as decrease in ROS production at 1 uM preincubated for 10 mins followed by substrate addition measured after 15 mins by DCFDA probe-based fluorescence assay2018Journal of medicinal chemistry, 05-10, Volume: 61, Issue:9
Tight-Binding Inhibition of Human Monoamine Oxidase B by Chromone Analogs: A Kinetic, Crystallographic, and Biological Analysis.
AID1192621Inhibition of human recombinant microsomal MAO-B expressed in Pichia pastoris incubated for 30 mins prior to substrate addition measured after 60 mins by MAO-Glo assay2015Bioorganic & medicinal chemistry, Feb-15, Volume: 23, Issue:4
Reversible and irreversible small molecule inhibitors of monoamine oxidase B (MAO-B) investigated by biophysical techniques.
AID126701In vitro inhibitory concentration against Monoamine oxidase B of rat brain homogenates; value ranges from 0.004-0.0142002Journal of medicinal chemistry, Nov-21, Volume: 45, Issue:24
Novel dual inhibitors of AChE and MAO derived from hydroxy aminoindan and phenethylamine as potential treatment for Alzheimer's disease.
AID1378859Reversible inhibition of human recombinant MAO-B expressed in baculovirus infected BTI-TN5B1-4 cells using p-tyramine as substrate assessed as recovery of enzyme activity at 10 fold IC50 preincubated for 30 mins followed by 100 fold dilution and substrate2017European journal of medicinal chemistry, Oct-20, Volume: 139Synthesis and structure-activity relationship study of novel 3-heteroarylcoumarins based on pyridazine scaffold as selective MAO-B inhibitors.
AID1320872Inhibition of human serum BuChE using butyrylthiocholine as substrate preincubated for 5 mins followed by substrate addition measured for 5 mins by Ellman's method2016European journal of medicinal chemistry, Oct-04, Volume: 121New cinnamic - N-benzylpiperidine and cinnamic - N,N-dibenzyl(N-methyl)amine hybrids as Alzheimer-directed multitarget drugs with antioxidant, cholinergic, neuroprotective and neurogenic properties.
AID1397357Tmax in C57BL/6 mouse plasma at 10.8 mg/kg, iv administered as single dose measured 24 hrs by UPLC-MS/MS analysis2018Journal of medicinal chemistry, 08-23, Volume: 61, Issue:16
Development of Novel Monoamine Oxidase-B (MAO-B) Inhibitors with Reduced Blood-Brain Barrier Permeability for the Potential Management of Noncentral Nervous System (CNS) Diseases.
AID1459559Inhibition of recombinant human MAO-B assessed as reduction in 4-hydroxyquinolone production using kynuramine as substrate after 20 mins by fluorescence assay2017European journal of medicinal chemistry, Jan-05, Volume: 125Synthesis and evaluation of 7-substituted coumarin derivatives as multimodal monoamine oxidase-B and cholinesterase inhibitors for the treatment of Alzheimer's disease.
AID444058Volume of distribution at steady state in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1397353Acute toxicity in C57BL/6 mouse assessed as lethargy at 10.8 mg/kg, iv after 1 hr post-injection2018Journal of medicinal chemistry, 08-23, Volume: 61, Issue:16
Development of Novel Monoamine Oxidase-B (MAO-B) Inhibitors with Reduced Blood-Brain Barrier Permeability for the Potential Management of Noncentral Nervous System (CNS) Diseases.
AID1397364Ratio of AUClast in brain to plasma in C57BL/6 mouse at 10.8 mg/kg, iv administered as single dose measured 24 hrs by UPLC-MS/MS analysis2018Journal of medicinal chemistry, 08-23, Volume: 61, Issue:16
Development of Novel Monoamine Oxidase-B (MAO-B) Inhibitors with Reduced Blood-Brain Barrier Permeability for the Potential Management of Noncentral Nervous System (CNS) Diseases.
AID1631764Inhibition of rat mitochondrial MAO-B using DAB as substrate incubated for 30 mins by HPLC analysis2016Journal of medicinal chemistry, 07-14, Volume: 59, Issue:13
New 6-Aminoquinoxaline Derivatives with Neuroprotective Effect on Dopaminergic Neurons in Cellular and Animal Parkinson Disease Models.
AID733943Inhibition of recombinant human MAO-B assessed as inhibition of kynuramine oxidation by spectrophotometry2013Bioorganic & medicinal chemistry, Jan-01, Volume: 21, Issue:1
Synthesis and biological evaluation of novel propargyl amines as potential fluorine-18 labeled radioligands for detection of MAO-B activity.
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID1397434Acute toxicity in C57BL/6 mouse assessed as piloerection at 10.8 mg/kg, po after 1 hr post-injection2018Journal of medicinal chemistry, 08-23, Volume: 61, Issue:16
Development of Novel Monoamine Oxidase-B (MAO-B) Inhibitors with Reduced Blood-Brain Barrier Permeability for the Potential Management of Noncentral Nervous System (CNS) Diseases.
AID588217FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID675162Irreversible inhibition of recombinant human MAO-B assessed as recovered enzyme activity measuring residual rate of 4-hydroxyquinoline formation at 10 times IC50 preincubated for 30 mins followed by dilution to 0.1 times IC50 measured after 20 mins2012Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
Selected chromone derivatives as inhibitors of monoamine oxidase.
AID1368627Inhibition of recombinant human MAO-A using p-tyramine as substrate preincubated for 15 mins followed by substrate addition measured after 20 mins by amplex red reagent based spectrophotometric assay2018Bioorganic & medicinal chemistry, 01-01, Volume: 26, Issue:1
Synthesis and evaluation of biaryl derivatives for structural characterization of selective monoamine oxidase B inhibitors toward Parkinson's disease therapy.
AID126184Ex vivo inhibitory activity against rat brain monoamine oxidase (MAO) type A at a dose of 5 mg/kg administered orally at 1 hr1995Journal of medicinal chemistry, Nov-24, Volume: 38, Issue:24
Selective and potent monoamine oxidase type B inhibitors: 2-substituted 5-aryltetrazole derivatives.
AID1322904Inhibition of human recombinant MAOB using p-tyramine as substrate preincubated for 30 mins followed by substrate addition measured for 1 hr by horse-radish peroxidase/amplex red-based fluorometric method2016European journal of medicinal chemistry, Oct-04, Volume: 121Donepezil-like multifunctional agents: Design, synthesis, molecular modeling and biological evaluation.
AID604264Inhibition of human MAO-A expressed in BTI insect cells using p-tyramine as substrate after 60 mins2011Bioorganic & medicinal chemistry letters, Jul-15, Volume: 21, Issue:14
Pyrazoline based MAO inhibitors: synthesis, biological evaluation and SAR studies.
AID1152193Reversible inhibition of recombinant human MAO-B using kynuramine as substrate assessed as enzyme residual activity at 4 times IC50 incubated for 15 mins measured after 24 hrs of dialysis by fluorescence spectrophotometry analysis relative to control2014Bioorganic & medicinal chemistry letters, Jun-15, Volume: 24, Issue:12
α-Tetralone derivatives as inhibitors of monoamine oxidase.
AID1383067Inhibition of human MAO-B expressed in baculovirus infected insect cell membranes using kynuramine as substrate after 15 to 20 mins by discontinuous fluorimetric method
AID349915Selectivity index, ratio of IC50 for human recombinant MAO-A to IC50 for human recombinant MAO-B2009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
Chalcones: a valid scaffold for monoamine oxidases inhibitors.
AID102894Compound was evaluated for the time-dependence inhibition of MAO-B at 20 minutes pre-incubation periods1993Journal of medicinal chemistry, Apr-30, Volume: 36, Issue:9
5-[4-(benzyloxy)phenyl]-1,3,4-oxadiazol-2(3H)-one derivatives and related analogues: new reversible, highly potent, and selective monamine oxidase type B inhibitors.
AID599359Inhibition of human recombinant MAOB expressed in BTI insect cells using p-tyramine substrate by fluorometric method2009Bioorganic & medicinal chemistry letters, Jun-15, Volume: 19, Issue:12
A new series of 3-phenylcoumarins as potent and selective MAO-B inhibitors.
AID1708806Cytotoxicity against human HepG2 cells assessed as cell viability at 30 uM incubated for 2 hrs by MTT assay relative to control2021Journal of medicinal chemistry, 02-25, Volume: 64, Issue:4
New 2-Pyrazoline and Hydrazone Derivatives as Potent and Selective Monoamine Oxidase A Inhibitors.
AID416573Inhibition of human recombinant MAOB expressed in BTI-TN-5B1-4 cells assessed as effect on H2O2 production from para-tyramine by fluorimetric method2009Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7
Synthesis, molecular modeling, and selective inhibitory activity against human monoamine oxidases of 3-carboxamido-7-substituted coumarins.
AID610971Selectivity index, ratio of IC50 for human MAO-A to IC50 for human MAO-B2011Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
Chromone, a privileged scaffold for the development of monoamine oxidase inhibitors.
AID452241Inhibition of MAO-A in rat liver homogenate by spectrophotometry-based Holt method2010Bioorganic & medicinal chemistry letters, Jan-01, Volume: 20, Issue:1
Towards development of selective and reversible pyrazoline based MAO-inhibitors: Synthesis, biological evaluation and docking studies.
AID449968Competitive inhibition of MAOB in rat liver homogenate by spectrophotometrically2009Bioorganic & medicinal chemistry, Sep-15, Volume: 17, Issue:18
Synthesis and molecular modeling of some novel hexahydroindazole derivatives as potent monoamine oxidase inhibitors.
AID1759291Inhibition of MAO-A (unknown origin) at 10 uM relative to control2021Bioorganic & medicinal chemistry letters, 06-01, Volume: 41Discovery of new tranylcypromine derivatives as highly potent LSD1 inhibitors.
AID125856In vitro inhibitory concentration against Monoamine oxidase A of rat brain homogenates; value ranges from 1.1-1.32002Journal of medicinal chemistry, Nov-21, Volume: 45, Issue:24
Novel dual inhibitors of AChE and MAO derived from hydroxy aminoindan and phenethylamine as potential treatment for Alzheimer's disease.
AID395324Lipophilicity, log D at pH 7.4 by liquid chromatography2009Journal of medicinal chemistry, Mar-26, Volume: 52, Issue:6
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.
AID229512Ratio of IC50 value against MAO-A to that of MAO-B.2002Journal of medicinal chemistry, Nov-21, Volume: 45, Issue:24
Novel dual inhibitors of AChE and MAO derived from hydroxy aminoindan and phenethylamine as potential treatment for Alzheimer's disease.
AID1556715Irreversible inhibition of human recombinant MAO-B expressed in baculovirus infected BTI-TN-5B1-4 insect cells assessed as decrease in H2O2 production at 30 nM using p-tyramine as substrate at concentration of 10 uM for first 15 mins followed by increasin2019European journal of medicinal chemistry, Oct-01, Volume: 179Carboxamides vs. methanimines: Crystal structures, binding interactions, photophysical studies, and biological evaluation of (indazole-5-yl)methanimines as monoamine oxidase B and acetylcholinesterase inhibitors.
AID1252747Inhibition of recombinant human MAOA using p-tyramine as substrate assessed as H2O2 production preincubated for 15 mins followed by substrate addition by fluorometric analysis2015European journal of medicinal chemistry, Oct-20, Volume: 103Novel 2H-chromen-2-one derivatives of resveratrol: Design, synthesis, modeling and use as human monoamine oxidase inhibitors.
AID444054Oral bioavailability in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1900897Inhibition of MAO-B (unknown origin) at 1 mM relative to control2022European journal of medicinal chemistry, Feb-05, Volume: 229Synthesis of novel thiazolyl hydrazone derivatives as potent dual monoamine oxidase-aromatase inhibitors.
AID1708800Irreversible inhibition of human MAO-A assessed as residual enzyme activity at 4 fold IC50 incubated for 15 mins and measured before dialysis relative to control2021Journal of medicinal chemistry, 02-25, Volume: 64, Issue:4
New 2-Pyrazoline and Hydrazone Derivatives as Potent and Selective Monoamine Oxidase A Inhibitors.
AID693561Inhibition of human MAO-B expressed in baculovirus infected BTI-TN-5B1-4 cells using p-tyramine as substrate incubated for 15 mins prior to substrate addition measured for 15 mins by Amplex red assay2012European journal of medicinal chemistry, Dec, Volume: 58Recent advances in the development of selective human MAO-B inhibitors: (hetero)arylidene-(4-substituted-thiazol-2-yl)hydrazines.
AID136940Compound was evaluated for MAO-A activity after 21 days of chronic peritoneal administration in mouse fore brain at dose of 0.2 mg/kg1992Journal of medicinal chemistry, Oct-02, Volume: 35, Issue:20
Aliphatic propargylamines: potent, selective, irreversible monoamine oxidase B inhibitors.
AID1657017Inactivation of CYP2B1 (unknown origin)2020Journal of medicinal chemistry, 06-11, Volume: 63, Issue:11
Acetylene Group, Friend or Foe in Medicinal Chemistry.
AID669062Decrease in DOPAC level in Sprague-Dawley rat striatum at 5.3 umol/kg, sc measured after 1 hr compound administration2012Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7
Synthesis and evaluation of a set of para-substituted 4-phenylpiperidines and 4-phenylpiperazines as monoamine oxidase (MAO) inhibitors.
AID134973Compound tested for the prevention of DSP- 4- induced depletion of noradrenaline (NA) in mouse hippocampus ex vivo2001Bioorganic & medicinal chemistry letters, Oct-22, Volume: 11, Issue:20
Synthesis of N-propargylphenelzine and analogues as neuroprotective agents.
AID1176894Selectivity index, ratio of IC50 for human recombinant MAOA to IC50 for human recombinant MAOB2015Bioorganic & medicinal chemistry letters, Feb-01, Volume: 25, Issue:3
Potent and selective MAO-B inhibitory activity: amino- versus nitro-3-arylcoumarin derivatives.
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID235091Residual activity was obtained.1996Journal of medicinal chemistry, Nov-22, Volume: 39, Issue:24
Synthesis and selective monoamine oxidase B-inhibiting properties of 1-methyl-1,2,3,6-tetrahydropyrid-4-yl carbamate derivatives: potential prodrugs of (R)- and (S)-nordeprenyl.
AID461712Inhibition of human recombinant MAOB expressed in BTI-TN-5B1-4 cells by para-tyramine oxidation assay2010Bioorganic & medicinal chemistry, Feb, Volume: 18, Issue:3
A new series of flavones, thioflavones, and flavanones as selective monoamine oxidase-B inhibitors.
AID604281Inhibition of human recombinant MAO-B using p-tyramine substrate by fluorometric method2011Bioorganic & medicinal chemistry letters, Jul-15, Volume: 21, Issue:14
MAO inhibitory activity modulation: 3-Phenylcoumarins versus 3-benzoylcoumarins.
AID515171Inhibition of human recombinant MAOB expressed in baculovirus infected BTI insect cells assessed as hydrogen peroxide production after 15 mins by Amplex red assay2010European journal of medicinal chemistry, Oct, Volume: 45, Issue:10
Synthesis of new 3-aryl-4,5-dihydropyrazole-1-carbothioamide derivatives. An investigation on their ability to inhibit monoamine oxidase.
AID1636270Inhibition of human recombinant MAO-B preincubated for 30 mins followed by p-tyramine hydrochloride addition measured after 30 mins by Amplex red fluorescence based spectrophotometry2016Bioorganic & medicinal chemistry, 10-15, Volume: 24, Issue:20
Design, synthesis and biological evaluation of N-methyl-N-[(1,2,3-triazol-4-yl)alkyl]propargylamines as novel monoamine oxidase B inhibitors.
AID718020Reversible inhibition of human recombinant MAO-B expressed in insect cell microsome assessed as enzyme activity recovery using kynuramine as substrate preincubated for 30 mins at 10xIC50 measured after 20 mins following 100-fold compound dilution with add2012Bioorganic & medicinal chemistry, Dec-15, Volume: 20, Issue:24
Inhibition of monoamine oxidase by 8-[(phenylethyl)sulfanyl]caffeine analogues.
AID136957MAO activities in the mouse brain after oral administration of compound towards 5-HT (5 x 10e-4 M) substrate1992Journal of medicinal chemistry, Oct-02, Volume: 35, Issue:20
Aliphatic propargylamines: potent, selective, irreversible monoamine oxidase B inhibitors.
AID461845Competitive inhibition of MAOB in rat liver homogenate after 60 mins by Lineweaver-Burke plot analysis2010Bioorganic & medicinal chemistry, Mar-01, Volume: 18, Issue:5
Development of selective and reversible pyrazoline based MAO-A inhibitors: Synthesis, biological evaluation and docking studies.
AID1057042Inhibition of human MAO-B2013Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23
1,3-Dialkyl-substituted tetrahydropyrimido[1,2-f]purine-2,4-diones as multiple target drugs for the potential treatment of neurodegenerative diseases.
AID1657018Inactivation of CYP2B1 (unknown origin) assessed as Kinact2020Journal of medicinal chemistry, 06-11, Volume: 63, Issue:11
Acetylene Group, Friend or Foe in Medicinal Chemistry.
AID678715Inhibition of human CYP2D6 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 4-methylaminoethyl-7-methoxycoumarin as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID176270MAO activity evaluated in dissected forebrain of rat after 2 hr of administration1992Journal of medicinal chemistry, Oct-02, Volume: 35, Issue:20
Aliphatic propargylamines: potent, selective, irreversible monoamine oxidase B inhibitors.
AID743804Potentiation of L-dopa/carbidopa activity in reserpine-treated CD1 mouse assessed as increase in straightening at 10 mg/kg, ip administered 22 hrs post reserpine challenge followed by L-dopa/carbidopa adminstration at 30 mins measured after 1 hr relative 2013European journal of medicinal chemistry, May, Volume: 63Novel (coumarin-3-yl)carbamates as selective MAO-B inhibitors: synthesis, in vitro and in vivo assays, theoretical evaluation of ADME properties and docking study.
AID234048Selectivity for B form was estimated by the ratio of IC50 (MAO A) at 60 min to that of (MAO B)1993Journal of medicinal chemistry, Apr-30, Volume: 36, Issue:9
5-[4-(benzyloxy)phenyl]-1,3,4-oxadiazol-2(3H)-one derivatives and related analogues: new reversible, highly potent, and selective monamine oxidase type B inhibitors.
AID599357Inhibition of human recombinant MAOA expressed in BTI insect cells using p-tyramine substrate by fluorometric method2009Bioorganic & medicinal chemistry letters, Jun-15, Volume: 19, Issue:12
A new series of 3-phenylcoumarins as potent and selective MAO-B inhibitors.
AID1413450Selectivity index, ratio of Ki for recombinant human MAO-B to Ki for recombinant human MAO-A
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID1241459Inhibition of BChE in equine serum using butyrylthiocholine iodide substrate by Ellman assay2015Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
Evaluation of Homobivalent Carbolines as Designed Multiple Ligands for the Treatment of Neurodegenerative Disorders.
AID528279Inhibition of human recombinant MAO-B expressed in baculovirus infected BT1 cells2010Bioorganic & medicinal chemistry letters, Nov-15, Volume: 20, Issue:22
Synthesis and molecular modelling studies of prenylated pyrazolines as MAO-B inhibitors.
AID1421880Inhibition of human recombinant MAOB expressed in baculovirus infected BTI-TN-5B1- 4 cells using p-tyramine as substrate assessed as decrease in H2O2 production by amplex red-based fluorescence assay2018European journal of medicinal chemistry, Oct-05, Volume: 158Multi-target-directed ligands for Alzheimer's disease: Discovery of chromone-based monoamine oxidase/cholinesterase inhibitors.
AID125378The ability of the compound(25 umol/kg/day) to inactivate monoamine oxidase (MAO) was tested on brain mitochondrial membranes of mice, for 3 days.1996Journal of medicinal chemistry, Nov-22, Volume: 39, Issue:24
Synthesis and selective monoamine oxidase B-inhibiting properties of 1-methyl-1,2,3,6-tetrahydropyrid-4-yl carbamate derivatives: potential prodrugs of (R)- and (S)-nordeprenyl.
AID639312Selectivity index, ratio of IC50 for human recombinant MAOA to IC50 for human recombinant MAOB2012Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1
Hydroxycoumarins as selective MAO-B inhibitors.
AID1708794Inhibition of recombinant human MAO-B expressed in baculovirus infected BTI insect cells using p-tyramine as substrate incubated for 30 mins by Amplex red reagent based fluorescence analysis2021Journal of medicinal chemistry, 02-25, Volume: 64, Issue:4
New 2-Pyrazoline and Hydrazone Derivatives as Potent and Selective Monoamine Oxidase A Inhibitors.
AID136809Compound was evaluated for MAO-A activity after 10 days of chronic peritoneal administration in mouse fore brain at dose of 0.2 mg/kg1992Journal of medicinal chemistry, Oct-02, Volume: 35, Issue:20
Aliphatic propargylamines: potent, selective, irreversible monoamine oxidase B inhibitors.
AID1286742Inhibition of recombinant human MAO-B using p-tyramine as substrate assessed as H2O2 production preincubated for 15 mins followed by substrate addition measured for 15 mins by amplex red assay2016ACS medicinal chemistry letters, Jan-14, Volume: 7, Issue:1
Monoamine Oxidase Inhibitory Activity of Novel Pyrazoline Analogues: Curcumin Based Design and Synthesis.
AID102738Compound was evaluated for the time-dependence inhibition of MAO-A at 60 minutes of preincubated period. values are same with or without pre-incubation1993Journal of medicinal chemistry, Apr-30, Volume: 36, Issue:9
5-[4-(benzyloxy)phenyl]-1,3,4-oxadiazol-2(3H)-one derivatives and related analogues: new reversible, highly potent, and selective monamine oxidase type B inhibitors.
AID678716Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using diethoxyfluorescein as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID1176892Inhibition of human recombinant MAOB expressed in BTI-TN-5B1-4 cells using p-tyramine substrate assessed as reduction in H2O2 production2015Bioorganic & medicinal chemistry letters, Feb-01, Volume: 25, Issue:3
Potent and selective MAO-B inhibitory activity: amino- versus nitro-3-arylcoumarin derivatives.
AID604267Reversible inhibition of human MAO-A expressed in BTI insect cells using p-tyramine as substrate after 60 mins2011Bioorganic & medicinal chemistry letters, Jul-15, Volume: 21, Issue:14
Pyrazoline based MAO inhibitors: synthesis, biological evaluation and SAR studies.
AID695111Reversible inhibition of human recombinant MAOB using kynuramine as substrate assessed as residual activity at 10 times IC50 preincubated for 30 mins followed by 100 fold dilution measured after 20 mins by fluorescence spectrophotometry relative to contro2012Bioorganic & medicinal chemistry letters, Nov-01, Volume: 22, Issue:21
Novel sulfanylphthalimide analogues as highly potent inhibitors of monoamine oxidase B.
AID1322907Selectivity ratio of IC50 for human recombinant AChE to IC50 for human recombinant BuChE2016European journal of medicinal chemistry, Oct-04, Volume: 121Donepezil-like multifunctional agents: Design, synthesis, molecular modeling and biological evaluation.
AID768157Inhibition of human recombinant MAO-B using benzylamine hydrochloride as substrate assessed as H2O2 synthesis after 1 hr by fluorescence assay2013Bioorganic & medicinal chemistry, Sep-01, Volume: 21, Issue:17
Oxazolopyridines and thiazolopyridines as monoamine oxidase B inhibitors for the treatment of Parkinson's disease.
AID1460876Inhibition of human recombinant MAOA assessed as reduction in H2O2 production from p-tyramine incubated for 15 mins by Amplex red reagent based fluorimetric method2017Journal of natural products, 04-28, Volume: 80, Issue:4
Anisucoumaramide, a Bioactive Coumarin from Clausena anisum-olens.
AID279955Selectivity index, ratio of Ki for MAOB/Ki for MAOA2007Journal of medicinal chemistry, Mar-08, Volume: 50, Issue:5
New pyrrole inhibitors of monoamine oxidase: synthesis, biological evaluation, and structural determinants of MAO-A and MAO-B selectivity.
AID125399Compound was evaluated for the inhibition of deamination of dopamine (DA) by MAO at 5 x 10e-4 M1992Journal of medicinal chemistry, Oct-02, Volume: 35, Issue:20
Aliphatic propargylamines: potent, selective, irreversible monoamine oxidase B inhibitors.
AID1460879Selectivity index, ratio of IC50 for human recombinant MAOA to IC50 for human recombinant MAOB2017Journal of natural products, 04-28, Volume: 80, Issue:4
Anisucoumaramide, a Bioactive Coumarin from Clausena anisum-olens.
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID469779Reversible inhibition of human recombinant MAOB after washing with sodium phosphate buffer at 20 nM by centrifugation-ultrafiltration method2010European journal of medicinal chemistry, Feb, Volume: 45, Issue:2
Synthesis and inhibitory activity against human monoamine oxidase of N1-thiocarbamoyl-3,5-di(hetero)aryl-4,5-dihydro-(1H)-pyrazole derivatives.
AID779070Inhibition of recombinant human MAO-B expressed in insect cells using kynuramine as substrate assessed as formation of 4-hydroxyquinoline measured every 5 mins for 30 mins2013Bioorganic & medicinal chemistry, Nov-01, Volume: 21, Issue:21
Development of a novel fluorine-18 labeled deuterated fluororasagiline ([(18)F]fluororasagiline-D2) radioligand for PET studies of monoamino oxidase B (MAO-B).
AID1152907Inhibition of electric eel AChE using acetylthiocholine iodide as substrate preincubated for 20 mins followed by substrate addition measured after 5 mins by Ellman's method2014European journal of medicinal chemistry, Jun-10, Volume: 80Donepezil + propargylamine + 8-hydroxyquinoline hybrids as new multifunctional metal-chelators, ChE and MAO inhibitors for the potential treatment of Alzheimer's disease.
AID1383065Inhibition of human MAO-A expressed in baculovirus infected insect cell membranes using kynuramine as substrate after 15 to 20 mins by discontinuous fluorimetric method
AID1759290Inhibition of LSD1 (unknown origin)2021Bioorganic & medicinal chemistry letters, 06-01, Volume: 41Discovery of new tranylcypromine derivatives as highly potent LSD1 inhibitors.
AID669063Decrease in DOPAC level in Sprague-Dawley rat striatum at 53 umol/kg, sc measured after 1 hr compound administration2012Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7
Synthesis and evaluation of a set of para-substituted 4-phenylpiperidines and 4-phenylpiperazines as monoamine oxidase (MAO) inhibitors.
AID639310Inhibition of human recombinant MAOB expressed in baculovirus-infected BTI insect cells assessed as using transformed p-tyramine after 15 mins by fluorimetric assay2012Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1
Hydroxycoumarins as selective MAO-B inhibitors.
AID566355Inhibition of human monoamine oxidase B2010Bioorganic & medicinal chemistry, Nov-01, Volume: 18, Issue:21
Discovery of {1-[4-(2-{hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl}-1H-benzimidazol-1-yl)piperidin-1-yl]cyclooctyl}methanol, systemically potent novel non-peptide agonist of nociceptin/orphanin FQ receptor as analgesic for the treatment of neuropathic pain: de
AID416572Inhibition of human recombinant MAOA expressed in BTI-TN-5B1-4 cells assessed as effect on H2O2 production from para-tyramine by fluorimetric method2009Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7
Synthesis, molecular modeling, and selective inhibitory activity against human monoamine oxidases of 3-carboxamido-7-substituted coumarins.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID461844Competitive inhibition of MAOA in rat liver homogenate after 60 mins by Lineweaver-Burke plot analysis2010Bioorganic & medicinal chemistry, Mar-01, Volume: 18, Issue:5
Development of selective and reversible pyrazoline based MAO-A inhibitors: Synthesis, biological evaluation and docking studies.
AID1695578Inhibition of human recombinant MAO-B at 1 mM using tyramine as substrate preincubated with enzyme for 30 mins followed by incubation with substrate for 30 mins by Amplex Red reagent based fluorometric method relative to control2020RSC medicinal chemistry, Sep-01, Volume: 11, Issue:9
Novel 1,3,4-thiadiazole compounds as potential MAO-A inhibitors - design, synthesis, biological evaluation and molecular modelling.
AID1708802Irreversible inhibition of human MAO-B assessed as residual enzyme activity at 4 fold IC50 incubated for 15 mins and measured before dialysis relative to control2021Journal of medicinal chemistry, 02-25, Volume: 64, Issue:4
New 2-Pyrazoline and Hydrazone Derivatives as Potent and Selective Monoamine Oxidase A Inhibitors.
AID1708805Cytotoxicity against human HepG2 cells assessed as cell viability at 15 uM incubated for 2 hrs by MTT assay relative to control2021Journal of medicinal chemistry, 02-25, Volume: 64, Issue:4
New 2-Pyrazoline and Hydrazone Derivatives as Potent and Selective Monoamine Oxidase A Inhibitors.
AID1891688Inhibition of human recombinant MAOA using kynuramine substrate incubated for 20 mins by fluorescence spectrophotometry2022Bioorganic & medicinal chemistry letters, 07-01, Volume: 67The evaluation of N-propargylamine-2-aminotetralin as an inhibitor of monoamine oxidase.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID509549Inhibition of human recombinant MAOA expressed in baculovirus infected insect BTI-TN-5B1-4 cells assessed as production of hydrogen peroxide from p-tyramine by amplex red assay2010Journal of medicinal chemistry, Sep-09, Volume: 53, Issue:17
Synthesis, stereochemical separation, and biological evaluation of selective inhibitors of human MAO-B: 1-(4-arylthiazol-2-yl)-2-(3-methylcyclohexylidene)hydrazines.
AID1533829Inhibition of recombinant human MAO-B using kynuramine as substrate after 20 mins by fluorescence assay2019European journal of medicinal chemistry, Feb-01, Volume: 163Design, synthesis and evaluation of pentacycloundecane and hexacycloundecane propargylamine derivatives as multifunctional neuroprotective agents.
AID1708795Selectivity index, ratio of Ki for inhibition of recombinant human MAO-A to Ki for inhibition of recombinant human MAO-B using p-tyramine as substrate2021Journal of medicinal chemistry, 02-25, Volume: 64, Issue:4
New 2-Pyrazoline and Hydrazone Derivatives as Potent and Selective Monoamine Oxidase A Inhibitors.
AID678713Inhibition of human CYP2C9 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-methoxy-4-trifluoromethylcoumarin-3-acetic acid as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID1444066Irreversible inhibition of human cerebral cortex MAO-B using [14C]-phenylethylamin as substrate pretreated for 60 mins followed by substrate addition after 20 mins by liquid scintillation counting method2017European journal of medicinal chemistry, Apr-21, Volume: 130Discovery of highly selective and potent monoamine oxidase B inhibitors: Contribution of additional phenyl rings introduced into 2-aryl-1,3,4-oxadiazin-5(6H)-one.
AID710372Inhibition of bovine brain MAOA using kinuramine as substrate preincubated for 30 mins prior to substrate addition measured after 30 mins by fluorometric assay2012Journal of medicinal chemistry, Dec-13, Volume: 55, Issue:23
Synthesis of new 7-oxycoumarin derivatives as potent and selective monoamine oxidase A inhibitors.
AID1241463Inhibition of human NR1-1a/NR2B expressed in mouse L13-E6 cells assessed as inhibition of glutamate-induced excitotoxicity incubated for 16 hrs by LDH release assay2015Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
Evaluation of Homobivalent Carbolines as Designed Multiple Ligands for the Treatment of Neurodegenerative Disorders.
AID723213Inhibition of human MAOB after 1 hr by luminescence assay2013Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3
Synthesis of (E)-8-(3-chlorostyryl)caffeine analogues leading to 9-deazaxanthine derivatives as dual A(2A) antagonists/MAO-B inhibitors.
AID1397350Metabolic stability in mouse liver microsomes assessed as parent compound remaining at 1 uM after 60 mins by UPLC-MS/MS analysis2018Journal of medicinal chemistry, 08-23, Volume: 61, Issue:16
Development of Novel Monoamine Oxidase-B (MAO-B) Inhibitors with Reduced Blood-Brain Barrier Permeability for the Potential Management of Noncentral Nervous System (CNS) Diseases.
AID1140812Inhibition of human recombinant MAO-B expressed in baculovirus-infected BTI-TN-5B1-4 cell microsomes assessed as decrease in H2O2 production using p-tyramine as substrate preincubated for 15 mins by Amplex Red reagent based fluorimetric method2014Bioorganic & medicinal chemistry, May-15, Volume: 22, Issue:10
Identification of the stereochemical requirements in the 4-aryl-2-cycloalkylidenhydrazinylthiazole scaffold for the design of selective human monoamine oxidase B inhibitors.
AID629039Selectivity index, ratio of IC50 for human recombinant MAO-B to IC50 for human recombinant MAO-A2011European journal of medicinal chemistry, Dec, Volume: 46, Issue:12
2D MI-DRAGON: a new predictor for protein-ligands interactions and theoretic-experimental studies of US FDA drug-target network, oxoisoaporphine inhibitors for MAO-A and human parasite proteins.
AID733498Irreversible inhibition of human MAO-B expressed in baculovirus infected BT1-TN-5B1-4 cells by centrifugation-ultrafiltration method2013European journal of medicinal chemistry, Jan, Volume: 591,5-Diphenylpenta-2,4-dien-1-ones as potent and selective monoamine oxidase-B inhibitors.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID1282047Selectivity index, ratio of IC50 for recombinant human microsomal MAO-A to recombinant human microsomal MAO-B2016Bioorganic & medicinal chemistry, Apr-15, Volume: 24, Issue:8
Novel tricyclic pyrazolo[1,5-d][1,4]benzoxazepin-5(6H)-one: Design, synthesis, model and use as hMAO-B inhibitors.
AID1368628Selectivity index, ratio of IC50 for recombinant human MAO-A to IC50 for recombinant human MAO-B2018Bioorganic & medicinal chemistry, 01-01, Volume: 26, Issue:1
Synthesis and evaluation of biaryl derivatives for structural characterization of selective monoamine oxidase B inhibitors toward Parkinson's disease therapy.
AID776660Competitive reversible inhibition of human recombinant MAO-A expressed in baculovirus infected BT1 insect cells using p-tyramine as substrate assessed as H2O2 production after 15 mins by fluorimetric analysis2013European journal of medicinal chemistry, Nov, Volume: 69Monoamine oxidase inhibitory activity of 3,5-biaryl-4,5-dihydro-1H-pyrazole-1-carboxylate derivatives.
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID773440Inhibition of MAO-B (unknown origin)2013Bioorganic & medicinal chemistry letters, Oct-15, Volume: 23, Issue:20
Inhibition of monoamine oxidase by 3,4-dihydro-2(1H)-quinolinone derivatives.
AID514199Inhibition of human recombinant MAOB expressed in baculovirus infected BTI-TN-5B1-4 insect cells assessed as hydrogen peroxide production from p-tyramine at 20 nM after 15 mins2010Bioorganic & medicinal chemistry, Jul-15, Volume: 18, Issue:14
Synthesis, semipreparative HPLC separation, biological evaluation, and 3D-QSAR of hydrazothiazole derivatives as human monoamine oxidase B inhibitors.
AID444056Fraction escaping gut-wall elimination in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID468865Inhibition of human recombinant MAOB2010European journal of medicinal chemistry, Feb, Volume: 45, Issue:2
Synthesis and inhibitory activity against human monoamine oxidase of N1-thiocarbamoyl-3,5-di(hetero)aryl-4,5-dihydro-(1H)-pyrazole derivatives.
AID497342Inhibition of human MAOA by fluorimetry2010Bioorganic & medicinal chemistry, Aug-01, Volume: 18, Issue:15
Investigations on the 2-thiazolylhydrazyne scaffold: synthesis and molecular modeling of selective human monoamine oxidase inhibitors.
AID1286747Irreversible inhibition of recombinant human MAO-A using p-tyramine as substrate incubated for 1 hr by centrifugation ultra filtration method2016ACS medicinal chemistry letters, Jan-14, Volume: 7, Issue:1
Monoamine Oxidase Inhibitory Activity of Novel Pyrazoline Analogues: Curcumin Based Design and Synthesis.
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1176895Octanol/water partition coefficient, log P of the compound2015Bioorganic & medicinal chemistry letters, Feb-01, Volume: 25, Issue:3
Potent and selective MAO-B inhibitory activity: amino- versus nitro-3-arylcoumarin derivatives.
AID733497Irreversible inhibition of human MAO-B expressed in baculovirus infected BT1-TN-5B1-4 cells measured after repeated wash-out by centrifugation-ultrafiltration method2013European journal of medicinal chemistry, Jan, Volume: 591,5-Diphenylpenta-2,4-dien-1-ones as potent and selective monoamine oxidase-B inhibitors.
AID1351085Inhibition of human MAO-B using tyramine hydrochloride as substrate after 30 mins by Amplex Red reagent based horseradish peroxidase enzyme-coupled fluorescence assay2018European journal of medicinal chemistry, Jan-20, Volume: 144Design, synthesis and biological assessment of new thiazolylhydrazine derivatives as selective and reversible hMAO-A inhibitors.
AID1586574Inhibition of Sprague-Dawley rat liver MAO-B using p-tyramine as substrate preincubated for 15 mins and measured after 45 mins by resorufin-based fluorescence assay2019European journal of medicinal chemistry, Jan-15, Volume: 162(Pyrrolo-pyridin-5-yl)benzamides: BBB permeable monoamine oxidase B inhibitors with neuroprotective effect on cortical neurons.
AID1759294Inhibition of MAO-B (unknown origin)2021Bioorganic & medicinal chemistry letters, 06-01, Volume: 41Discovery of new tranylcypromine derivatives as highly potent LSD1 inhibitors.
AID1891690Selectivity index, ratio of IC50 for inhibition of human recombinant MAOA to IC50 for human recombinant MAOB2022Bioorganic & medicinal chemistry letters, 07-01, Volume: 67The evaluation of N-propargylamine-2-aminotetralin as an inhibitor of monoamine oxidase.
AID1851411Inhibition of human MAO-A assessed as inhibition of H2O2 production using p-tyramine as substrate2022Bioorganic & medicinal chemistry letters, 10-15, Volume: 74Synthesis and human monoamine oxidase inhibitory activity of novel C2-, C3- and C4-substituted phthalonitriles.
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID622917Selectivity index, ratio of IC50 for human recombinant MAO-A to IC50 for human recombinant MAO-B2011Journal of medicinal chemistry, Oct-27, Volume: 54, Issue:20
Synthesis and study of a series of 3-arylcoumarins as potent and selective monoamine oxidase B inhibitors.
AID1528934Irreversible inhibition of recombinant human MAOB expressed in Pichia pastoris assessed as ratio of Kinact to Ki using varying levels of kynuramine as substrate measured after 5 mins by Michaelis-Menten equation analysis
AID604266Selectivity index, ratio of Ki for human MAO-A to Ki for human MAO-B expressed in BTI insect cells2011Bioorganic & medicinal chemistry letters, Jul-15, Volume: 21, Issue:14
Pyrazoline based MAO inhibitors: synthesis, biological evaluation and SAR studies.
AID1708804Cytotoxicity against human HepG2 cells assessed as cell viability at 7.5 uM incubated for 2 hrs by MTT assay relative to control2021Journal of medicinal chemistry, 02-25, Volume: 64, Issue:4
New 2-Pyrazoline and Hydrazone Derivatives as Potent and Selective Monoamine Oxidase A Inhibitors.
AID1458410Time dependent inhibition of human recombinant microsomal MAOB expressed in baculovirus infected BTI-TN-5B1- 4 cells assessed as decrease in H2O2 production at 50 nM after 15 mins by amplex red-based fluorescence assay2017Journal of medicinal chemistry, 08-24, Volume: 60, Issue:16
Coumarin versus Chromone Monoamine Oxidase B Inhibitors: Quo Vadis?
AID1551711Anti-neuroinflammatory activity in MPTP-induced C57BL/6 mouse of Parkinson's disease assessed as increase in tyrosine hydroxylase positive cells in substantia nigra at 10 mg/kg, po pretreated for 30 mins followed by MPTP challenge for 7 days and subsequen2019European journal of medicinal chemistry, Jul-01, Volume: 173Discovery of coumarin Mannich base derivatives as multifunctional agents against monoamine oxidase B and neuroinflammation for the treatment of Parkinson's disease.
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID1458408Selectivity index, ratio of IC50 for human recombinant microsomal MAOA to IC50 for human recombinant microsomal MAOB2017Journal of medicinal chemistry, 08-24, Volume: 60, Issue:16
Coumarin versus Chromone Monoamine Oxidase B Inhibitors: Quo Vadis?
AID125708Inhibition of Monoamine oxidase A of rat liver mitochondrial membranes1992Journal of medicinal chemistry, Oct-02, Volume: 35, Issue:20
Aliphatic propargylamines: potent, selective, irreversible monoamine oxidase B inhibitors.
AID1459562Inhibition of equine serum BuChE using S-butylthiocholine iodide as substrate preincubated for 10 mins followed by substrate addition measured after 10 mins by Ellman's method2017European journal of medicinal chemistry, Jan-05, Volume: 125Synthesis and evaluation of 7-substituted coumarin derivatives as multimodal monoamine oxidase-B and cholinesterase inhibitors for the treatment of Alzheimer's disease.
AID776658Selectivity index, ratio of Ki for human recombinant MAO-A to Ki for human recombinant MAO-B2013European journal of medicinal chemistry, Nov, Volume: 69Monoamine oxidase inhibitory activity of 3,5-biaryl-4,5-dihydro-1H-pyrazole-1-carboxylate derivatives.
AID497517Selectivity index, ratio of IC50 for human recombinant MAOA to IC50 for human recombinant MAOB2010Bioorganic & medicinal chemistry, Aug-01, Volume: 18, Issue:15
Investigations on the 2-thiazolylhydrazyne scaffold: synthesis and molecular modeling of selective human monoamine oxidase inhibitors.
AID233813Ratio of the concentrations of the inhibitors need to decrease the activity of A and B forms of MAO enzyme at the same rate1985Journal of medicinal chemistry, Feb, Volume: 28, Issue:2
Enzyme-activated irreversible inhibitors of monoamine oxidase: phenylallylamine structure-activity relationships.
AID1528915Selectivity ratio of IC50 for recombinant human microsomal MAOA expressed in baculovirus infected BTI insect cells to IC50 for recombinant human microsomal MAOB expressed in baculovirus infected BTI insect cells
AID1397354Acute toxicity in C57BL/6 mouse assessed as piloerection at 10.8 mg/kg, sc after 1 hr post-injection2018Journal of medicinal chemistry, 08-23, Volume: 61, Issue:16
Development of Novel Monoamine Oxidase-B (MAO-B) Inhibitors with Reduced Blood-Brain Barrier Permeability for the Potential Management of Noncentral Nervous System (CNS) Diseases.
AID1231604Antioxidant activity assessed as trolox equivalent of AAPH radical scavenging activity compound preincubated for 10 mins followed by AAPH challenge measured every min for 120 mins by ORAC-FL assay2015Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13
Synthesis and evaluation of selegiline derivatives as monoamine oxidase inhibitor, antioxidant and metal chelator against Alzheimer's disease.
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1378854Inhibition of human recombinant MAO-A expressed in baculovirus infected BTI-TN5B1-4 cells using p-tyramine as substrate assessed as reduction in H2O2 production preincubated for 15 mins followed by substrate addition measured after 15 mins by Amplex red d2017European journal of medicinal chemistry, Oct-20, Volume: 139Synthesis and structure-activity relationship study of novel 3-heteroarylcoumarins based on pyridazine scaffold as selective MAO-B inhibitors.
AID1252748Inhibition of recombinant human MAOB using p-tyramine as substrate assessed as H2O2 production preincubated for 15 mins followed by substrate addition by fluorometric analysis2015European journal of medicinal chemistry, Oct-20, Volume: 103Novel 2H-chromen-2-one derivatives of resveratrol: Design, synthesis, modeling and use as human monoamine oxidase inhibitors.
AID349909Inhibition of human recombinant MAO-A assessed as hydrogen peroxide production2009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
Chalcones: a valid scaffold for monoamine oxidases inhibitors.
AID1416665Reversible inhibition of recombinant human MAO-B expressed in baculovirus infected insect cells assessed as residual activity at 10 times IC50 pretreated for 30 mins followed by 100 fold compound dilution and p-tyramine substrate addition measured for 15 2017MedChemComm, Sep-01, Volume: 8, Issue:9
MAO inhibitory activity of bromo-2-phenylbenzofurans: synthesis,
AID497343Inhibition of human MAOB by fluorimetry2010Bioorganic & medicinal chemistry, Aug-01, Volume: 18, Issue:15
Investigations on the 2-thiazolylhydrazyne scaffold: synthesis and molecular modeling of selective human monoamine oxidase inhibitors.
AID767285Selectivity index, ratio of IC50 for human MAO-A to IC50 for human MAO-B2013Bioorganic & medicinal chemistry letters, Sep-15, Volume: 23, Issue:18
Design, synthesis, and in vitro hMAO-B inhibitory evaluation of some 1-methyl-3,5-diphenyl-4,5-dihydro-1H-pyrazoles.
AID244288Selectivity for rat Monoamine oxidase A as ratio of Ki(MAO-B)/Ki(MAO-A)2005Journal of medicinal chemistry, Jun-30, Volume: 48, Issue:13
Design, synthesis, and biological activities of pyrrolylethanoneamine derivatives, a novel class of monoamine oxidases inhibitors.
AID767288Inhibition of human recombinant microsomal MAO-B expressed in baculovirus-infected insect BTI-TN-5B1-4 cells assessed as p-tyramine conversion to H2O2 by fluorescence assay2013Bioorganic & medicinal chemistry letters, Sep-15, Volume: 23, Issue:18
Design, synthesis, and in vitro hMAO-B inhibitory evaluation of some 1-methyl-3,5-diphenyl-4,5-dihydro-1H-pyrazoles.
AID136953Compound was evaluated for MAO-B activity after 21 days of chronic peritoneal administration in mouse fore brain at dose of 0.2 mg/kg1992Journal of medicinal chemistry, Oct-02, Volume: 35, Issue:20
Aliphatic propargylamines: potent, selective, irreversible monoamine oxidase B inhibitors.
AID1695579Inhibition of human recombinant MAO-B at 100 uM using tyramine as substrate preincubated with enzyme for 30 mins followed by incubation with substrate for 30 mins by Amplex Red reagent based fluorometric method relative to control2020RSC medicinal chemistry, Sep-01, Volume: 11, Issue:9
Novel 1,3,4-thiadiazole compounds as potential MAO-A inhibitors - design, synthesis, biological evaluation and molecular modelling.
AID311934Dissociation constant, pKa of the compound2008Journal of medicinal chemistry, Jan-24, Volume: 51, Issue:2
Identification of new functional inhibitors of acid sphingomyelinase using a structure-property-activity relation model.
AID1512063Inhibition of human recombinant MAO-B expressed in insect cells microsomes assessed as inhibition of 4-hydroxyquinoline formation using kynuramine as substrate incubated for 20 mins by fluorescence spectrophotometry analysis2019Bioorganic & medicinal chemistry letters, 11-01, Volume: 29, Issue:21
1,3,4-Oxadiazol-2-ylbenzenesulfonamides as privileged structures for the inhibition of monoamine oxidase B.
AID449666Selectivity index, ratio of IC50 for human recombinant MAOA to IC50 for human recombinant MAOB2009Bioorganic & medicinal chemistry letters, Sep-01, Volume: 19, Issue:17
Synthesis and evaluation of 6-methyl-3-phenylcoumarins as potent and selective MAO-B inhibitors.
AID1524509Inhibition of recombinant human MAOA expressed in baculovirus infected BTI insect cells using p-tyramine as substrate preincubated for 30 mins followed by substrate addition and measured over 15 mins by Amplex red reagent/horseradish peroxidase coupled fl2019Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9
Discovery of novel 2,3-dihydro-1H-inden-1-amine derivatives as selective monoamine oxidase B inhibitors.
AID610970Inhibition of human MAO-B assessed as inhibition of p-tyramine oxidation to p-hydroxyphenyl-acetaldehyde after 15 mins by fluorimetric method2011Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
Chromone, a privileged scaffold for the development of monoamine oxidase inhibitors.
AID102893Compound was evaluated for the time-dependence inhibition of MAO-B at 0 minute pre-incubation periods1993Journal of medicinal chemistry, Apr-30, Volume: 36, Issue:9
5-[4-(benzyloxy)phenyl]-1,3,4-oxadiazol-2(3H)-one derivatives and related analogues: new reversible, highly potent, and selective monamine oxidase type B inhibitors.
AID1397351Metabolic stability in human liver microsomes assessed as parent compound remaining at 1 uM after 60 mins by UPLC-MS/MS analysis2018Journal of medicinal chemistry, 08-23, Volume: 61, Issue:16
Development of Novel Monoamine Oxidase-B (MAO-B) Inhibitors with Reduced Blood-Brain Barrier Permeability for the Potential Management of Noncentral Nervous System (CNS) Diseases.
AID126217Relative affinity for MAO-A and MAO-B of rat liver.1992Journal of medicinal chemistry, Oct-02, Volume: 35, Issue:20
Aliphatic propargylamines: potent, selective, irreversible monoamine oxidase B inhibitors.
AID387974Selectivity ratio of Ki for bovine MAO-A over Ki for bovine MAO-B2008Bioorganic & medicinal chemistry, Nov-15, Volume: 16, Issue:22
Synthesis, structure-activity relationships and molecular modeling studies of new indole inhibitors of monoamine oxidases A and B.
AID1484649Inhibition of recombinant human MAO-B using kynuramine as substrate by fluorescence spectroscopy2017European journal of medicinal chemistry, Jul-28, Volume: 135The evaluation of 1,4-benzoquinones as inhibitors of human monoamine oxidase.
AID669072Selectivity ratio of pIC50 for MAO B over MAO A in rat cerebral cortex2012Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7
Synthesis and evaluation of a set of para-substituted 4-phenylpiperidines and 4-phenylpiperazines as monoamine oxidase (MAO) inhibitors.
AID1636269Inhibition of human recombinant MAO-A preincubated for 30 mins followed by p-tyramine hydrochloride addition measured after 30 mins by Amplex red fluorescence based spectrophotometry2016Bioorganic & medicinal chemistry, 10-15, Volume: 24, Issue:20
Design, synthesis and biological evaluation of N-methyl-N-[(1,2,3-triazol-4-yl)alkyl]propargylamines as novel monoamine oxidase B inhibitors.
AID1397341Inhibition of human recombinant MAO-A expressed in baculovirus infected BTI-TN-5B1-4 insect cells using tyramine as substrate preincubated for 1 hr followed by substrate addition and measured after 30 mins by resazurin dye-based fluorescence assay2018Journal of medicinal chemistry, 08-23, Volume: 61, Issue:16
Development of Novel Monoamine Oxidase-B (MAO-B) Inhibitors with Reduced Blood-Brain Barrier Permeability for the Potential Management of Noncentral Nervous System (CNS) Diseases.
AID349924Inhibition of human MAO-B at 20 nM after repeated washing2009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
Chalcones: a valid scaffold for monoamine oxidases inhibitors.
AID749462Induction of adipogenesis in human bone marrow MSC assessed as adiponectin production after 14 days by ELISA in IDX condition2013Bioorganic & medicinal chemistry letters, Jun-01, Volume: 23, Issue:11
The opposite effect of isotype-selective monoamine oxidase inhibitors on adipogenesis in human bone marrow mesenchymal stem cells.
AID626694Inhibition of human recombinant MAO-B expressed in insect cells assessed as inhibition of kynuramine oxidation after 30 mins by fluorescence assay2011Journal of medicinal chemistry, Oct-27, Volume: 54, Issue:20
Synthesis of three novel fluorine-18 labeled analogues of L-deprenyl for positron emission tomography (PET) studies of monoamine oxidase B (MAO-B).
AID1192631Binding affinity to human recombinant microsomal MAO-B by ITC2015Bioorganic & medicinal chemistry, Feb-15, Volume: 23, Issue:4
Reversible and irreversible small molecule inhibitors of monoamine oxidase B (MAO-B) investigated by biophysical techniques.
AID1282044Inhibition of recombinant human microsomal MAO-A expressed in baculovirus-infected insect cells using p-tyramine as substrate assessed as H2O2 production at 60 uM pretreated for 15 mins followed by addition of Amplex Red, horseradish peroxidase and substr2016Bioorganic & medicinal chemistry, Apr-15, Volume: 24, Issue:8
Novel tricyclic pyrazolo[1,5-d][1,4]benzoxazepin-5(6H)-one: Design, synthesis, model and use as hMAO-B inhibitors.
AID604268Reversible inhibition of human MAO-B expressed in BTI insect cells using p-tyramine as substrate after 60 mins2011Bioorganic & medicinal chemistry letters, Jul-15, Volume: 21, Issue:14
Pyrazoline based MAO inhibitors: synthesis, biological evaluation and SAR studies.
AID1636274Irreversible inhibition of human recombinant MAO-B at 200 nM preincubated for 30 mins followed by 100 fold enzyme dilution and p-tyramine hydrochloride substrate addition measured after 40 mins by Amplex red fluorescence based spectrophotometry2016Bioorganic & medicinal chemistry, 10-15, Volume: 24, Issue:20
Design, synthesis and biological evaluation of N-methyl-N-[(1,2,3-triazol-4-yl)alkyl]propargylamines as novel monoamine oxidase B inhibitors.
AID1900898Inhibition of MAO-B (unknown origin) at 10 mM relative to control2022European journal of medicinal chemistry, Feb-05, Volume: 229Synthesis of novel thiazolyl hydrazone derivatives as potent dual monoamine oxidase-aromatase inhibitors.
AID1493744Inhibition of recombinant human MAO-B using kynuramine as substrate after 20 mins by fluorescence assay2018European journal of medicinal chemistry, Jan-01, Volume: 143Design, synthesis and biochemical evaluation of novel multi-target inhibitors as potential anti-Parkinson agents.
AID514141Inhibition of human recombinant MAOA expressed in baculovirus infected BTI-TN-5B1-4 insect cells assessed as hydrogen peroxide production from p-tyramine by amplex red assay2010Bioorganic & medicinal chemistry, Jul-15, Volume: 18, Issue:14
Synthesis, semipreparative HPLC separation, biological evaluation, and 3D-QSAR of hydrazothiazole derivatives as human monoamine oxidase B inhibitors.
AID102578Compound was evaluated for the reversibility test for the percentage inhibition of MAO B at 6.25 nM after the test at 12.5 nM1993Journal of medicinal chemistry, Apr-30, Volume: 36, Issue:9
5-[4-(benzyloxy)phenyl]-1,3,4-oxadiazol-2(3H)-one derivatives and related analogues: new reversible, highly potent, and selective monamine oxidase type B inhibitors.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID102897In vitro inhibitory activity on rat brain MAO-B.1993Journal of medicinal chemistry, Apr-30, Volume: 36, Issue:9
5-[4-(benzyloxy)phenyl]-1,3,4-oxadiazol-2(3H)-one derivatives and related analogues: new reversible, highly potent, and selective monamine oxidase type B inhibitors.
AID125384Displacement of [14C]5-HT from mouse forebrain homogenate Monoamine oxidase1983Journal of medicinal chemistry, Jul, Volume: 26, Issue:7
Synthesis and monoamine oxidase inhibitory activities of alpha-allenic amines in vivo and in vitro. Different activities of two enantiomeric allenes.
AID116717Acute cytotoxicity was evaluated as LD50 in mice (ip)1988Journal of medicinal chemistry, Jun, Volume: 31, Issue:6
2,4-Dihydro-3H-1,2,4-triazole-3-thiones as potential antidepressant agents.
AID1252750Selectivity ratio of IC50 for recombinant human MAOA to IC50 for recombinant human MAOB2015European journal of medicinal chemistry, Oct-20, Volume: 103Novel 2H-chromen-2-one derivatives of resveratrol: Design, synthesis, modeling and use as human monoamine oxidase inhibitors.
AID657237Inhibition of MAO-A in Sprague-Dawley rat brain homogenate using kynuramine as substrate preincubated for 10 mins measured by fluorimetric assay2012Bioorganic & medicinal chemistry letters, May-01, Volume: 22, Issue:9
Synthesis and inhibitory effect of piperine derivates on monoamine oxidase.
AID1241461Inhibition of human NR1-1a/NR2A expressed in mouse L12-G10 cells assessed as inhibition of glutamate-induced excitotoxicity incubated for 16 hrs by LDH release assay2015Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
Evaluation of Homobivalent Carbolines as Designed Multiple Ligands for the Treatment of Neurodegenerative Disorders.
AID361943Inhibition of human recombinant MAOB after washing at 20 nM by centrifugation-ultrafiltration method2008Journal of medicinal chemistry, Aug-28, Volume: 51, Issue:16
Synthesis, stereochemical identification, and selective inhibitory activity against human monoamine oxidase-B of 2-methylcyclohexylidene-(4-arylthiazol-2-yl)hydrazones.
AID1459900Reversible inhibition of recombinant human MAO-B assessed as residual activity pre-incubated for 15 mins followed by dialysis for 24 hrs and subsequent kynuramine addition measured after 20 mins by fluorescence spectrophotometric analysis relative to untr2017European journal of medicinal chemistry, Jan-05, Volume: 125Benzyloxynitrostyrene analogues - A novel class of selective and highly potent inhibitors of monoamine oxidase B.
AID238291Inhibitory concentration for rat Monoamine oxidase A2005Journal of medicinal chemistry, Jun-30, Volume: 48, Issue:13
Design, synthesis, and biological activities of pyrrolylethanoneamine derivatives, a novel class of monoamine oxidases inhibitors.
AID610979Reversible inhibition of human MAOB expressed assessed as inhibition of p-tyramine oxidation to p-hydroxyphenyl-acetaldehyde at 25 uM measured before repeated washing by centrifugation-ultrafiltration method2011Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
Chromone, a privileged scaffold for the development of monoamine oxidase inhibitors.
AID125405In vitro inhibition of Monoamine oxidase at rat hyphalamic mitochondrial PEA by displacing 2.5 uM of [14C]PEA.1983Journal of medicinal chemistry, Jul, Volume: 26, Issue:7
Synthesis and monoamine oxidase inhibitory activities of alpha-allenic amines in vivo and in vitro. Different activities of two enantiomeric allenes.
AID314094Inhibition of MAOA2008Journal of medicinal chemistry, Feb-14, Volume: 51, Issue:3
Multi-target-directed ligands to combat neurodegenerative diseases.
AID126682Concentration required to inhibit Monoamine oxidase B in rat brain using [14C]phenylethylamine1988Journal of medicinal chemistry, Jun, Volume: 31, Issue:6
2,4-Dihydro-3H-1,2,4-triazole-3-thiones as potential antidepressant agents.
AID1528914Inhibition of recombinant human microsomal MAOB expressed in baculovirus infected BTI insect cells using p-tyramine as substrate preincubated for 15 mins followed by substrate addition and measured over 20 mins by amplex red reagent-based horseradish pero
AID126694In vitro ability to inhibit Monoamine oxidase B activity in rat whole brain in vitro2001Bioorganic & medicinal chemistry letters, Oct-22, Volume: 11, Issue:20
Synthesis of N-propargylphenelzine and analogues as neuroprotective agents.
AID681116TP_TRANSPORTER: transepithelial transport (basal to apical) in MDR1-expressing MDCKII cells2002The Journal of pharmacology and experimental therapeutics, Dec, Volume: 303, Issue:3
Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs.
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1493755Irreversible inhibition of recombinant human MAO-B assessed as residual activity at 4 times IC50 using kynuramine as substrate pre-incubated for 15 mins followed by 2 fold dilution of compound for 24 hrs and subsequent substrate addition measured after 202018European journal of medicinal chemistry, Jan-01, Volume: 143Design, synthesis and biochemical evaluation of novel multi-target inhibitors as potential anti-Parkinson agents.
AID1512069Irreversible inhibition of human recombinant MAO-B expressed in insect cells microsomes assessed as enzyme residual activity preincubated at concentration of 4 times IC50 with enzyme for 15 mins followed by dialysis of enzyme-inhibitor mixture for 24 hrs 2019Bioorganic & medicinal chemistry letters, 11-01, Volume: 29, Issue:21
1,3,4-Oxadiazol-2-ylbenzenesulfonamides as privileged structures for the inhibition of monoamine oxidase B.
AID743806Potentiation of L-dopa/carbidopa activity in reserpine-treated CD1 mouse assessed as increase in velocity at 10 mg/kg, ip administered 22 hrs post reserpine challenge followed by L-dopa/carbidopa adminstration at 30 mins measured after 1 hr relative to co2013European journal of medicinal chemistry, May, Volume: 63Novel (coumarin-3-yl)carbamates as selective MAO-B inhibitors: synthesis, in vitro and in vivo assays, theoretical evaluation of ADME properties and docking study.
AID678717Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-benzyloxyquinoline as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID29359Ionization constant (pKa)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID125698The ability of the compound(25 umol/kg/day) to inactivate monoamine oxidase A(MAO-A) was tested on brain mitochondrial membranes of mice, for 3 day.1996Journal of medicinal chemistry, Nov-22, Volume: 39, Issue:24
Synthesis and selective monoamine oxidase B-inhibiting properties of 1-methyl-1,2,3,6-tetrahydropyrid-4-yl carbamate derivatives: potential prodrugs of (R)- and (S)-nordeprenyl.
AID743809Selectivity index, ratio of IC50 for human recombinant microsomal MAO-A to IC50 for human recombinant microsomal MAO-B2013European journal of medicinal chemistry, May, Volume: 63Novel (coumarin-3-yl)carbamates as selective MAO-B inhibitors: synthesis, in vitro and in vivo assays, theoretical evaluation of ADME properties and docking study.
AID751611Irreversible inhibition of human recombinant monoamine oxidase-B using kynuramine as substrate assessed as residual enzyme activity treated at 10 times IC50 preincubated for 30 mins prior to substrate addition followed by 100 fold dilution measured after 2013Bioorganic & medicinal chemistry letters, Mar-01, Volume: 23, Issue:5
Inhibition of monoamine oxidase by phthalide analogues.
AID1409012Inhibition of recombinant human MAO-B using kynuramine as substrate after 20 mins by fluorescence spectrophotometric analysis2018Bioorganic & medicinal chemistry, 11-01, Volume: 26, Issue:20
Synthesis and evaluation of 2-substituted 4(3H)-quinazolinone thioether derivatives as monoamine oxidase inhibitors.
AID1320870Inhibition of human recombinant AChE using acetylthiocholine iodide as substrate preincubated for 5 mins followed by substrate addition measured for 5 mins by Ellman's method2016European journal of medicinal chemistry, Oct-04, Volume: 121New cinnamic - N-benzylpiperidine and cinnamic - N,N-dibenzyl(N-methyl)amine hybrids as Alzheimer-directed multitarget drugs with antioxidant, cholinergic, neuroprotective and neurogenic properties.
AID1695731Inhibition of alpha-synuclein fibril formation (unknown origin) incubated for 6 days by thioflavin S based fluorescence assay2019European journal of medicinal chemistry, Apr-01, Volume: 167Toward the discovery and development of effective modulators of α-synuclein amyloid aggregation.
AID1322906Inhibition of human recombinant AChE expressed in HEK293 cells using acetylthiocholine iodide as substrate preincubated for 30 mins followed by substrate addition measured after 30 mins by Ellman's method2016European journal of medicinal chemistry, Oct-04, Volume: 121Donepezil-like multifunctional agents: Design, synthesis, molecular modeling and biological evaluation.
AID604279Inhibition of human recombinant MAO-A using p-tyramine substrate by fluorometric method2011Bioorganic & medicinal chemistry letters, Jul-15, Volume: 21, Issue:14
MAO inhibitory activity modulation: 3-Phenylcoumarins versus 3-benzoylcoumarins.
AID1586576Selectivity index, ratio of IC50 for human recombinant MAO-A expressed in baculovirus infected BTI-TN-5B1-4 insect cells to IC50 for human recombinant MAO-B expressed in baculovirus infected BTI-TN-5B1-4 insect cells2019European journal of medicinal chemistry, Jan-15, Volume: 162(Pyrrolo-pyridin-5-yl)benzamides: BBB permeable monoamine oxidase B inhibitors with neuroprotective effect on cortical neurons.
AID1068740In vivo inhibition of MAO-A in Sprague-Dawley rat assessed as 3-methoxytyramine level in brain striatum at 53 umol/kg, sc after 1 hr by HPLC/EC analysis relative to control2014European journal of medicinal chemistry, Feb-12, Volume: 73A novel series of 6-substituted 3-(pyrrolidin-1-ylmethyl)chromen-2-ones as selective monoamine oxidase (MAO) A inhibitors.
AID781326pKa (acid-base dissociation constant) as determined by Avdeef ref: DOI: 10.1002/047145026X2014Pharmaceutical research, Apr, Volume: 31, Issue:4
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
AID743807Potentiation of L-dopa/carbidopa activity in reserpine-treated CD1 mouse assessed as increase in motor activity at 10 mg/kg, ip administered 22 hrs post reserpine challenge followed by L-dopa/carbidopa adminstration at 30 mins measured after 1 hr relative2013European journal of medicinal chemistry, May, Volume: 63Novel (coumarin-3-yl)carbamates as selective MAO-B inhibitors: synthesis, in vitro and in vivo assays, theoretical evaluation of ADME properties and docking study.
AID254307Inhibition constant against human recombinant Monoamine oxidase-B 2005Bioorganic & medicinal chemistry letters, Oct-15, Volume: 15, Issue:20
Docking studies on monoamine oxidase-B inhibitors: estimation of inhibition constants (K(i)) of a series of experimentally tested compounds.
AID509551Selectivity ratio of IC50 for human recombinant MAOA to IC50 for human recombinant MAOB2010Journal of medicinal chemistry, Sep-09, Volume: 53, Issue:17
Synthesis, stereochemical separation, and biological evaluation of selective inhibitors of human MAO-B: 1-(4-arylthiazol-2-yl)-2-(3-methylcyclohexylidene)hydrazines.
AID1397356Cmax in C57BL/6 mouse plasma at 10.8 mg/kg, iv administered as single dose measured 24 hrs by UPLC-MS/MS analysis2018Journal of medicinal chemistry, 08-23, Volume: 61, Issue:16
Development of Novel Monoamine Oxidase-B (MAO-B) Inhibitors with Reduced Blood-Brain Barrier Permeability for the Potential Management of Noncentral Nervous System (CNS) Diseases.
AID1528928Reversible inhibition of recombinant human MAOB expressed in Pichia pastoris using varying levels of kynuramine as substrate measured after 5 mins by Michaelis-Menten equation analysis
AID1514372Inhibition of MAO-B (unknown origin) using (4S)-4,5-dihydro-2-(6-hydroxybenzothiazolyl)-4-thiazolecarboxylic acid as substrate by MAO-Glo assay2018Bioorganic & medicinal chemistry, 12-15, Volume: 26, Issue:23-24
Design, synthesis and in vitro evaluation of stilbene derivatives as novel LSD1 inhibitors for AML therapy.
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID1320874Inhibition of human recombinant MAOA using p-tyramine as substrate incubated for 15 mins by fluorimetric method2016European journal of medicinal chemistry, Oct-04, Volume: 121New cinnamic - N-benzylpiperidine and cinnamic - N,N-dibenzyl(N-methyl)amine hybrids as Alzheimer-directed multitarget drugs with antioxidant, cholinergic, neuroprotective and neurogenic properties.
AID410878Inhibition of MAOA in rat liver homogenates preincubated for 60 mins2008Bioorganic & medicinal chemistry letters, Dec-15, Volume: 18, Issue:24
Pyrazoline-based mycobactin analogues as MAO-inhibitors.
AID629008Inhibition of human recombinant MAOB expressed in baculovirus infected BTI-TN-5B1-4 insect cells assessed as hydrogen peroxide production from p-tyramine after 15 mins by amplex red assay2011European journal of medicinal chemistry, Dec, Volume: 46, Issue:12
2D MI-DRAGON: a new predictor for protein-ligands interactions and theoretic-experimental studies of US FDA drug-target network, oxoisoaporphine inhibitors for MAO-A and human parasite proteins.
AID425652Total body clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID1602879Inhibition of human recombinant MAO-A expressed in insect cells using p-tyramine as substrate preincubated for 30 mins followed by substrate addition measured for 15 mins by resorufin dye-based fluorescence assay2019Bioorganic & medicinal chemistry letters, 04-15, Volume: 29, Issue:8
Design, synthesis and biological evaluation of novel human monoamine oxidase B inhibitors based on a fragment in an X-ray crystal structure.
AID1524510Selectivity index, ratio of IC50 for recombinant human MAOA expressed in baculovirus infected BTI insect cells to IC50 for recombinant human MAOB expressed in baculovirus infected BTI insect cells2019Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9
Discovery of novel 2,3-dihydro-1H-inden-1-amine derivatives as selective monoamine oxidase B inhibitors.
AID1413449Inhibition of recombinant human MAO-B assessed as reduction in H2O2 production preincubated for 30 mins followed by p-tyramine substrate addition measured after 30 mins by amplex red reagent based fluorescence assay
AID1767577Inhibition of MAO-A (unknown origin) by multi-well spectrophotometry2021European journal of medicinal chemistry, Oct-15, Volume: 222Halting colorectal cancer metastasis via novel dual nanomolar MMP-9/MAO-A quinoxaline-based inhibitors; design, synthesis, and evaluation.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID593171Inhibition of human recombinant MAO-B expressed in baculovirus infected BTI-TN-5B1-4 insect sells assessed as hydrogen peroxide production at 20 nM measured after repeated washing by fluorimetric method2011Journal of medicinal chemistry, Apr-14, Volume: 54, Issue:7
Homoisoflavonoids: natural scaffolds with potent and selective monoamine oxidase-B inhibition properties.
AID1444065Irreversible inhibition of human cerebral cortex MAO-A using [14C]-5-hydroxytryptamine creatinine disulphate as substrate pretreated for 60 mins followed by substrate addition after 30 mins by liquid scintillation counting method2017European journal of medicinal chemistry, Apr-21, Volume: 130Discovery of highly selective and potent monoamine oxidase B inhibitors: Contribution of additional phenyl rings introduced into 2-aryl-1,3,4-oxadiazin-5(6H)-one.
AID1286743Selectivity index, ratio of Ki for recombinant human MAO-A to Ki for recombinant human MAO-B2016ACS medicinal chemistry letters, Jan-14, Volume: 7, Issue:1
Monoamine Oxidase Inhibitory Activity of Novel Pyrazoline Analogues: Curcumin Based Design and Synthesis.
AID1320875Inhibition of human recombinant MAOB using p-tyramine as substrate incubated for 15 mins by fluorimetric method2016European journal of medicinal chemistry, Oct-04, Volume: 121New cinnamic - N-benzylpiperidine and cinnamic - N,N-dibenzyl(N-methyl)amine hybrids as Alzheimer-directed multitarget drugs with antioxidant, cholinergic, neuroprotective and neurogenic properties.
AID125379Inhibitory activity of Monoamine oxidase at mouse forebrain homogenate by displacing [14C]5-HT1983Journal of medicinal chemistry, Jul, Volume: 26, Issue:7
Synthesis and monoamine oxidase inhibitory activities of alpha-allenic amines in vivo and in vitro. Different activities of two enantiomeric allenes.
AID118295Lowest dose potentiating the awakening effect of phenethylamine (10 mg/kg, subcutaneous) in mice pretreated with reserpine1983Journal of medicinal chemistry, Jul, Volume: 26, Issue:7
Synthesis and monoamine oxidase inhibitory activities of alpha-allenic amines in vivo and in vitro. Different activities of two enantiomeric allenes.
AID125381Inhibitory activity of Monoamine oxidase at mouse forebrain homogenate by displacing [14C]PEA1983Journal of medicinal chemistry, Jul, Volume: 26, Issue:7
Synthesis and monoamine oxidase inhibitory activities of alpha-allenic amines in vivo and in vitro. Different activities of two enantiomeric allenes.
AID1502984Inhibition of MAOB (unknown origin) using beetle luciferin as substrate by MAO-Glo assay2017European journal of medicinal chemistry, Nov-10, Volume: 140Design and synthesis of tranylcypromine derivatives as novel LSD1/HDACs dual inhibitors for cancer treatment.
AID743812Inhibition of human recombinant microsomal MAO-B expressed in baculovirus infected BTI-TN-5B1-4 cells using p-tyramine as substrate assessed as production of H2O2 incubated for 15 mins followed by substrate addition measured over 15 mins by fluorimetric a2013European journal of medicinal chemistry, May, Volume: 63Novel (coumarin-3-yl)carbamates as selective MAO-B inhibitors: synthesis, in vitro and in vivo assays, theoretical evaluation of ADME properties and docking study.
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID130605MAO activities in the mouse brain after intraperitoneal administration of compound towards PE (1.9 x 10e-5 M) substrate1992Journal of medicinal chemistry, Oct-02, Volume: 35, Issue:20
Aliphatic propargylamines: potent, selective, irreversible monoamine oxidase B inhibitors.
AID1528913Inhibition of recombinant human microsomal MAOA expressed in baculovirus infected BTI insect cells using p-tyramine as substrate preincubated for 15 mins followed by substrate addition and measured over 20 mins by amplex red reagent-based horseradish pero
AID1057043Inhibition of human MAO-A2013Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23
1,3-Dialkyl-substituted tetrahydropyrimido[1,2-f]purine-2,4-diones as multiple target drugs for the potential treatment of neurodegenerative diseases.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID449664Inhibition of human recombinant MAOA expressed in BTI cells2009Bioorganic & medicinal chemistry letters, Sep-01, Volume: 19, Issue:17
Synthesis and evaluation of 6-methyl-3-phenylcoumarins as potent and selective MAO-B inhibitors.
AID136958MAO activities in the mouse brain after oral administration of compound towards PE (1.9 x 10e-5 M) substrate1992Journal of medicinal chemistry, Oct-02, Volume: 35, Issue:20
Aliphatic propargylamines: potent, selective, irreversible monoamine oxidase B inhibitors.
AID461716Inhibition of human recombinant MAOB expressed in BTI-TN-5B1-4 cells at 20 nM after repeated washing by centrifugation-ultrafiltration method2010Bioorganic & medicinal chemistry, Feb, Volume: 18, Issue:3
A new series of flavones, thioflavones, and flavanones as selective monoamine oxidase-B inhibitors.
AID1057562Inhibition of MAO-B (unknown origin) using p-tyramine substrate by HPLC method2013Bioorganic & medicinal chemistry, Dec-15, Volume: 21, Issue:24
Chromenylchalcones with inhibitory effects on monoamine oxidase B.
AID1301270Selectivity index, ratio of IC50 for human recombinant microsomal MAO-A expressed in baculovirus infected BTI-TN-5B1-4 cells to IC50 for human recombinant microsomal MAO-B expressed in baculovirus infected BTI-TN-5B1-4 cells2016European journal of medicinal chemistry, Jul-19, Volume: 117(E)-3-Heteroarylidenechroman-4-ones as potent and selective monoamine oxidase-B inhibitors.
AID1176890Inhibition of human recombinant MAOA expressed in BTI-TN-5B1-4 cells using p-tyramine substrate assessed as reduction in H2O2 production2015Bioorganic & medicinal chemistry letters, Feb-01, Volume: 25, Issue:3
Potent and selective MAO-B inhibitory activity: amino- versus nitro-3-arylcoumarin derivatives.
AID1602880Inhibition of human recombinant MAO-B expressed in insect cells using p-tyramine as substrate preincubated for 30 mins followed by substrate addition measured for 15 mins by resorufin dye-based fluorescence assay2019Bioorganic & medicinal chemistry letters, 04-15, Volume: 29, Issue:8
Design, synthesis and biological evaluation of novel human monoamine oxidase B inhibitors based on a fragment in an X-ray crystal structure.
AID1231603Selectivity index, ratio of IC50 for human recombinant MAO-A to IC50 for human recombinant MAO-B2015Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13
Synthesis and evaluation of selegiline derivatives as monoamine oxidase inhibitor, antioxidant and metal chelator against Alzheimer's disease.
AID1421881Selectivity index, ratio of IC50 for human recombinant MAOA to IC50 for human recombinant MAOB2018European journal of medicinal chemistry, Oct-05, Volume: 158Multi-target-directed ligands for Alzheimer's disease: Discovery of chromone-based monoamine oxidase/cholinesterase inhibitors.
AID349923Inhibition of human MAO-B at 20 nM before washing2009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
Chalcones: a valid scaffold for monoamine oxidases inhibitors.
AID509550Inhibition of human recombinant MAOB expressed in baculovirus infected insect BTI-TN-5B1-4 cells assessed as production of hydrogen peroxide from p-tyramine by amplex red assay2010Journal of medicinal chemistry, Sep-09, Volume: 53, Issue:17
Synthesis, stereochemical separation, and biological evaluation of selective inhibitors of human MAO-B: 1-(4-arylthiazol-2-yl)-2-(3-methylcyclohexylidene)hydrazines.
AID444050Fraction unbound in human plasma2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID776659Competitive reversible inhibition of human recombinant MAO-B expressed in baculovirus infected BT1 insect cells using p-tyramine as substrate assessed as H2O2 production after 15 mins by fluorimetric analysis2013European journal of medicinal chemistry, Nov, Volume: 69Monoamine oxidase inhibitory activity of 3,5-biaryl-4,5-dihydro-1H-pyrazole-1-carboxylate derivatives.
AID234049Selectivity for B form estimated by ratio of IC50 for MAO-A to MAO-B.1993Journal of medicinal chemistry, Apr-30, Volume: 36, Issue:9
5-[4-(benzyloxy)phenyl]-1,3,4-oxadiazol-2(3H)-one derivatives and related analogues: new reversible, highly potent, and selective monamine oxidase type B inhibitors.
AID1397358AUClast in C57BL/6 mouse plasma at 10.8 mg/kg, iv administered as single dose measured 24 hrs by UPLC-MS/MS analysis2018Journal of medicinal chemistry, 08-23, Volume: 61, Issue:16
Development of Novel Monoamine Oxidase-B (MAO-B) Inhibitors with Reduced Blood-Brain Barrier Permeability for the Potential Management of Noncentral Nervous System (CNS) Diseases.
AID1397361Tmax in C57BL/6 mouse brain at 10.8 mg/kg, iv administered as single dose measured 24 hrs by UPLC-MS/MS analysis2018Journal of medicinal chemistry, 08-23, Volume: 61, Issue:16
Development of Novel Monoamine Oxidase-B (MAO-B) Inhibitors with Reduced Blood-Brain Barrier Permeability for the Potential Management of Noncentral Nervous System (CNS) Diseases.
AID622913Inhibition of human recombinant MAO-A expressed in insect BT1-TN-5B1-4 cells assessed as production of hydrogen peroxide from p-tyramine up to 15 mins by amplex red-based fluorometric assay2011Journal of medicinal chemistry, Oct-27, Volume: 54, Issue:20
Synthesis and study of a series of 3-arylcoumarins as potent and selective monoamine oxidase B inhibitors.
AID1192625Inhibition of MAO-A in rat whole brain homogenate2015Bioorganic & medicinal chemistry, Feb-15, Volume: 23, Issue:4
Reversible and irreversible small molecule inhibitors of monoamine oxidase B (MAO-B) investigated by biophysical techniques.
AID298031Lipophilicity, log D at pH7.42007Journal of medicinal chemistry, Sep-20, Volume: 50, Issue:19
High-throughput screening of drug-brain tissue binding and in silico prediction for assessment of central nervous system drug delivery.
AID1261182Irreversible inhibition of human MAO-A expressed in baculovirus infected BT1 cells microsome fraction assessed as enzyme activity recovered at 10 times of IC50 concentration preincubated for 30 mins followed by dilution to 0.1 times of IC50 concentration 2015Bioorganic & medicinal chemistry letters, Nov-15, Volume: 25, Issue:22
Monoamine oxidase inhibitory activities of heterocyclic chalcones.
AID1458404Inhibition of human recombinant microsomal MAOB expressed in baculovirus infected BTI-TN-5B1- 4 cells using p-tyramine as substrate assessed as decrease in H2O2 production after 15 mins by amplex red-based fluorescence assay2017Journal of medicinal chemistry, 08-24, Volume: 60, Issue:16
Coumarin versus Chromone Monoamine Oxidase B Inhibitors: Quo Vadis?
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID125700Ratio of IC50 against mouse brain MAO-A and MAO-B1992Journal of medicinal chemistry, Oct-02, Volume: 35, Issue:20
Aliphatic propargylamines: potent, selective, irreversible monoamine oxidase B inhibitors.
AID1322905Selectivity index, ratio of IC50 for human recombinant MAOB to IC50 for human recombinant MAOA2016European journal of medicinal chemistry, Oct-04, Volume: 121Donepezil-like multifunctional agents: Design, synthesis, molecular modeling and biological evaluation.
AID311933Inhibition of ASM in rat PC12 cells assessed as residual activity at 10 uM2008Journal of medicinal chemistry, Jan-24, Volume: 51, Issue:2
Identification of new functional inhibitors of acid sphingomyelinase using a structure-property-activity relation model.
AID1152909Selectivity index, ratio of IC50 for equine serum BuChE to IC50 for electric eel AChE2014European journal of medicinal chemistry, Jun-10, Volume: 80Donepezil + propargylamine + 8-hydroxyquinoline hybrids as new multifunctional metal-chelators, ChE and MAO inhibitors for the potential treatment of Alzheimer's disease.
AID1421899Irreversible inhibition of human recombinant microsomal MAOB expressed in baculovirus infected BTI-TN-5B1- 4 cells using p-tyramine as substrate assessed as decrease in H2O2 production at IC80 after 15 mins2018European journal of medicinal chemistry, Oct-05, Volume: 158Multi-target-directed ligands for Alzheimer's disease: Discovery of chromone-based monoamine oxidase/cholinesterase inhibitors.
AID497522Inhibition of human MAOB at 20 nM2010Bioorganic & medicinal chemistry, Aug-01, Volume: 18, Issue:15
Investigations on the 2-thiazolylhydrazyne scaffold: synthesis and molecular modeling of selective human monoamine oxidase inhibitors.
AID1412309Irreversible time dependent inhibition of human recombinant MAOB at 2 times IC50 using kynuramine as substrate preincubated up to 60 mins followed by 30 uM substrate addition by fluorescence assay
AID1156821Neuroprotective activity against amyloid beta (1 to 42)-induced cytotoxicity in rat PC12 cells at 0.01 to 100 uM pretreated for 24 hrs followed by addition of 25 uM amyloid beta (1 to 42) by MTT assay2014European journal of medicinal chemistry, Aug-18, Volume: 83Synthesis of α, β-unsaturated carbonyl based compounds as acetylcholinesterase and butyrylcholinesterase inhibitors: characterization, molecular modeling, QSAR studies and effect against amyloid β-induced cytotoxicity.
AID136807Compound was evaluated for MAO-A activity after 1 day of chronic peritoneal administration in mouse fore brain at dose of 0.2 mg/kg1992Journal of medicinal chemistry, Oct-02, Volume: 35, Issue:20
Aliphatic propargylamines: potent, selective, irreversible monoamine oxidase B inhibitors.
AID1532341Irreversible inhibition of human MAOB2018Bioorganic & medicinal chemistry letters, 12-15, Volume: 28, Issue:23-24
4-tert-Pentylphenoxyalkyl derivatives - Histamine H
AID1397432Acute toxicity in C57BL/6 mouse assessed as lethargy at 10.8 mg/kg, po after 1 hr post-injection2018Journal of medicinal chemistry, 08-23, Volume: 61, Issue:16
Development of Novel Monoamine Oxidase-B (MAO-B) Inhibitors with Reduced Blood-Brain Barrier Permeability for the Potential Management of Noncentral Nervous System (CNS) Diseases.
AID235637Selectivity index, monoamine oxidase A and monoamine oxidase B2003Journal of medicinal chemistry, Mar-13, Volume: 46, Issue:6
Simple, potent, and selective pyrrole inhibitors of monoamine oxidase types A and B.
AID1397433Acute toxicity in C57BL/6 mouse assessed as piloerection at 10.8 mg/kg, iv after 1 hr post-injection2018Journal of medicinal chemistry, 08-23, Volume: 61, Issue:16
Development of Novel Monoamine Oxidase-B (MAO-B) Inhibitors with Reduced Blood-Brain Barrier Permeability for the Potential Management of Noncentral Nervous System (CNS) Diseases.
AID277619Inhibition of MAO-B in bovine brain mitochondria fluorimetric method2007Journal of medicinal chemistry, Feb-08, Volume: 50, Issue:3
Monoamine oxidase isoform-dependent tautomeric influence in the recognition of 3,5-diaryl pyrazole inhibitors.
AID461711Inhibition of human recombinant MAOA expressed in BTI-TN-5B1-4 cells by para-tyramine oxidation assay2010Bioorganic & medicinal chemistry, Feb, Volume: 18, Issue:3
A new series of flavones, thioflavones, and flavanones as selective monoamine oxidase-B inhibitors.
AID279953Inhibition of bovine brain mitochondria MAOA by fluorometric assay2007Journal of medicinal chemistry, Mar-08, Volume: 50, Issue:5
New pyrrole inhibitors of monoamine oxidase: synthesis, biological evaluation, and structural determinants of MAO-A and MAO-B selectivity.
AID126691Inhibition of Monoamine oxidase B of rat liver mitochondrial membranes1992Journal of medicinal chemistry, Oct-02, Volume: 35, Issue:20
Aliphatic propargylamines: potent, selective, irreversible monoamine oxidase B inhibitors.
AID1456237Inhibition of recombinant human MAO-B expressed in baculovirus infected BTI insect cells using tyramine as substrate pretreated for 30 mins followed by substrate addition incubated for 30 mins measured at 5 mins interval by horse-radish peroxidase/amplex 2017European journal of medicinal chemistry, May-05, Volume: 131MAO enzymes inhibitory activity of new benzimidazole derivatives including hydrazone and propargyl side chains.
AID1556700Inhibition of human recombinant MAO-A expressed in baculovirus infected BTI-TN-5B1-4 insect cells assessed as decrease in H2O2 production using p-tyramine as substrate incubated for 20 mins by horse-radish peroxidase/amplex red-based fluorescence method2019European journal of medicinal chemistry, Oct-01, Volume: 179Carboxamides vs. methanimines: Crystal structures, binding interactions, photophysical studies, and biological evaluation of (indazole-5-yl)methanimines as monoamine oxidase B and acetylcholinesterase inhibitors.
AID514145Selectivity ratio of IC50 for human recombinant MAOA to IC50 for human recombinant MAOB2010Bioorganic & medicinal chemistry, Jul-15, Volume: 18, Issue:14
Synthesis, semipreparative HPLC separation, biological evaluation, and 3D-QSAR of hydrazothiazole derivatives as human monoamine oxidase B inhibitors.
AID710370Selectivity index, ratio of Ki for bovine brain MAOB to Ki for bovine brain MAOA2012Journal of medicinal chemistry, Dec-13, Volume: 55, Issue:23
Synthesis of new 7-oxycoumarin derivatives as potent and selective monoamine oxidase A inhibitors.
AID1241472Inhibition of human recombinant MAOB2015Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
Evaluation of Homobivalent Carbolines as Designed Multiple Ligands for the Treatment of Neurodegenerative Disorders.
AID1231602Inhibition of human recombinant MAO-B using benzylamine as substrate incubated for 15 mins prior to substrate addition measured after 20 mins by fluorescence plate reader analysis2015Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13
Synthesis and evaluation of selegiline derivatives as monoamine oxidase inhibitor, antioxidant and metal chelator against Alzheimer's disease.
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1282045Inhibition of recombinant human microsomal MAO-B expressed in baculovirus-infected insect cells using p-tyramine as substrate assessed as H2O2 production pretreated for 15 mins followed by addition of Amplex Red, horseradish peroxidase and substrate measu2016Bioorganic & medicinal chemistry, Apr-15, Volume: 24, Issue:8
Novel tricyclic pyrazolo[1,5-d][1,4]benzoxazepin-5(6H)-one: Design, synthesis, model and use as hMAO-B inhibitors.
AID604283Selectivity index, ratio of IC50 for human recombinant MAO-A to human recombinant MAO-B2011Bioorganic & medicinal chemistry letters, Jul-15, Volume: 21, Issue:14
MAO inhibitory activity modulation: 3-Phenylcoumarins versus 3-benzoylcoumarins.
AID693567Reversible inhibition of human MAO-B expressed in baculovirus infected BTI-TN-5B1-4 cells using p-tyramine as substrate at 200 nM incubated for 30 mins prior to substrate addition followed by 100 fold dilution measured for 15 mins by Amplex red assay2012European journal of medicinal chemistry, Dec, Volume: 58Recent advances in the development of selective human MAO-B inhibitors: (hetero)arylidene-(4-substituted-thiazol-2-yl)hydrazines.
AID610977Irreversible inhibition of human MAOB expressed assessed as inhibition of p-tyramine oxidation to p-hydroxyphenyl-acetaldehyde at 20 uM measured after repeated washing by centrifugation-ultrafiltration method2011Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
Chromone, a privileged scaffold for the development of monoamine oxidase inhibitors.
AID590300Competitive inhibition of rat liver MAO-A after 60 mins using p-tyramine as substrate by spectrophotometry2011Bioorganic & medicinal chemistry letters, Apr-01, Volume: 21, Issue:7
Development of selective and reversible pyrazoline based MAO-B inhibitors: virtual screening, synthesis and biological evaluation.
AID1460878Inhibition of human recombinant MAOB assessed as reduction in H2O2 production from p-tyramine incubated for 15 mins by Amplex red reagent based fluorimetric method2017Journal of natural products, 04-28, Volume: 80, Issue:4
Anisucoumaramide, a Bioactive Coumarin from Clausena anisum-olens.
AID449969Selectivity index, ratio of Ki for rat MAOA to Ki for rat MAOB2009Bioorganic & medicinal chemistry, Sep-15, Volume: 17, Issue:18
Synthesis and molecular modeling of some novel hexahydroindazole derivatives as potent monoamine oxidase inhibitors.
AID693562Selectivity ratio of IC50 for human MAO-A to IC50 for human MAO-B2012European journal of medicinal chemistry, Dec, Volume: 58Recent advances in the development of selective human MAO-B inhibitors: (hetero)arylidene-(4-substituted-thiazol-2-yl)hydrazines.
AID1708803Irreversible inhibition of human MAO-B assessed as residual enzyme activity at 4 fold IC50 incubated for 15 mins and measured 24 hrs post dialysis relative to control2021Journal of medicinal chemistry, 02-25, Volume: 64, Issue:4
New 2-Pyrazoline and Hydrazone Derivatives as Potent and Selective Monoamine Oxidase A Inhibitors.
AID1141991Inhibition of NMDA receptor in Wistar rat brain synaptoneurosomes homogenate assessed as calcium flux at 100 uM after 30 mins incubation by Fura-2/AM assay2014European journal of medicinal chemistry, Jun-10, Volume: 80Polycyclic propargylamine and acetylene derivatives as multifunctional neuroprotective agents.
AID125712In vitro ability to inhibit Monoamine oxidase A activity in rat whole brain in vitro2001Bioorganic & medicinal chemistry letters, Oct-22, Volume: 11, Issue:20
Synthesis of N-propargylphenelzine and analogues as neuroprotective agents.
AID478547Inhibition of human recombinant MAO-B assessed as inhibition of production of hydrogen peroxide after 15 mins by the Amplex Red fluorimetric method2010Bioorganic & medicinal chemistry letters, May-01, Volume: 20, Issue:9
Chromone-2- and -3-carboxylic acids inhibit differently monoamine oxidases A and B.
AID1459561Inhibition of electric eel AChE using acetylthiocholine iodide as substrate preincubated for 10 mins followed by substrate addition measured after 10 mins by Ellman's method2017European journal of medicinal chemistry, Jan-05, Volume: 125Synthesis and evaluation of 7-substituted coumarin derivatives as multimodal monoamine oxidase-B and cholinesterase inhibitors for the treatment of Alzheimer's disease.
AID717664Reversible inhibition of human recombinant MAOB expressed in insect cell microsomes using kynuramine as substrate assessed as residual activity at 10 times IC50 preincubated for 30 mins followed by 100 fold dilution measured after 20 mins by fluorescence 2012Bioorganic & medicinal chemistry letters, Dec-15, Volume: 22, Issue:24
Sulfanylphthalonitrile analogues as selective and potent inhibitors of monoamine oxidase B.
AID678722Covalent binding affinity to human liver microsomes assessed per mg of protein at 10 uM after 60 mins presence of NADPH2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID749472Induction of adipogenesis in human bone marrow MSC assessed as formation of intracellular lipid droplets at 10 uM after 15 days by oil red O staining in IDX condition relative to control2013Bioorganic & medicinal chemistry letters, Jun-01, Volume: 23, Issue:11
The opposite effect of isotype-selective monoamine oxidase inhibitors on adipogenesis in human bone marrow mesenchymal stem cells.
AID1054590Irreversible inhibition of recombinant human MAO-B expressed in baculovirus infected BT1 cells using benzylamine as substrate at 200 uM preincubated for 30 mins by Lineweaver-Burk plot analysis2013European journal of medicinal chemistry, , Volume: 70Novel polyamine analogues: from substrates towards potential inhibitors of monoamine oxidases.
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID136948Compound was evaluated for MAO-B activity after 10 days of chronic peritoneal administration in mouse fore brain at dose of 0.2 mg/kg1992Journal of medicinal chemistry, Oct-02, Volume: 35, Issue:20
Aliphatic propargylamines: potent, selective, irreversible monoamine oxidase B inhibitors.
AID1241471Inhibition of human recombinant MAOA2015Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
Evaluation of Homobivalent Carbolines as Designed Multiple Ligands for the Treatment of Neurodegenerative Disorders.
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1397345Efflux ratio of apparent permeability in MDCK2-MDR1 cells at 10 uM after 1 hr in presence of P-gp inhibitor verapamil by UPLC-MS/MS analysis2018Journal of medicinal chemistry, 08-23, Volume: 61, Issue:16
Development of Novel Monoamine Oxidase-B (MAO-B) Inhibitors with Reduced Blood-Brain Barrier Permeability for the Potential Management of Noncentral Nervous System (CNS) Diseases.
AID500287Induction of rabbit GAPDH tetramer segregation into monomers at 10 uM after 30 mins by SDS-PAGE2007Nature chemical biology, Jan, Volume: 3, Issue:1
Forward chemical genetic approach identifies new role for GAPDH in insulin signaling.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID515780Intrinsic solubility of the compound in water2010Bioorganic & medicinal chemistry, Oct-01, Volume: 18, Issue:19
QSAR-based solubility model for drug-like compounds.
AID1322902Inhibition of human recombinant BuChE expressed in HEK293 cells using S-butyrylthiocholine iodide as substrate preincubated for 30 mins followed by substrate addition measured after 30 mins by Ellman's method2016European journal of medicinal chemistry, Oct-04, Volume: 121Donepezil-like multifunctional agents: Design, synthesis, molecular modeling and biological evaluation.
AID1397362Cmax in C57BL/6 mouse brain at 10.8 mg/kg, iv administered as single dose measured 24 hrs by UPLC-MS/MS analysis2018Journal of medicinal chemistry, 08-23, Volume: 61, Issue:16
Development of Novel Monoamine Oxidase-B (MAO-B) Inhibitors with Reduced Blood-Brain Barrier Permeability for the Potential Management of Noncentral Nervous System (CNS) Diseases.
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID238322Inhibitory concentration for human Monoamine oxidase B2005Journal of medicinal chemistry, Jun-30, Volume: 48, Issue:13
Design, synthesis, and biological activities of pyrrolylethanoneamine derivatives, a novel class of monoamine oxidases inhibitors.
AID679754TP_TRANSPORTER: increase in Calcein-AM intracellular accumulation (Calcein-AM: ? uM, Selegiline: 100 uM) in MDR1-expressing MDCKII cells2002The Journal of pharmacology and experimental therapeutics, Dec, Volume: 303, Issue:3
Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs.
AID1406151Antioxidant activity assessed as trolox equivalent of AAPH-induced radical scavenging activity pretreated for 15 mins followed by APPH challenge measured every minute for 80 mins by ORAC-FL assay2018European journal of medicinal chemistry, Aug-05, Volume: 156Neurogenic and neuroprotective donepezil-flavonoid hybrids with sigma-1 affinity and inhibition of key enzymes in Alzheimer's disease.
AID706468Selectivity ratio of IC50 for human recombinant MAOA to IC50 for human recombinant MAOB2012Journal of medicinal chemistry, Oct-11, Volume: 55, Issue:19
Multitarget-directed benzylideneindanone derivatives: anti-β-amyloid (Aβ) aggregation, antioxidant, metal chelation, and monoamine oxidase B (MAO-B) inhibition properties against Alzheimer's disease.
AID1368626Inhibition of recombinant human MAO-B using benzylamine as substrate preincubated for 15 mins followed by substrate addition measured after 20 mins by amplex red reagent based spectrophotometric assay2018Bioorganic & medicinal chemistry, 01-01, Volume: 26, Issue:1
Synthesis and evaluation of biaryl derivatives for structural characterization of selective monoamine oxidase B inhibitors toward Parkinson's disease therapy.
AID604269Competitive inhibition of human MAO-A expressed in BTI insect cells using p-tyramine as substrate after 60 mins2011Bioorganic & medicinal chemistry letters, Jul-15, Volume: 21, Issue:14
Pyrazoline based MAO inhibitors: synthesis, biological evaluation and SAR studies.
AID639308Inhibition of human recombinant MAOA expressed in baculovirus-infected BTI insect cells assessed as conversion of p-tyramine into p-hydroxyphenyl-acetaldehyde after 15 mins by fluorimetric assay2012Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1
Hydroxycoumarins as selective MAO-B inhibitors.
AID409944Selectivity ratio of IC50 for human recombinant MAOA to IC50 for human recombinant MAOB2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID229759Relative affinity for MAO-B of mouse forebrain (ID50) and rat liver (IC50)1992Journal of medicinal chemistry, Oct-02, Volume: 35, Issue:20
Aliphatic propargylamines: potent, selective, irreversible monoamine oxidase B inhibitors.
AID410880Inhibition of rat liver monoamine oxidase by Lineweaver-Burke plot2008Bioorganic & medicinal chemistry letters, Dec-15, Volume: 18, Issue:24
Pyrazoline-based mycobactin analogues as MAO-inhibitors.
AID669060Displacement of [3H]-Ro 16-6491 from MAO-B receptor in rat cerebral cortex2012Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7
Synthesis and evaluation of a set of para-substituted 4-phenylpiperidines and 4-phenylpiperazines as monoamine oxidase (MAO) inhibitors.
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID629007Inhibition of human recombinant MAOA expressed in baculovirus infected BTI-TN-5B1-4 insect cells assessed as hydrogen peroxide production from p-tyramine after 15 mins by amplex red assay2011European journal of medicinal chemistry, Dec, Volume: 46, Issue:12
2D MI-DRAGON: a new predictor for protein-ligands interactions and theoretic-experimental studies of US FDA drug-target network, oxoisoaporphine inhibitors for MAO-A and human parasite proteins.
AID1397348Metabolic stability in mouse plasma assessed as parent compound remaining at 5 uM after 4 hrs by UPLC-MS/MS analysis2018Journal of medicinal chemistry, 08-23, Volume: 61, Issue:16
Development of Novel Monoamine Oxidase-B (MAO-B) Inhibitors with Reduced Blood-Brain Barrier Permeability for the Potential Management of Noncentral Nervous System (CNS) Diseases.
AID1586572Inhibition of Sprague-Dawley rat liver MAO-A using p-tyramine as substrate preincubated for 15 mins and measured after 45 mins by resorufin-based fluorescence assay2019European journal of medicinal chemistry, Jan-15, Volume: 162(Pyrrolo-pyridin-5-yl)benzamides: BBB permeable monoamine oxidase B inhibitors with neuroprotective effect on cortical neurons.
AID717662Inhibition of human recombinant MAOB expressed in insect cell microsomes using kynuramine as substrate after 20 mins by fluorescence spectrophotometric analysis2012Bioorganic & medicinal chemistry letters, Dec-15, Volume: 22, Issue:24
Sulfanylphthalonitrile analogues as selective and potent inhibitors of monoamine oxidase B.
AID346981Inhibition of MAO-A in rat liver homogenate after 60 mins by Lineweaver-Burke plot2009Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2
New pyrazoline bearing 4(3H)-quinazolinone inhibitors of monoamine oxidase: synthesis, biological evaluation, and structural determinants of MAO-A and MAO-B selectivity.
AID1378855Inhibition of human recombinant MAO-B expressed in baculovirus infected BTI-TN5B1-4 cells using p-tyramine as substrate assessed as reduction in H2O2 production preincubated for 15 mins followed by substrate addition measured after 15 mins by Amplex red d2017European journal of medicinal chemistry, Oct-20, Volume: 139Synthesis and structure-activity relationship study of novel 3-heteroarylcoumarins based on pyridazine scaffold as selective MAO-B inhibitors.
AID437351Inhibition of MAOA at 100 nM after 60 mins using tyramine as substrate relative to control2009European journal of medicinal chemistry, Oct, Volume: 44, Issue:10
Facile synthesis and in vitro properties of 1-alkyl- and 1-alkyl-N-propargyl-1,2,3,4-tetrahydroisoquinoline derivatives on PC12 cells.
AID747666Irreversible inhibition of human MAO-B using p-tyramine as substrate at IC80 incubated for 22 mins followed by substrate addition measured for 5 hrs by fluorescence assay2013Journal of medicinal chemistry, Jun-13, Volume: 56, Issue:11
Dual targeting of adenosine A(2A) receptors and monoamine oxidase B by 4H-3,1-benzothiazin-4-ones.
AID1519691Inhibition of human microsomal MAO-B expressed in baculovirus infected BTI-TN-5B1-4 cells assessed as reduction in 4-hydroxyquinoline formation using kynuramine as substrate preincubated with substrate for 10 mins followed by enzyme addition by spectropho2020European journal of medicinal chemistry, Jan-01, Volume: 185Design of novel monoamine oxidase-B inhibitors based on piperine scaffold: Structure-activity-toxicity, drug-likeness and efflux transport studies.
AID19424Partition coefficient (logD7.4)2001Journal of medicinal chemistry, Jul-19, Volume: 44, Issue:15
ElogD(oct): a tool for lipophilicity determination in drug discovery. 2. Basic and neutral compounds.
AID589433Selectivity index, ratio of IC50 for human recombinant MAO-A to IC50 for human recombinant MAO-B2011European journal of medicinal chemistry, Apr, Volume: 46, Issue:4
Synthesis, human monoamine oxidase inhibitory activity and molecular docking studies of 3-heteroarylcoumarin derivatives.
AID589434Inhibition of human recombinant MAO-A expressed in BTI-TN-5B1-4 cells assessed as H2O2 production using para-tyramine substrate by fluorimetric method2011European journal of medicinal chemistry, Apr, Volume: 46, Issue:4
Synthesis, human monoamine oxidase inhibitory activity and molecular docking studies of 3-heteroarylcoumarin derivatives.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1798967MAO Enzyme Inhibition Assay from Article 10.1021/jm801590u: \\Chalcones: a valid scaffold for monoamine oxidases inhibitors.\\2009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
Chalcones: a valid scaffold for monoamine oxidases inhibitors.
AID1797405MAO Activity Assay from Article 10.1021/jm060882y: \\New pyrrole inhibitors of monoamine oxidase: synthesis, biological evaluation, and structural determinants of MAO-A and MAO-B selectivity.\\2007Journal of medicinal chemistry, Mar-08, Volume: 50, Issue:5
New pyrrole inhibitors of monoamine oxidase: synthesis, biological evaluation, and structural determinants of MAO-A and MAO-B selectivity.
AID1801059Amplex Red MAO Assay from Article 10.1016/j.bioorg.2015.07.001: \\Development of fluorinated methoxylated chalcones as selective monoamine oxidase-B inhibitors: Synthesis, biochemistry and molecular docking studies.\\2015Bioorganic chemistry, Oct, Volume: 62Development of fluorinated methoxylated chalcones as selective monoamine oxidase-B inhibitors: Synthesis, biochemistry and molecular docking studies.
AID1801003Fluorimetric Assay from Article 10.1016/j.bioorg.2014.11.008: \\Monoamine oxidase inhibitory activity of 2-aryl-4H-chromen-4-ones.\\2015Bioorganic chemistry, Feb, Volume: 58Monoamine oxidase inhibitory activity of 2-aryl-4H-chromen-4-ones.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1345977Human Monoamine oxidase B (Catecholamine turnover)2005Journal of medicinal chemistry, Jun-30, Volume: 48, Issue:13
Design, synthesis, and biological activities of pyrrolylethanoneamine derivatives, a novel class of monoamine oxidases inhibitors.
AID1345977Human Monoamine oxidase B (Catecholamine turnover)2011Bioorganic & medicinal chemistry letters, Apr-01, Volume: 21, Issue:7
Development of selective and reversible pyrazoline based MAO-B inhibitors: virtual screening, synthesis and biological evaluation.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (2,442)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990511 (20.93)18.7374
1990's917 (37.55)18.2507
2000's569 (23.30)29.6817
2010's368 (15.07)24.3611
2020's77 (3.15)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 66.35

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index66.35 (24.57)
Research Supply Index7.97 (2.92)
Research Growth Index4.55 (4.65)
Search Engine Demand Index143.90 (26.88)
Search Engine Supply Index2.43 (0.95)

This Compound (66.35)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials319 (12.39%)5.53%
Reviews381 (14.80%)6.00%
Case Studies89 (3.46%)4.05%
Observational4 (0.16%)0.25%
Other1,782 (69.20%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (30)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
"Pharmacokinetic Profile of Betahistine Serum Concentration With and Without Selegiline in Healthy Volunteers - a Prospective Mono-center Open-labeled Phase I Trial (PK-BeST)" [NCT05938517]Phase 115 participants (Actual)Interventional2021-06-02Completed
A Pilot Study Assessing Efficacy, Safety, and Tolerability of EmSam in Bipolar Depression [NCT00535262]Phase 43 participants (Actual)Interventional2007-03-31Terminated(stopped due to Current lack of medication support.)
Usefulness of Selegiline for Smoking Cessation [NCT00129311]Phase 2101 participants (Actual)Interventional2004-07-31Completed
A Multi-center, Open-Label Study to Evaluate the Efficacy and Safety of Selegiline for the Treatment of Excessive Daytime Sleepiness in Parkinson's Disease [NCT04870372]Phase 4141 participants (Actual)Interventional2020-03-01Completed
An Open-label Trial of Oral Selegiline 5 or 10 mg and Tadalafil 2.5mg Co-administration to Male Patients With Parkinson's Disease and Moderate Erectile Dysfunction. [NCT02225548]Phase 410 participants (Anticipated)Interventional2014-09-30Recruiting
Adding Orally Disintegrating Selegiline (Zelapar) to Patients Taking Dopamine Agonists and Experiencing Complications [NCT00443872]Phase 477 participants (Actual)Interventional2007-03-31Completed
A Phase III Randomized Double-blind, 12 Week, Placebo Controlled Trial of Transdermal Selegiline in Borderline Personality Disorder (BPD) to Evaluate Efficacy and Safety [NCT01912391]Phase 330 participants (Actual)Interventional2012-10-31Completed
The Effects of a Single Dose on Reward and Emotional Processing in Healthy Volunteers [NCT04130087]54 participants (Anticipated)Interventional2019-09-18Recruiting
Phase II, Placebo-Controlled, Double-Blind Study of the Selegiline Transdermal System (STS) in the Treatment of HIV-Associated Cognitive Impairment [NCT00013585]Phase 2127 participants (Actual)InterventionalCompleted
A Phase IV, Double-Blind, Placebo-Controlled, Randomized, Flexible Dose Study of the Safety and Efficacy of EMSAM in Adolescents With Major Depression [NCT00531947]Phase 4308 participants (Actual)Interventional2007-07-31Completed
A Clinical Trial of Selegiline Plus Docetaxel for the Treatment of Metastatic, Castrate-resistant Prostate Adenocarcinoma [NCT04586543]Phase 2110 participants (Anticipated)Interventional2020-05-18Recruiting
Selegiline for Treatment of Cannabis Dependence [NCT00218517]Phase 219 participants (Actual)Interventional2005-03-31Completed
Safety and Efficacy of Selegiline in Outpatient Treatment for Cocaine [NCT00000336]Phase 20 participants Interventional1995-01-31Completed
[NCT01495195]Phase 212 participants (Actual)Interventional2012-02-29Completed
A PHASE IV, OPEN-LABEL STUDY OF THE ADHESION AND DERMAL TOLERABILITY OF EMSAM (SELEGILINE TRANSDERMAL SYSTEM) IN HEALTHY ADULT SUBJECTS OF TWO AGE GROUPS (18 - 64 YEARS, AND 65 YEARS AND OLDER) [NCT00531596]Phase 4300 participants (Actual)Interventional2007-04-30Completed
Pharmacokinetic Comparison of the 6mg/24hr and 12mg/24hr EMSAM (Selegiline Transdermal System) in Healthy Elderly and Non-Elderly Volunteers [NCT00532116]Phase 432 participants (Actual)Interventional2007-04-30Completed
Parallel Group, Placebo-Controlled, Tolerability and Safety Study of Thioctic Acid and Deprenyl in HIV Dementia [NCT00002154]Phase 232 participants InterventionalCompleted
A Phase III, Open-Label Study of the Safety, Tolerability and Efficacy of the Selegiline Transdermal System in Elderly Subjects With Major Depression [NCT00285766]Phase 3300 participants Interventional2002-08-31Completed
Efficacy of Selegiline Augmentation of Antipsychotic Medication to Treat Negative Symptoms in Inpatients With Chronic Schizophrenia [NCT00456976]Early Phase 170 participants Interventional2007-04-30Completed
Selegiline Patch for Treatment of Nicotine Dependence [NCT01330030]Phase 2243 participants (Actual)Interventional2005-07-31Completed
HIV-Associated Cognitive Impairment and Oxidative Stress: An In Vivo Proton Magnetic Resonance Spectroscopy Study of Cerebral Injury [NCT00027040]90 participants InterventionalCompleted
Double-Blind, Placebo-Controlled Trial of Selegiline Transdermal System for the Treatment of Cocaine Dependence [NCT00032929]Phase 3269 participants (Actual)Interventional2001-03-31Completed
Testing a Full Substitution Therapy Approach As Treatment of Tobacco Dependence [NCT00390923]40 participants (Anticipated)Interventional2007-07-31Terminated(stopped due to Preliminary results did not support the utility of combining selegeline + NRT.)
Assessment of Potential Interactions Between Intravenous Methamphetamine and Oral Selegiline [NCT00033072]Phase 116 participants Interventional2001-09-30Active, not recruiting
An Open-Label, Parallel Group Study to Assess the Inhibition of Brain MAO-B by RO4602522 After Repeated Dosing in Patients With Alzheimer's Disease and in Healthy Control Subjects [NCT01701089]Phase 117 participants (Actual)Interventional2012-09-30Completed
Pharmacological Modulation of Cocaine Effects [NCT00000201]Phase 20 participants InterventionalCompleted
Selegiline in Treatment of Cocaine Dependence [NCT00000188]Phase 250 participants (Actual)Interventional1994-09-30Completed
Infusion Laboratory: Protocol 1 - Selegeline [NCT00000337]Phase 10 participants Interventional1994-11-30Completed
Phase 2, Double-Blind, Placebo-Controlled Trial of Selegiline Transdermal System (STS) as an Aid for Smoking Cessation. [NCT00439413]Phase 2246 participants (Actual)Interventional2007-06-30Completed
Tolerability and Efficacy of Switch From Oral Selegiline to Orally Disintegrating Selegiline (Zelapar) in Patients With Parkinson's Disease. [NCT00640159]Phase 448 participants (Actual)Interventional2007-01-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00129311 (2) [back to overview]7 Day Point Prevalence of Cigarette Abstinence
NCT00129311 (2) [back to overview]7 Day Point Prevalence of Cigarette Abstinence
NCT00439413 (2) [back to overview]Abstinence
NCT00439413 (2) [back to overview]Quit Rate
NCT00443872 (10) [back to overview]Barratt Impulsiveness Scale Score for Those With Impulsive Behavior
NCT00443872 (10) [back to overview]Beck Anxiety Inventory Scores for All Subjects
NCT00443872 (10) [back to overview]Beck Depression Inventory for All Subjects
NCT00443872 (10) [back to overview]Circumference of Lower Leg/Foot at Greatest Point of Swelling for Pedal Edema
NCT00443872 (10) [back to overview]Epworth Sleepiness Scale Score for Those With Daytime Sleepiness
NCT00443872 (10) [back to overview]Mini Mental State Examination (MMSE) Scores for All Subjects
NCT00443872 (10) [back to overview]Neuropsychiatric Inventory (NPI) Hallucinations Scale Score for Those With Hallucinations
NCT00443872 (10) [back to overview]PDQ-39 Quality of Life Assessment Total Scores
NCT00443872 (10) [back to overview]Percentage of Participants With Reduction in Adverse Events
NCT00443872 (10) [back to overview]Unified Parkinson's Disease Rating Scale (UPDRS) Scores
NCT00531947 (19) [back to overview]Hematology - Hematocrit (Change From Baseline)
NCT00531947 (19) [back to overview]Hematology - Hemoglobin (Change From Baseline)
NCT00531947 (19) [back to overview]Hematology - Red Blood Cell (Change From Baseline)
NCT00531947 (19) [back to overview]Physical Examination (Screening vs. EOS)
NCT00531947 (19) [back to overview]12 Lead ECG (Change From Baseline)
NCT00531947 (19) [back to overview]CDRS-R Total Score (Best Description) Week 12 (mITT w/LOCF Population)
NCT00531947 (19) [back to overview]CDRS-R Total Score (Best Description) Week 12 (mITT w/OC Population)
NCT00531947 (19) [back to overview]CDRS-R Total Score (Child) (mITT w/LOCF Population) Week 12
NCT00531947 (19) [back to overview]CDRS-R Total Score (Child) Week 12 (mITT w/OC Population)
NCT00531947 (19) [back to overview]CDRS-R Total Score (Parent/Other) Week 12 (mITT w/LOCF Population)
NCT00531947 (19) [back to overview]CDRS-R Total Score (Parent/Other) Week 12 (mITT w/OC Population)
NCT00531947 (19) [back to overview]CGI-C Percent Responders (mITT w/LOCF Population)
NCT00531947 (19) [back to overview]CGI-S - Week 12 (mITT w/LOCF Population)
NCT00531947 (19) [back to overview]Hematology - White Blood Cell (WBC) (Change From Baseline)
NCT00531947 (19) [back to overview]Urinalysis (Change From Baseline)
NCT00531947 (19) [back to overview]Vital Signs-Blood Pressure (Change From Baseline)
NCT00531947 (19) [back to overview]Vital Signs-Heart Rate (Change From Baseline)
NCT00531947 (19) [back to overview]12 Lead ECG (Change From Baseline)Ventricular Heart Rate
NCT00531947 (19) [back to overview]CGI-C - Week 12 (mITT w/LOCF Population)
NCT00640159 (2) [back to overview]Clinical Global Impression Scale
NCT00640159 (2) [back to overview]MDS-UPDRS Scale at Baseline and Day 40
NCT01330030 (1) [back to overview]Expired-air Carbon Monoxide Confirmed Smoking Abstinence

7 Day Point Prevalence of Cigarette Abstinence

(NCT00129311)
Timeframe: 6-month follow up

Interventionparticipants (Number)
Selegiline6
Placebo8

[back to top]

7 Day Point Prevalence of Cigarette Abstinence

(NCT00129311)
Timeframe: Week 8

Interventionparticipants (Number)
Selegiline8
Placebo10

[back to top]

Abstinence

The proportion is determined by dividing the number who achieved abstinence at the end of treatment as defined for the primary outcome measure and are still abstinent by self report and separately by self report with confirmation by exhaled CO by the total number randomized to the treatment group. (NCT00439413)
Timeframe: week 14

Interventionparticipants (Number)
Selegiline Transdermal System16
Placebo10

[back to top]

Quit Rate

The number of subjects in each treatment group who ceased smoking as measured by four weeks of self-reported abstinence confirmed by at least two exhales - carbon monoxide (CO) measurements during the last four weeks of treatment (study weeks 6 through 9). (NCT00439413)
Timeframe: Study weeks 6 through 9

Interventionparticipants (Number)
Selegiline Transdermal System18
Matching Placebo15

[back to top]

Barratt Impulsiveness Scale Score for Those With Impulsive Behavior

This is a measure of impulsiveness. There are 30 questions regarding the presence of impulsive and non-impulsive behaviors each scored from 1 (rarely/never) to 4 (almost always/always). The total score reflects the sum of the 30 items. A higher score represents more impulsiveness. (NCT00443872)
Timeframe: Baseline and 3 months

Interventionunits on a scale (Mean)
Baseline3 months (12 weeks)
PD Patients With DA Related AE (Impulse Control Disorder)64.161.3

[back to top]

Beck Anxiety Inventory Scores for All Subjects

The Beck Anxiety Inventory is a general measure of anxiety. There are 21 questions each with responses ranging from 0 (no issue or problem) to 3 (severe - I could barely stand it), all questions are related to the presence of signs or symptoms of anxiety. The total possible score is 63 and a higher score represents greater anxiety. The total score is calculated by adding the responses for each of the 21 items. (NCT00443872)
Timeframe: Baseline and 3 months

Interventionunits on a scale (Mean)
Baseline3 months (12 weeks)
All PD Patients With DA Related AEs (BAI)11.510.9

[back to top]

Beck Depression Inventory for All Subjects

The Beck Depression Inventory is a general measure of depression. There are 21 questions each with responses ranging from 0 (no issue or problem) to 3 (maximum issue/distress), all questions are related to emotions, mood, feelings, etc. The total possible score is 63 (higher scores represent more depression). The total score is calculated by adding the scores of the 21 items. (NCT00443872)
Timeframe: Baseline and 3 months

Interventionunits on a scale (Mean)
Baseline3 months (12 weeks)
All PD Patients With DA Related AEs (BDI)10.29.4

[back to top]

Circumference of Lower Leg/Foot at Greatest Point of Swelling for Pedal Edema

The circumference of the lower leg/ankle with the greatest swelling was measured using a standard tape measure at baseline and 12 weeks for both the right and left ankles. (NCT00443872)
Timeframe: Baseline and 3 months

Interventioncentimeters (Mean)
Left foot baselineLeft foot 3 months (12 weeks)Right foot baselineRight Foot 3 months (12 weeks)
PD Patiens With DA Related AE (Pedal Edema)25.824.626.425.2

[back to top]

Epworth Sleepiness Scale Score for Those With Daytime Sleepiness

This is a measure of daytime sleepiness. The test is a list of eight situations in which one rates their tendency to become sleepy on a scale of 0, no change of dozing to 3, high chance of dozing. The total score ranges fro 0-24, with higher values representing excessive sleepiness. A score of greater than 10 represents clinically significant sleepiness. (NCT00443872)
Timeframe: Baseline and 3 months

Interventionunits on a scale (Mean)
Baseline3 months (12 weeks)
PD Patients With DA Related AE (Daytime Sleepiness)13.59.0

[back to top]

Mini Mental State Examination (MMSE) Scores for All Subjects

The MMSE is a general measure of cognition (i.e., measures attention, memory, visuospatial construction, etc). It has 30 items, each item representing 1 point. The total score ranges from 0-30 with 30 being a perfect score (no cognitive impairment) and 0 being the lowest score (greatest possible level of impairment). The total score is calculated by adding the scores of each item. (NCT00443872)
Timeframe: Baseline and 3 months

Interventionunits on a scale (Mean)
Baseline3 months (12 weeks)
All PD Patients With DA Related AEs (MMSE)28.829.2

[back to top]

Neuropsychiatric Inventory (NPI) Hallucinations Scale Score for Those With Hallucinations

Report of hallucinations with insight maintained based on the hallucinations questions of the Neuropsychiatric Inventory (NPI). The participant and their caregiver are asked a series of questions to determine if hallucinations are present. If present they rate the frequency of hallucinations on a scale of 1 (rarely, less than once a week) to 4, very often (once or more daily). They also rate the severity of the hallucinations, as mild (1 - present but harmless and cause little distress), moderate (2 - distressing and disruptive) or severe (3 - very disruptive, major source of behavioral disturbance, may need meds). The frequency and severity scores are multiplied (maximum score 12, with higher scores representing more distress/disability) for the total score. (NCT00443872)
Timeframe: Baseline and 3 months

Interventionunits on a scale (Mean)
Baseline3 months (12 weeks)
PD Patients With DA Related AE (Hallucinations)3.31.3

[back to top]

PDQ-39 Quality of Life Assessment Total Scores

The PDQ-39 is a measure of quality of life, it has 8 sub scales and a total score. For this study only the total score was examined. There are a total of 39 questions related to the following 8 sub scales: ability/difficulty to perform motor activities, ability to perform daily activities, cognition, emotional well being, stigma, social support, communication, bodily discomfort; each question with 5 responses (0, no/never, 4 always). The total score is calculated by adding the scores for each of the 39 items, dividing by 39 x 4 (maximum score for all 39 items) and then multiplying by 100 to get a percentage score ranging from 0-100 with 100 representing the most disability and greatest impact on quality of life. (NCT00443872)
Timeframe: Baseline and 3 months

Interventionunits on a scale (Mean)
Baseline3 months (12 weeks)
All Subjects PDQ-3928.624.4

[back to top]

Percentage of Participants With Reduction in Adverse Events

The primary outcome measure was the reduction of daytime sleepiness, hallucinations, pedal edema, and impulse control disorders after a reduction of dopamine agonist dose with the addition of an monoamine oxidase (MAO)-B inhibitor (orally disintegrating selegiline). Percentages of participants with reduction in individual adverse events as well as reduction in any adverse events are reported. (NCT00443872)
Timeframe: 3 Months

Interventionpercentage of participants (Number)
Excessive Daytime Sleepiness (n=50)Hallucinations (n=15)Pedal Edema (n=26)Impulse Control Disorder (n=25)Any Adverse Event (n=60)
PD Patients With DA Related AE94867384100

[back to top]

Unified Parkinson's Disease Rating Scale (UPDRS) Scores

"The UPDRS activities of daily living sub scale has 14 questions regarding the ability to perform daily activities like dressing, eating, etc. These questions are completed by the patient and each question has 5 responses ranging from 0 (no problems) to 4 (severe disability/cannot do). The total score for this sub scale is the sum of the scores for the 14 questions (higher scores represent greater disability), maximum score is 56.~The motor assessment is completed by the investigator. There are 14 questions evaluating motor function in various body parts, representing 27 individual items (i.e., some questions, such as rigidity, are rated for 5 different body parts, other questions, such as finger tapping, are rated on both the right and left sides, and other questions are rated individually). Each item has 5 responses, 0 being none/no disability and 4 being the most severe disability. The 27 items are summed (higher scores represent greater disability); maximum score is 108." (NCT00443872)
Timeframe: Baseline and 3 months

Interventionunits on a scale (Mean)
ADLs baselineADLs 3 months (12 weeks)Motor baselineMotor 3 months (12 weeks)
All Subjects With DA Related AEs (UPDRS Data)11.910.323.621.4

[back to top]

Hematology - Hematocrit (Change From Baseline)

A summary of a secondary safety outcome measure, Hematology - Hematocrit(HCT)(Change from Baseline), by treatment assigned, is shown for the safety population. (NCT00531947)
Timeframe: 12 Weeks

Interventionpercent (Mean)
Placebo-0.58
EMSAM-1.13

[back to top]

Hematology - Hemoglobin (Change From Baseline)

A summary of a secondary safety outcome measure, Hematology - Hemoglobin(HGB)(Change from Baseline), by treatment assigned, is shown for the safety population. (NCT00531947)
Timeframe: 12 Weeks

Interventiong/dL (Mean)
Placebo-0.18
EMSAM-0.36

[back to top]

Hematology - Red Blood Cell (Change From Baseline)

A summary of a secondary safety outcome measure, Hematology - Red Blood Cell (RBC)(Change from Baseline), by treatment assigned, is shown for the safety population. (NCT00531947)
Timeframe: 12 Weeks

Interventionx10^12/L (Mean)
Placebo-0.04
EMSAM-0.12

[back to top]

Physical Examination (Screening vs. EOS)

Number of physical examination findings that were normal at screening, but abnormal at end of study are presented. Four subjects receiving placebo and four subjects receiving EMSAM had abnormal findings on physical examination at the end of study that were normal at screening. (NCT00531947)
Timeframe: 12 Weeks

InterventionNumber of Abnormal Exams (Number)
Placebo4
EMSAM4

[back to top]

12 Lead ECG (Change From Baseline)

A summary of a secondary safety outcome measure, 12 Lead electrocardiogram (ECG) (Change from Baseline) measured in milliseconds (msec), by treatment assigned, is shown for the safety population. Mean change from Baseline in PR interval, QRS duration, QT interval, and QTc (Bazett and Fridericia corrections) interval are presented. (NCT00531947)
Timeframe: 12 Weeks

,
Interventionmsec (Mean)
PR IntervalQRS DurationQT IntervalQTc (Bazett Correction) IntervalQTc (Fridericia Correction) Interval
EMSAM-0.901.13.80-2.90-0.60
Placebo0.70-0.01.30-4.10-2.30

[back to top]

CDRS-R Total Score (Best Description) Week 12 (mITT w/LOCF Population)

"A summary of a secondary efficacy outcome measure, Children's Depression Rating Scale (CDRS-R) Total Score (Best Description), at Week 12 (EOS), by treatment assigned, is shown for the modified intent-to-treat (mITT) population, with the last observation carried forward (LOCF) in time.~Best Description ratings are used when ratings based on interviews with different sources (e.g., child, parent, other ratings) differ for a particular symptom. The evaluator must determine which of these ratings most accurately represents the current affective functioning of the child, and circle that rating in the Best Description of Child Column.~CDRS-R (Best Description)total raw scores range from 17(minimum) 113(maximum). A lower score indicates a lower likelihood of a depressive disorder, a higher score indicates a higher likelihood of a depressive disorder. Two subscales are summed to calculate a total score: Evaluated Symptom Area and Ratings of Observed Nonverbal Behavior." (NCT00531947)
Timeframe: 12 Weeks

,
Interventionunits on a scale (Mean)
Baseline - ObservedWeek 12 - ObservedWeek 12 - Change From Baseline
EMSAM59.537-22.5
Placebo60.738-22.7

[back to top]

CDRS-R Total Score (Best Description) Week 12 (mITT w/OC Population)

"A summary of a secondary efficacy outcome measure, Children's Depression Rating Scale (CDRS-R) Total Score (Best Description), at Week 12 (EOS), by treatment assigned, is shown for the modified intent-to-treat (mITT) population, with observed cases (w/OC).~Best Description ratings are used when ratings based on interviews with different sources (e.g., child, parent, other ratings) differ for a particular symptom area. The evaluator must determine which of these ratings most accurately represents the current affective functioning of the child, and circle that rating in the Best Description of Child Column.~CDRS-R (Best Description) total raw scores range from 17(minimum) 113(maximum). A lower score indicates a lower likelihood of a depressive disorder, a higher score indicates a higher likelihood of a depressive disorder. Two subscales are summed to calculate a total score: Evaluated Symptom Area and Ratings of Observed Nonverbal Behavior." (NCT00531947)
Timeframe: 12 Weeks

,
Interventionunits on a scale (Mean)
Baseline - ObservedWeek 12 - ObservedWeek 12 - Change From Baseline
EMSAM59.432.4-26.6
Placebo60.732.1-27

[back to top]

CDRS-R Total Score (Child) (mITT w/LOCF Population) Week 12

"A summary of the primary efficacy outcome measure, Children's Depression Rating Scale (CDRS-R) Total Score, as reported by the Child, at Week 12 (EOS), by treatment assigned, is shown for the modified intent-to-treat (mITT) population, with the last observation carried forward (LOCF) in time.~CDRS-R total raw scores range from 17(minimum) 113(maximum). A lower score indicates a lower likelihood of a depressive disorder, a higher score indicates a higher likelihood of a depressive disorder. Two subscales are summed to calculate a total score: Evaluated Symptom Area and Ratings of Observed Nonverbal Behavior." (NCT00531947)
Timeframe: baseline and 12 Weeks

,
Interventionunits on a scale (Mean)
Baseline - ObservedWeek 12 - ObservedWeek 12 - Change From Baseline
EMSAM56.735.4-21.4
Placebo57.936.4-21.5

[back to top]

CDRS-R Total Score (Child) Week 12 (mITT w/OC Population)

"A summary of the secondary efficacy outcome measure, Children's Depression Rating Scale (CDRS-R) Total Score (Scored by Child), at Week 12 (EOS), by treatment assigned, is shown for the modified intent-to-treat (mITT) population with observed cases (w/OC).~CDRS-R (Child) total raw scores range from 17(minimum) 113(maximum). A lower score indicates a lower likelihood of a depressive disorder, a higher score indicates a higher likelihood of a depressive disorder. Two subscales are summed to calculate a total score: Evaluated Symptom Area and Ratings of Observed Nonverbal Behavior." (NCT00531947)
Timeframe: 12 Weeks

,
Interventionunits on a scale (Mean)
Baseline - ObservedWeek 12 - ObservedWeek 12 - Change From Baseline
EMSAM56.631.1-25.3
Placebo58.130.8-25.5

[back to top]

CDRS-R Total Score (Parent/Other) Week 12 (mITT w/LOCF Population)

"A summary of a secondary efficacy outcome measure, Children's Depression Rating Scale (CDRS-R) Total Score (Scored by Parent/Other), at Week 12 (EOS), by treatment assigned, is shown for the modified intent-to-treat (mITT) population, with the last observation carried forward (LOCF) in time.~CDRS-R (Parent/Other) total raw scores range from 14 (minimum) 94 (maximum). A lower score indicates a lower likelihood of a depressive disorder, a higher score indicates a higher likelihood of a depressive disorder. One subscale is summed to calculate a total score: Evaluated Symptom Area. Ratings of Observed Nonverbal Behavior subscale is not included in Parent/Other total calculation." (NCT00531947)
Timeframe: Baseline and 12 Weeks

,
Interventionunits on a scale (Mean)
Baseline- ObservedWeek 12- ObservedWeek 12 - Change From Baseline
EMSAM48.830.5-18.3
Placebo49.430.7-18.7

[back to top]

CDRS-R Total Score (Parent/Other) Week 12 (mITT w/OC Population)

"A summary of a secondary efficacy outcome measure, Children's Depression Rating Scale (CDRS-R) Total Score (Scored by Parent/Other), at Week 12 (EOS), by treatment assigned, is shown for the modified intent-to-treat (mITT) population with observed cases (w/OC).~CDRS-R (Parent/Other) total raw scores range from 14 (minimum) 94 (maximum). A lower score indicates a lower likelihood of a depressive disorder, a higher score indicates a higher likelihood of a depressive disorder. One subscale is summed to calculate a total score: Evaluated Symptom Area. Ratings of Observed Nonverbal Behavior subscale is not included in Parent/Other total calculation." (NCT00531947)
Timeframe: 12 Weeks

,
Interventionunits on a scale (Mean)
Baseline - ObservedWeek 12 - ObservedWeek 12 - Change From Baseline
EMSAM48.925.8-22.2
Placebo49.625.5-22.6

[back to top]

CGI-C Percent Responders (mITT w/LOCF Population)

A summary of the CGI-C percent responders at Week 12 (EOS), by treatment assigned, is shown for the mITT population with LOCF. CGI-C responders were defined as a score of 1 or 2 at the end of the study. A non-responder was defined as a score of ≥3 at end of study. Maximum score is 100%. (NCT00531947)
Timeframe: 12 Weeks

,
InterventionPercent Responder (Number)
Percent Non-ResponderPercent Responder
EMSAM41.458.6
Placebo40.759.3

[back to top]

CGI-S - Week 12 (mITT w/LOCF Population)

A summary of the Clinical Global Impression of Severity (CGI-S) at baseline and Week 12 (EOS), by treatment assigned, is shown for the mITT population with LOCF. The CGI-s is the clinician's assessment of severity of illness (depression). Scores range from 1(minimum) to 7(maximum). A lower score indicates lower illness severity, a higher score indicates higher levels of illness severity. (NCT00531947)
Timeframe: Baseline and 12 Weeks

,
Interventionunits on a scale (Mean)
Baseline CGI-S ScaleWeek 12 CGI-S Scale
EMSAM4.5273.007
Placebo4.4943.000

[back to top]

Hematology - White Blood Cell (WBC) (Change From Baseline)

A summary of a secondary safety outcome measure, Hematology (Change from Baseline), by treatment assigned, is shown for the safety population. Mean change from Baseline in ABS BASOPHILS (X10^9/L), ABS EOSINOPHILS (X10^9/L), ABS LYMPHOCYTES (X10^9/L), ABS MONOCYTES (X10^9/L), and ABS NEUTROPHILS (X10^9/L) are presented. (NCT00531947)
Timeframe: 12 Weeks

,
Intervention(X10^9/L) (Mean)
ABS BASOPHILS (X10^9/L)ABS EOSINOPHILS (X10^9/L)ABS LYMPHOCYTES (X10^9/L)ABS MONOCYTES (X10^9/L)ABS NEUTROPHILS (X10^9/L)PLATELETS (X10^9/L)WBC (X10^9/L)
EMSAM0.000.01-0.03-0.00-0.101.82-0.12
Placebo-0.00-0.01-0.090.010.01-0.01-0.09

[back to top]

Urinalysis (Change From Baseline)

A summary of a secondary safety outcome measure, Urinalysis (Change from Baseline), by treatment assigned, is shown for the safety population. Mean changes from baseline are provided for PH and specific gravity. (NCT00531947)
Timeframe: 12 Weeks

,
Interventionunits on a scale (Mean)
PHSpecific Gravity
EMSAM-0.110.00
Placebo-0.020.00

[back to top]

Vital Signs-Blood Pressure (Change From Baseline)

Summary mean change in blood pressure (systolic/diastolic) measured in millimeters of mercury (mmHg) (supine, standing, and orthostatic change)results for all subjects are presented. (NCT00531947)
Timeframe: 12 Weeks

,
InterventionmmHg (Mean)
Supine Systolic Blood PressureSupine Diastolic Blood PressureStanding Systolic Blood PressureStanding Diastolic Blood PressureOrthostatic Change in Systolic Blood PressureOrthostatic Change in Diastolic Blood Pressure
EMSAM-0.31.4-2.5-0.1-2.3-1.5
Placebo0.91.1-1.20.8-2.1-0.4

[back to top]

Vital Signs-Heart Rate (Change From Baseline)

Summary mean change in heart rate measured in beats per minute (beats/min or BPM) (supine, standing, and orthostatic change)results for all subjects are presented. (NCT00531947)
Timeframe: 12 Weeks

,
InterventionBPM (Mean)
Supine Heart RateStanding Heart RateOrthostatic Change in Heart Rate
EMSAM-.102.62.80
Placebo.20-0.6-.80

[back to top]

12 Lead ECG (Change From Baseline)Ventricular Heart Rate

A summary of a secondary safety outcome measure, 12 Lead electrocardiogram (ECG) (Change from Baseline)Ventricular Heart Rate measured in beats per minute(beats/min or BPM), by treatment assigned, is shown for the safety population. Mean change from baseline is presented. (NCT00531947)
Timeframe: 12 Weeks

InterventionBPM (Mean)
Placebo-1.70
EMSAM-2.40

[back to top]

CGI-C - Week 12 (mITT w/LOCF Population)

"A summary of the Clinicians Global Impression of Change (CGI-C) Score at Week 12 (EOS), by treatment assigned, is shown for the mITT population with LOCF. The CGI-c assesses the overall change in the severity of illness (depression). The clinician rates the subject's change based on a bipolar scale from 1(minimum; Very much improved) to 7(maximum; Very much worse). A lower score indicates lower levels of depression as compared to baseline, a higher score indicates higher levels of depression as compared to baseline. A score of 4 (Unchanged) indicates no change in illness compared to baseline. The scale is not calculated as a statistical change score; the clinician rates their impression of change overall." (NCT00531947)
Timeframe: 12 Weeks

Interventionunits on a scale (Mean)
Placebo2.387
EMSAM2.386

[back to top]

Clinical Global Impression Scale

Baseline assessments included a clinical global impression scale. This is compared to day 40 assessment. The clinical global impression scale consists of a 3-item observer-rated scale that measures illness severity, global improvement or change and therapeutic response. Each item is rated between 1-7. The minimum score is 3. The maximum score is 21. A score of 3 means the patient's symptoms are very much improved. A score of 21 means the patient is very much worse. (NCT00640159)
Timeframe: baseline versus 40 days

Interventionunits on a scale (Mean)
Clinical Global Impression scale at baselineClinical Global Impression scale at day 40
All Study Participants2127

[back to top]

MDS-UPDRS Scale at Baseline and Day 40

Baseline assessment include The Movement Disorders Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS). This is compared to day 40 assessment. The MDS-UPDRS consist of 65 items. Each item can be rated between 0-4. The minimum sore is Zero. Zero means the patient is absent of Parkinson's disease symptoms. The maximum score is 260. 260 means the patient has severe Parkinson's disease symptoms. (NCT00640159)
Timeframe: baseline versus day 40

Interventionscore on a scale (Mean)
MDS-UPDRS at baselineMDS-UPDRS at day 40
All Study Participants1922

[back to top]

Expired-air Carbon Monoxide Confirmed Smoking Abstinence

expired-air carbon monoxide confirmed smoking abstinence at 52 weeks (NCT01330030)
Timeframe: 52 weeks

Interventionparticipants not smoking (Number)
Drug Selegiline24
Matching Placebo25

[back to top]